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ABSTRACT 
Non-melanoma skin cancer, comprising basal cell carcinoma (BCC) and squamous cell 
carcinoma (SCC) is the most commonly diagnosed cancer in Caucasian populations. 
Established risk factors include exposure to solar ultra-violet radiation and immunosup-
pression, such as that experienced by organ transplant recipients (OTR). A role for cu-
taneous human papillomaviruses (HPV) in the aetiology of SCC has been suggested, 
but remains uncertain. The aims of this thesis were to examine the association between 
SCC and antibodies against the L 1 antigen of 38 HPV types using Luminex technology 
among Caucasian individuals and to investigate the seroepidemiology of cutaneous HPV 
types. Data came from a small prospective study of 39 cases and 80 controls (the Ox-
ford component of the European Prospective Investigation into Cancer and Nutrition) and 
from case-control studies nested among high-risk cohorts of OTR from London and from 
Oxford (119 prevalent cases and 425 controls). 
Around 85% of controls were seroactive to at least one HPV type. In the prospective 
study, there were no statistically significant differences in the seroprevalence of antibod-
ies against any of the HPV types examined between incident cases and controls. In the 
case-control studies, as expected, antibodies against HPV 16 were associated with a 
self-reported history of an abnormal cervical smear and antibodies against HPV 6 were 
associated with a self-reported history of genital warts, validating the methodology. How-
ever, no clear associations between any of the HPV types examined (including betaHPVs) 
and prevalent SCC were identified. Adjustment for potential confounding factors, such as 
self-reported history of sun exposure made no material difference to the results. Limita-
tions of the studies are the low statistical power and the use of new serological assays. 
These serological data do not provide evidence in support of a role for HPV in the aetiol-
ogy of cutaneous SCC. 
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CHAPTER 1 
Rationale and outline of the work described in this thesis 
1.1 Introduction, aims and outline of the thesis 
Non-melanoma skin cancer (NMSC), comprising basal cell carcinoma (BCC) and squa-
mous cell carcinoma (SCC) is the most common cancer in populations of European de-
scent. The main and well-established environmental factor associated with the devel-
opment of NMSCs is ultraviolet (UV) radiation, causing genetic mutations which might 
subsequently lead to oncogenic transformations. Immunosuppressed patients, in partic-
ular organ transplant recipients (OTR), have a higher risk of NMSCs and especially SCCs 
than the rest of the population. The risk increases with increasing level of immunosup-
pression and with time since transplantation. Furthermore, squamous cell carcinomas 
occur significantly more frequently than basal cell carcinomas in transplant recipients, 
reversing the ratio usually found in the general population (4 BCCs to 1 SCC). In Chap-
ter 2, there is a brief background on the history of transplantation, immunosuppressive 
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treatments and on the first reports of skin malignancies among OTR, together with basic 
descriptions of the anatomy of the skin and a short review of the epidemiology of skin can-
cer in the general population. Chapter 3 describes the epidemiology of non-melanoma 
skin cancer among OTR. 
Results in allograft recipients suggest a viral involvement in the pathogenesis of SCC 
since highest incidences are also reported in the transplant population for tumours of 
viral origins such as non-Hodgkin's lymphoma (Epstein Barr virus) and Kaposi Sarcoma 
(human herpes virus 8). The main aim of this thesis is to investigate the role of HPV in 
the aetiology of NMSC using serological data from a small prospective study from the 
Oxford component of the European Prospective Investigation into Cancer and Nutrition 
(EPIC-Oxford) and from nested case-control studies among cohorts of high risk OTR in 
London and in Oxford. 
A large body of research has been undertaken to examine the potential role of HPV in 
the aetiology of skin cancers. The oncogenic mechanism of HPV in cervical cancers 
is well understood and the causative association is now established; however, it is still 
uncertain what role, if any, HPV plays in the aetiology of non-melanoma skin cancers. 
The hypothesis tested in this thesis is therefore: Is human papillomavirus a cause of 
squamous cell carcinoma? 
Chapter 4 gives a review of the current epidemiological evidence on the association be-
tween HPV and, SCC and BCC. In Chapter 5, I describe methods of the small prospective 
pilot study from EPIC-Oxford, together with new data from nested case-control studies 
(with questionnaire data and biological material) conducted among high risk cohorts of 
OTR from London and from Oxford. Patients with end-stage renal disease on dialysis, 
at increased risk of infections and cancers probably due to abnormalities of the immune 
system, and immunocompetent patients were also included to compare seroprevalence 
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across different immune status. 
To date, few data are available on the seroprevalence and risk factors associated with 
HPV types other than those associated with cancer of uterine cervix. Chapter 6 shows 
results on the seroepidemiology of HPV among OTR and on an examination of the sero-
prevalence and epidemiology of HPV among different ethnic groups and among people 
with different immunological status. In chapter 7 results on the role of HPV and other 
factors in the development of NMSC and particularly SCC among OTR are described. 
The final chapter summarises the findings of this thesis and gives suggestions for future 
work (Chapter 8). 
1.2 My role in the preparation of this thesis 
The idea of this thesis on HPV and sec was conceived by my supervisor Dr Robert 
Newton. The comparison between HPV seroprevalence of transplant, IC and dialysis 
patients were conceived by co-supervisors Dr Harwood and Dr Proby. Data used for this 
work include new data collected from London and Oxford and existing data from EPIC-
Oxford. The main questionnaire was written by Dr Robert Newton. 
The study in London was set up in 2002 by Dr Newton in collaboration with Dr Harwood 
and Dr Proby. I joined the study in January 2004 and took a prominent role in collab-
oration with the research nurse (Liza Mitchell) on collection, collation and cleaning of 
data. I liaised with the renal transplant and dermatology centres to obtain databases and 
I selected patients with end stage renal failure. 
For the EPIC study, I selected plasma samples, organised the shipping to Heidelberg, 
performed statistical analyses and drafted the publication. In 2005, I conducted the case-
control study among OTR from Oxford, in consultation with Dr Robert Newton. I obtained 
ethical approval, updated the London questionnaire, invited all patients to participate and 
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supervised the data and specimen collection and shipping for the Oxford study. I liaised 
with the Oxford Cancer Intelligence Unit to obtain incidence rates of malignant melanoma 
(MM) for the Oxford region by calendar year, age group and sex, and calculated stan-
dardised incidence ratio of MM. I conducted the vast majority of data entry (Krys Baker 
entered the first 100 patients from London) and cleaning for both OTR centres and, I did 
the quality control. I have checked all histological reports from hospital records. The liter-
ature reviews, all statistical analyses and the writing up of the studies conducted are also 
my own work. 
1.3 Publications relating to this thesis 
• Casabonne D, Waterboer T, Michael K.M, Pawlita M, Lally A, Mitchell L, Imko-
Walczuk B, Wojnarowska F, Newton R, Proby C, Harwood c. The sero-epidemiology 
of human papillomavirus among Caucasian transplant recipients (Submitted). 
• Casabonne D, Waterboer T, Mitchell L, Michael K.M, Pawlita M, Newton R, Harwood 
C, Proby C. The seroprevalence of human papillomavirus by immune status and by 
ethnicity in London (Submitted). 
• Casabonne D, Lally A, Mitchell L, Michael K.M, Waterboer T, Pawlita M, Imko-
Walczuk B, Wojnarowska F, Proby C, Harwood C, Newton R. A case-control study 
of cutaneous squamous cell carcinoma among Caucasian organ transplant recip-
ients: the role of antibodies against human papillomavirus (HPV) and other risk 
factors. Int J Cancer. In press. 
• Proby C.M, Wisgerhof H.C, Casabonne D., Green A.C, Harwood C.A., Bouwes 
Bavinck J-N. Chapter: The epidemiology of transplant-associated keratinocyte can-
cers in different geographical regions. In Cancer Treatment and Research Series: 
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Advances in Cutaneous Transplant Oncology; Edited by Eggert Stockfleth, Claas 
Ulrich, Charlotte Proby, Sylvie Euvrard and Jan Nico Bouwes Bavinck. In press . 
• Casabonne D, Michael KM, Waterboer T, Pawlita M, Forslund 0, Burk RD, Travis 
RC, Key T J, Newton R. A prospective pilot study of antibodies against human pa-
pillomaviruses and cutaneous squamous cell carcinoma nested in the Oxford com-
ponent of the European Prospective Investigation into Cancer and Nutrition. Int J 
Cancer 2007; 121: 1862-1868. [1] 
• Imko-Walczuk B, Lally A, Le Mire L, Casabonne D, Hollowood K, Bordea C, Woj-
narowska F. Melanomas in renal transplant recipients: the London experience, and 
invitation to participate in a European study: reply from authors. Br J Dermatol 
2007; 156 (1):167-169. [2] 
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CHAPTER 2 
Background on transplantation and skin cancer 
2.1 Introduction 
This chapter gives a short history of transplantation, immunosuppression and describes 
the first reports on skin cancer in the transplant recipient population. It also includes basic 
definitions of skin cancer and particularly non-melanoma skin cancer. It ends with a short 
description of the epidemiology of skin cancers in the general population. 
2.2 A brief history of transplantation 
The earliest report on transplantation came from China from the 5th century BC [3]. 
The physician Pien Ch'iao exchanged hearts of two soldiers 'to balance their opposite 
personality'. However the best known record of early transplantation has been attributed 
to Cosmas and Damian (the patron saints of surgeons). These twin Arabs, converted to 
Christianity, were born in Cilicia in Asia Minor during the 3rd century [4]. According to 
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the legend they amputated the gangrenous leg of the sacristan Deacon Justan ian and 
grafted the leg of an Ethiopian Moor gladiator recently buried (Figure 2.1). 
Figure 2.1: Oil painting , attributed to the Master of Los Balbases, Saints Cosmas and Damian 
(1495) (Source: http://library.wel/come.ac.uk) 
Since this period, many unsuccessful transplantations took place and it is only during the 
20th century that transplantation expanded remarkably. In 1906, cornea was success-
fully grafted by Eduard Zirm in Austria, however for organ transplantations the problem of 
rejection seemed insurmountable. In 1912, Alexis Carrel earned the Nobel Prize for his 
work on transplantation and sutures of blood vessels. He also noticed that organs were 
failing because of 'biological ' factors. Around the world , multiple allograft and xenograft 
attempts were performed and surgical problems were gradually overcome but patients 
still had a very short survival [4] . 
An important step forward for patients with end-stage renal diseases was the develop-
ment of the first renal dialysis machine during the Second World War by Willem Johan 
Kolff in the Netherlands. One of his later ach ievements was a heart-lung machine [5] 
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Frank Macfarlane Burnet and Peter Medawar brought a major insight into the transplan-
tation world with the concept of 'acquired immunological tolerance'. They demonstrated 
that individuals acquire early in life the faculty to tolerate their own cells and to reject 
non-self or foreign cells. Hence, the exposure to an antigen at a fetal stage could induce 
tolerance later in life or inhibit the production of antibodies against this foreign organism. 
They won the Nobel Prize in 1960 for their work [6]. 
In 1954, Joseph Murray and his team at the Peter Bent Birmingham Hospital in Boston 
performed a kidney transplantation between homozygotic twins. The kidney was placed 
in the iliac fossa and the ureter was connected to the recipient bladder. The patient sur-
vived 9 years. This was the first successful organ transplantation [7]. The first successful 
transplantation of cadaveric kidney, lung, liver, pancreas, intestine, heart and heart-lung 
were achieved respectively in 1961, 1963, 1963, 1966, 1967, 1967 and 1981 [7]. 
None of these could have been achieved without the prevention of graft rejection: the 
discovery of corticosteroids (1936), X-ray irradiation and the introduction of immunosup-
pressive treatments. From 1960, the first efficient drug regimen consisted of azathioprine 
and prednisone. During this period, the first-year survival rate for liver transplants was 
only around 24-33%. With the discovery of ciclosporin in 1972, a new era started [8]. For 
instance, two year survival rate for liver recipients were only estimated at around 70% in 
most centres [7]. Progressively, newer immunosuppressive drugs such as OKT3 (1987), 
tacrolimus (1997), mycophenolate mofetil (1998), sirolimus (1999) have been introduced 
with better efficiency against rejection than the triple therapy (azathioprine, prednisone 
and ciclosporin) [9]. 
Nowadays, as reported by UK Transplant (NHS), between April 2006 and March 2007, 
3,087 solid-organ transplantations were performed from 702 living donors (23%) and 
2385 from cadaveric donors (77%) [10]. These figures include donors with multiple recip-
21 
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ients. 
2.3 First reports on malignancies among OTR 
In 1909, Paul Ehrlich postulated that the immune system protects humans and other 
species from cancer development. Fifty years later, Lewis Thomas and Frank MacFar-
lane Burnet proposed the concept of immunological surveillance [11]. The idea was 
that lymphocytes could identify and kill malignant or foreign cells and that cancers would 
originate in cells which had not been destroyed [12]. Hence, an increased incidence of 
malignancies would be expected in patients with weaker immune system. Transplantation 
was a good opportunity to test this hypothesis. 
At the end of the sixties and the early seventies, strong evidence of an increase in can-
cers among transplant recipients was accumulating through case reports [13, 14, 15]. In 
the following decade, cohort studies were set up to confirm these observations. To do 
this, cancer incidence rates from transplant recipients were compared with the 'expected' 
ones in the general population. In 1973, Fraumeni and Hoover conducted the first study 
in 6297 patients followed for at least one month after transplantation between 1951 and 
1971 [16]. Based on low incidence rates from the Third National Cancer Survey in the 
USA, they reported a statistically significant 4-fold increased risk of skin and lip cancers 
in transplant recipients compared with the general population. A non statistically signifi-
cant increase of 30% was also reported using high incidence rates. In 1979, Kinlen et at. 
established a collaborative study between United Kingdom, Australia and New Zealand 
and corroborated results of the previous cohort [17, 18]. 
Overall a two-fold to six-fold increased incidence of all cancers has been found in organ 
transplant recipients compared with the general population [16, 17, 18, 19, 20, 21, 22, 
23.24.25,26.27.28,29,30,31,32,33,34,35,36,37,38, 39. 40, 41, 42. 43. 44] 
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[15-43]. Higher incidences have been reported for lymphomas, Kaposi sarcoma (KS) 
ano-genital , skin and lips cancers and in cancers associated with the type of organ trans-
planted [20, 17]. Most of these cancers, with the exception of skin cancers, have a 
proven viral etiology. Non-Hodgkin's lymphoma (NHL) has been associated with Epstein 
Barr virus, KS with human herpes virus 8, cervical and anal cancers with human papillo-
mavirus. 
In HIV-infected patients, another secondary immunodeficiency condition , an excess risk 
is also mainly found for those cancers with a viral aetiology [40, 45] and an excess of 
non-melanoma skin cancers are also reported. 
2.4 Skin cancers in the general population 
2.4.1 Definition 
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Figure 2.2: The skin (Source: http://www.healthandage.com) 
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The skin acts as a barrier and is constituted of three layers (Figure 2.2): epidermis, dermis 
and subcutaneous tissue. The epidermis, the outer layer of the skin, mainly consists of 
keratinocytes, melanocytes, Langerhans cells and Merkel Cells. The outermost layer, 
called the stratum corneum, is composed of dead and dying cells. The dermis is the 
middle layer of the skin located between the epidermis and subcutaneous tissue. The 
major cells in the dermis are fibroblasts which produce and secrete collagen and elastin 
fibers. The dermis also contains capillaries, lymphatic tissues, sebaceous glands, sweat 
glands, hair follicles as well as a relatively small number of nerve and muscle cells. The 
primary function of the dermis is to sustain and support the epidermis. Subcutanous 
tissue or hypodermis is the innermost layer of the skin located under the dermis and 
mainly consists of fat. Subcutaneous fat acts as a shock absorber and heat insulator. 
There are two main types of skin cancers. Non-melanoma skin cancer (NMSC) includes 
basal cell carcinoma (BCC), squamous cell carcinoma (SCC) and some less common 
types of cancers like Merkel cell carcinoma, KS, T-cell lymphoma of the skin and sarcoma. 
The second type is malignant melanoma (MM). SCC, BCC and MM all originate in the 
epidermis. SCC develops from keratinocytes, BCC from basal keratinocytes possibly 
located in hair follicles and MM from the melanocytes also located in the basal layer. 
Bowen's disease (BO) is a squamous cell carcinoma in situ (CIS). Figures 2.3, 2.4, 2.5, 
2.6, 2.7, 2.8 show photos of squamous cell carcinoma, basal cell carcinoma, malignant 
melanoma, CIS, actinic keratoses and viral warts respectively. 
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Figure 2.3: Squamous cell carcinoma 
Figure 2.4: Basal cell carcinoma 
Figure 2.5: Malignant melanoma 
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Figure 2.6: Carcinoma in situ - Bowen's disease 
Figure 2.7: Actinic keratoses 
Figure 2.8: Viral warts 
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2.4.2 Skin cancer epidemiology in the general population 
Skin cancer is the commonest cancer in Caucasian populations worldwide [46]. Hispan-
ics and Asians have fewer skin cancers and the lowest occurrence rates are reported 
among populations with black or type VI skin. In 2005, in the UK, over 85,000 new skin 
cancers were reported of whom around 9583 people were diagnosed with MM. Over the 
same period, there were respectively around 45,500 and 38,500 new breast and lung 
cancer registrations. These data were obtained from Cancer Research UK [47]. It is im-
portant to note that these statistics are underestimating the true number of NMSC since 
these malignancies are poorly registered in many tumour registries 1. NMSC is the com-
monest cancer in white populations, but being rarely fatal and badly registered it is often 
omitted or excluded from cancer reports. 
In the Caucasian population, BCC, a slow-growing and locally destructive lesion, is the 
most frequent skin cancer representing around 75% of all NMSC whereas 20% are SCCs. 
In the Black population, SCC is more common [48]. NMSC are usually easy to treat with 
early diagnosis and BCCs rarely metastasize [49] whereas SCCs have higher potential 
to do so [50]. The overall rate of metastasis from SCC depends on the time of presenta-
tion, the size, the site, the depth, the use of previous treatments, the immunosuppressed 
status and the histologic differentiation of the lesion [51]. Rates of metastasis have been 
estimated as 2% to 5% for low risk SCC but between 10% and 30% for high risk SCC 
[52, 53, 51, 54]. Malignant melanoma is less common (around 3% of all skin cancers) 
but is the most dangerous type of skin cancers as they have significant metastatic poten-
tial. Malignant melanoma is the third most common cancer death in 15-39 years old in 
the UK and accounts for 75% of skin cancer related deaths [47]. Patients with skin can-
cers have a very good prognosis when lesions are detected early and promptly removed. 
1 www.statistics.gov.uk 
27 
2- Bacl<ground on transplanfiltion and si<tn cancer 
Treatments range from local surgical excision, cryotherapy, curettage, radiotherapy, skin 
grafts, Mohs' micrographic surgery and chemotherapy, depending on severity and site. 
Five-year survival for patients with MM are closely linked with Breslow thickness. In the 
UK, for in situ melanoma, more than 95% of patients are alive after 5 years whereas only 
30-50% of patients with MM greater than 4mm survive the first five years [47]. Mortality 
from malignant melanoma represents 1 % of all deaths from cancers [47]. In contrast, 
NMSe are only rarely fatal. For instance, in Australia, mortality rates are 2 per 100000 
for males and 0.6 per 100000 in females whereas for lung cancer in males and breast 
cancer in female mortality rates are 36.4 and 18.2 per 100000 respectively (2001 data 
standardised to the 2000 World Standard Population) [55]. In 2005, 511 people died in 
the UK from NMSe [47]. 
Around the world, skin cancer incidence in White populations has been dramatically in-
creasing over the last two-three decades [56, 57, 46, 58]. Ko et al. (1994) looked at 
age-standardised incidence rates in North Humberside for Bee, see, Bowen's disease 
(BO) and MM in the years 1978, 1980 and 1984 and all years between 1987 and 1991. 
They found that age-standardised incidences between 1978 and 1991 increased by 2.5 
for Bee, 5 for BO and 1.5 for see and MM [46]. In 2000, in the United Kingdom, MM rates 
increased by 16% in a year and 24% over the last 5 years [47]. The ageing population 
or improved diagnostics cannot solely explain this increase and sun exposure behaviour 
changes, due to greater affluence, increased leisure time and facility to travel to sunny 
countries, may partly explain this rise [47]. In some parts of the world, for instance Aus-
tralia, there is some evidence that the skin cancer increase has stopped or started to 
decline in some populations due to successful public awareness campaigns [56]. 
The main and well-established risk factor associated with the development of skin cancers 
is UV radiation exposure, mainly UV-B radiation (280 to 315nm) but also UV-A radiation 
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(UV-A 1: 340 to 400nm and UV-A2: 315 to 340) [50] but not UV-C (100 to 280nm). UV 
radiation promotes mutations in DNA, including those in critical tumour suppressor gene, 
such as p53 [59, 60]. DNA damaged cells normally undergo apoptosis, but failure to 
destroy them may lead to development of malignancies [61]. UV radiation can induce 
local cutaneous immunosuppression (for a review [62]). The conclusion from the Interna-
tional Agency for Research on Cancer's monograph on solar and ultraviolet radiation was 
that "there is sufficient evidence in humans for the carcinogenicity of solar radiation. So-
lar radiation causes cutaneous malignant melanomas and non-melanocytic skin cancer" 
[63]. The sun exposure pattern seems however to differ between cancer types. A recent 
meta-analysis concluded that MM seems to be associated with intermittent sun exposure 
[64], whereas SCC risk would increase with continuous sun exposure [61]. For BCC, it is 
unclear and one hypothesis is that after reaching a plateau of sun exposure individuals 
would not be at further increased risk of BCC with increase of sun exposure [65, 61] or 
that it could also be due to intermittent sun exposure [66, 67]. Other risk factors ensuing 
from UV radiation are: 
• Skin phototype (cf Fitzpatrick classification on Page 45): People with low ability to 
tan and who burn easily are more likely to develop skin cancer. Light eye colour, 
red hair and fair complexion have shown a less conclusive association [61,63]. 
• Ethnicity: Caucasians are more likely to develop non-melanoma skin cancers than 
people with darker pigmentation. Cancer in Black or other darkly pigmented popu-
lations do not necessarily occur on non sun-exposed areas [68, 69]. 
• Anatomic location: SCCs tend to occur on sun exposed areas, mainly the head 
and neck, whereas BCCs and MM also develop on intermittent or non sun-exposed 
body sites such as the trunk and legs [57, 56, 61, 63, 12]. 
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• Geographical location: Highest skin cancer risks have been reported in people of 
European origin living near the Equator, with incidences declining with increasing 
latitudes [57, 56, 61, 63, 12]. In 2002, a survey found that non-melanoma skin 
cancers accounted for around 374,000 new cases of cancers in Australia (256,000 
and 118,000 people with BCCs and SCCs respectively). The age-standardised in-
cidence estimates using the 2000 World Standard Population were, for BCC, 1,150 
and 820 per 100,000 in males and females respectively and for SCC, 560 and 320 
per 100,000 in males and females respectively (2001 data standardised to the 2000 
World Standard Population) [55]. In developing countries, NMSC occur mainly in 
patients of European origin [70]. 
• Migration: In countries with high ambient sun exposure, such as Australia, the high-
est risk of NMSC appears in the Australian-born Caucasian individuals rather than 
Caucasian immigrants who moved to Australia later in life [63, 61], probably reflect-
ing the importance of early life UV exposure. 
• Occupation: Outdoor workers have a higher risk of skin cancers, particularly of 
SCC, than those who work indoors [63] 
• Solar skin damage: Actinic or solar keratoses and Bowen's disease (partial and full 
thickness epidermal dysplasia respectively) are precursors of SCC [61,71,72] and 
their presence is indicative of high risk for NMSC. 
• Age: Incidence of all skin cancers increases with age and they occur mainly among 
the elderly. NMSC is most common in those over the age of 50 years [47]. 
Non-melanoma skin cancers are more common in men than women, whereas MM is 
more common among women [47]. Other risk factors for NMSC include exposure to 
chemicals (principally arsenic and tar derivatives), chronic inflammation such as burns 
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and scars, psoralen and UV-A (PUVA) treatment or previous exposure to ionising radia-
tion [73, 74, 69, 75, 76, 77, 52,12,50]. Patients with previous skin cancers or precursor 
lesions such as actinic keratoses or Bowen's disease are also at increased risk of de-
veloping a subsequent cutaneous malignancy [78]. Family history is also a risk factor, 
especially for melanoma [72, 79, 80, 81]. Patients with genetic diseases resulting in 
reduced repair of UV induced DNA damage or reduced melanin synthesis (xeroderma 
pigmentosa and albinism respectively) have a higher risk of developing skin cancers [12]. 
An association between smoking and SCC has been reported in some [82, 45] but not all 
studies [83]. Immunocompromised patients such as transplant recipients (Chapter 3) and 
to a lesser extent HIV sera-positive patients [45, 84, 85, 86, 87] are more likely to develop 
skin cancers [40]. Nutritional studies have looked at the association between diet and 
NMSC. It is unclear if fat intake is associated with the development of skin malignancies 
[88]. 
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Literature review: Epidemiology of squamous cell carcinoma and 
basal cell carcinoma among organ transplant recipients 
3.1 Introduction 
The purpose of this chapter is to give an overview of the published literature on the 
epidemiology of non-melanoma skin cancer in transplant recipients. This chapter is par-
ticularly important in assessing all factors which could potentially confound or affect the 
association between HPV and the development of NMSC in transplant recipients. 
3.2 Limitations 
Cancer Registries in the United Kingdom often fail to register non-melanoma skin cancers 
(ICD 10_C44) since these lesions are rarely life threatening and often not reported 1. 
1 www.statistics.gov.uk 
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This problem occurs in almost all countries; indeed, Cancer Incidence in Five Continents 
(Volume VIII) reports cancer incidence for all sites excluding non-melanoma skin cancers_ 
For instance, since 1995 the Oxford Cancer Intelligence Unit records only the first NMSe 
of each type occurring in a patient. In other words a patient having a BCC and a see 
will have both recorded whereas a patient with two BCC only or two SCC will only have 
the first lesion recorded. Prior to this date, all lesions were recorded. However, nationally 
the registration of non-melanoma skin cancer is very variable with some registries only 
recording SCC. 
These differences between Cancer Registries imply inaccuracies and incompleteness 
of data which need to be kept in mind when making comparisons or interpretations. It 
should also be borne in mind that transplant recipients are more likely to have had a 
higher dermatological surveillance than the general population and to have had all their 
lesions recorded in dermatological clinics. 
3.3 Standardised Incidence Ratios (SIR) 
A systematic review was performed through a Pubmed search using synonyms for rele-
vant words on studies reporting on SIR for SCC and/or BeC, and published up to Octo-
ber 2008 [search terms: basal cell carcinoma, squamous cell carcinoma, standardised 
incidence ratio, skin cancer, cutaneous, non-melanoma, transplant, general population], 
supplemented by searches of references in identified papers, by hand searches of rel-
evant journals. No restriction was placed on language of publication. No attempt was 
made to identify unpublished studies or to obtain unpublished data from published stud-
ies. All published studies reporting on SCC and/or BCC were included in this review_ 
Black squares indicate the SIR and horizontal lines represent 95% confidence interval 
(Figure 3.1). 
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Eleven studies have compared SCC and BCC incidence rates among transplant recipi-
ents with those from the general population [89, 23, 28, 39, 17,32, 34, 37, 20, 43, 44]. 
Studies have been undertaken in Europe, the USA and Canada. All of them have found 
that transplant recipients are at increased risk of developing NMSC compared to the 
general population. This result is mainly driven by a strong and statistically significant 
increased risk of SCC. Rate ratios for SCC and BCC lie respectively between 18 and 250 
and between 1.2 and 16. 
Several dissimilarities due to study design and methods used might possibly explain these 
variations. 
• Counting lesions 
Highest SIRs have been found in two studies which counted each new tumour in 
an individual separately, as compared to other studies which only counted the first 
tumour of each type [32, 37]. They found respectively a 250-fold and 100-fold in-
creased risk in transplant recipients for SCC lesions. The highest risk for BCC 
tumours was also found by the Dutch study with a 10-fold increased risk in trans-
plant recipients compared with the general population. Some studies do not specify 
how lesions were recorded in their comparison group. 
• Organ type 
SIRs appear higher in studies which looked at organ types other than kidney alone 
[23, 28, 37, 20]. Risk ratios for SCC lie between 56 and 177. However, 95% con-
fidence intervals are wide and overlap with those from studies based on kidney 
transplants only. None of these studies collected information on BeC lesions. 
• Choice of the "standard population" 
Expected rates of NMSC are estimated from a variety of difference sources, such 
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as: 
- National cancer registries 
Of the six studies which used their national cancer registry data, five are from 
Scandinavian countries [89, 23, 37, 20, 44]. This predominance is explained by 
their longer history of cancer registration. In Finland, for instance, this started 
in 1952 2. Scandinavian studies compared the observed number of cases with 
expected numbers based on national calendar year, age-, and sex-specific 
incidences. 
- Combination of national and city cancer registries 
One study has been undertaken in the Netherlands where National Cancer 
Registration started only in 1989. Haagsma et al. (2001) used the Eindhoven 
Cancer Registry as a comparison group for the period before 1989 [28]. 
- City or regional cancer registries 
Kinlen et al. (1979) used the Birmingham Cancer Registry as a good represen-
tation of the UK population [17]. Two other studies used cancer registries with 
the same latitude: Detroit Cancer Registry for the study undertaken in Toronto 
and Eindhoven Cancer Registry for the study based in Leiden [34, 32]. 
- National Surveys 
Hoxtell at al. (1977) used a cancer survey to derive their ratios [39] . 
• Inclusion of lips cancers 
One study grouped NMSC and lips cancers [28] and 2 other studies did not specify 
clearly if lips cancers were included in their calculations [20, 23]. 
2httpllwww.cancerregistry.filv2001/v2001introduction.html 
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Excess risks of other cancer sites has also been shown among transplant recipients_ For 
example, increased SIRs have been found for NHL and KS. NHL is 5 to 49 times more 
common in transplant recipients than in the general population and Kaposi sarcoma is 
between 150 to 500 times more frequent [16, 17, 18, 26, 30, 20, 27, 29, 36, 31, 25, 42, 
41,40,43]. 
3.4 Ratio SCC/BCC 
In Australia, the ratio of SCC to BCC was estimated to be approximately 1 :4 in the gen-
eral population in 1985 [57], although Staples et al. (1998) indicates a possible shift 
towards SCC with a ratio of 2.5:1 in 1998 secondary to a reduction in BCC occurrence 
in younger people [56]. Studies around the world have reported a wide range of esti-
mates. For instance, a ratio of 1 :3.7 was obtained among patients from Hong Kong and 
1 :6.8 in southern European countries [90, 91]. SCC skin lesions are predominant in or-
gan transplant recipients. As a result, a reversed BCC to SCC ratio is often observed 
in immunosuppressed people compared with the general population. Figures have to be 
compared across studies with caution, as the way of counting lesions and the length of 
follow-up vary from study to study. For instance, Mithoefer et al. (2002) examined 151 
liver transplant patients who developed 56 squamous cell (in 23 patients), 23 basal cell 
(16 patients) and 7 melanomas (in 6 patients). Ratio SCC/BCC could be reported as 2.4 
(56/23) or as 1.4 (23/16) [92]. Ratios (SCC/BCC) range between 0.3 and 16 when multi-
ple lesions in one person are counted separately and from 0.6 to 3.5 using when only the 
first lesion per person is considered. Transplant recipients with skin cancers have often 
already developed multiple skin lesions at the time of their first skin examination. Hardie 
et al. (1980) found that half of their patients who were examined every 3 months had 
multiple skin lesions at first diagnosis [22]. 
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Two outstanding results arise from an Australian and a Scottish study where see was 
respectively 16 and 15 times more frequent than BCC [14, 93]. These two studies con-
sidered the total number of lesions in respectively 7 and 10 patients only. Curiously, 
some Spanish and Italian studies did not find the expected reversed ratio although there 
was still a higher proportion of SCC than in the general population [94, 95, 96, 97, 98, 99]. 
In summary, the SCC to BeC ratio appears difficult to quantify precisely due to the oc-
currence of multiple lesions, difference in follow-up time and mean age of the cohort. 
Nevertheless, the prevalence of SCC appears exceptionally elevated when compared to 
the general population and exceeds the number of BCC. 
3.5 Cumulative incidence 
The cumulative incidence of SCC and BCC in transplant recipients increases sharply with 
the time since transplantation [100, 101, 102, 103, 23, 33, 32, 97]. However, dissimilar-
ities between these tumour types are observable (Figure 3.2). Cumulative incidence for 
SCC increases more sharply with time than for BCC. 
Hartevelt et al. (1990) found that the cumulative risk at 20 years after transplantation 
for SCC and BCC were respectively 35% and 10% [32]. This result is supported by a 
British study which found that the risk of developing SCC post transplantation appears 
to increase exponentially whereas the risk of developing BCC seems to increase linearly 
with increasing years of immunosuppression [100]. Jensen et al. (1999) reported a more 
rapid rise in the cumulative incidence for SCC in heart rather than in kidney transplant 
recipients. At ten years after transplantation, the cumulative incidence for sce in heart 
and kidney transplant recipients was respectively 21 % and 7% [23]. No studies relating 
to transplantation of other organs (such as liver) are available for comparison. 
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3.6 Multiplicity, recurrence and aggressiveness 
Almost all studies of NMSe among transplant recipients, show that patients tend to have 
multiple tumour lesions, with a higher recurrence rate than in the general population. In 
addition, see in particular, tend to behave more aggressively. For instance, Hoxtell et 
al. (1977), Lindelof et al. (2000) and Mc Gregor et al. (1995) found respectively on an 
average of 1.9, 2.4 and 3.8 skin malignancies per patients [39, 37, 104]. In Blohme et al. 
(1984) two patients develop several hundred lesions each over a period of several years 
[36]. In Australia, Bouwes-Bavinck et al. (1996) found 2751 NMSC in 271 patients [103]. 
The prevalence of patients with multiple skin lesions varies from study to study due to 
differences in length of follow-up and age of patients. It ranges between 26% and 73% 
[92, 22, 32, 34, 36, 37, 105, 106]. Euvrard et al. (2007), who followed their patients for 
5 years, reported that 71 % of them developed at least two lesions with an overall mean 
number of see higher in kidney than in heart transplant patients [107]. Some studies 
also found that patients had multiple skin lesions at first presentation [22, 34]. It is also 
very common to find several skin cancers with different histological types in the same 
patient. Bouwes-Bavinck et al. (1996) found in their study that 83 patients had see, 52 
patients had Bee and 136 had both types [103]. Transplant-associated sec are more 
frequently recurrent and/or aggressive in behaviour than see in the general population 
[108, 109, 100, 110, 111, 112, 113]; similarly, patients with multiple lesions appear to get 
more aggressive see [114]. 
3.7 Mortality and survival 
The principle causes of mortality among transplant patients are cardiovascular diseases 
(40-55% of all death causes) followed by malignancies and infections (15-20% each) 
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[115]_ As described earlier, see are more likely to progress to metastasis among trans-
plant recipients compared with the general population and hence, mortality rates from 
see are higher in this population. Ong et al. (1999) reported that 11 patients out of 152 
died from skin cancers (6 see, 4 MM, 1 Merkel eell carcinoma) representing 27% of 
all deaths after 4 years (15% for See) [116]. McGregor et al. (1995) found that 3% of 
patients diagnosed with skin cancer, subsequently died of metastatic see (2 out of 59) 
[104]. In an Australian study, of the 19 patients diagnosed with NMSe, 8 died from the 
disease and 5 others relapsed, but were alive at the end of follow-up [117]. Jain et al. 
(1998) found one and three years survival of 91 % and 86% for liver transplant recipients 
with skin cancer [118]. Adamson et al. (1998) classified Bee and see as aggressive 
and non-aggressive tumours. Survival figures were 100% at 1 year, 88% at 3 years, 75% 
at 5 years and 53% at 7 years for aggressive skin tumours and respectively 100%, 100%, 
82% and 82% for so-called non-aggressive tumours [110]. 
3.8 Age at transplant and time from transplant in relation to 
the first appearance of NMSCs 
In immunocompetent people, NMse occur most frequently in people in their 60s and 70s 
or older whereas in transplant recipients lesions develop on average 15-20 years earlier 
[46, 119, 113]. This trend is observed in all studies. 
As might be expected, there is a correlation between the age of the patient at trans-
plantation and the time from transplantation to the time to development of the first skin 
tumour - a coefficient of correlation of 0.4 and 0.3 was found [99, 105]. There is some 
evidence that Bee occur on average between one and two years earlier than see 
[116, 102,98, 120, 121] but, only for the study by Ong et al. (1999) this difference 
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was statistically significant [116]. Mihalov et al. (1996) found the same result in heart 
transplant recipients (about 2 years earlier) but not in kidney transplant recipients where 
the opposite trend was noticed (about 1 year later) [121]. No difference was found be-
tween SCC and BCC onset in a Canadian study (median: 4 years for both type of lesions) 
[122]. Post transplant Iymphoproliferative diseases (PTLD) and KS occur on average ear-
lier than skin cancers after transplantation. KS appears the earliest on average between 
9 and 27 months after transplantation followed by PTLD which occurs on average be-
tween 33 and 78 months [123, 124, 125, 126, 127, 128, 129, 130, 131]_ Non-Hodgkin's 
Lymphoma (NHL) occurs most frequently in the first year after transplantation and its in-
cidence then falls and remains constant thereafter [17, 132, 127]_ KS is a rare neoplasm 
in western populations found in HIV infected homosexual men and among individuals of 
Mediterranean or African origin [133]. Webb et al. (1997) reported KS cases only in 
Afro-Caribbean and Mediterranean transplant patients [100]. Highest prevalence of KS 
in transplant recipients is found mainly in the Middle-East or regions where the underly-
ing viral cause - HHV8 - is endemic [134, 135, 124, 125, 136, 21]_ The highest preva-
lence has been observed in Saudi Arabia, where it comprises 88% of the total number 
(14/16) of post transplant tumours [137]. High prevalence is also seen in Iran, Pakistan, 
South Korea and Russia with KS representing around 45% of all post-transplant tumours 
[135, 126, 138, 139, 140]. 
In summary, PTLD and KS appear earlier than NMSC in transplant recipients and the 
older the patient the earlier the first skin cancer occurs with BCC probably appearing on 
average earlier than SCC. 
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3.9 Risk factors (excluding human papillomaviruses) 
3.9.1 DeSign of studies 
Most studies that looked at risk factors associated with the development of post-transplant 
see and Bee used retrospective cohort designs. Eligible patients contributed person 
years from the date of transplantation until the date of registration of skin cancers, or the 
end of follow-up. However, for many studies the date of the end of follow-up is not clearly 
stated [120, 101, 89, 121]. Few studies were based on case-control design [141, 142, 
143,101]. 
3.9.2 Solar and ultraviolet (UV) exposure 
Sun exposure 
Almost all studies have reported a significant positive association between skin cancers 
and exposure to UV radiation in transplant recipients [99, 105, 19, 101,92, 142, 144, 145, 
91,146,147,81,143,148]. These studies looked at different variables to quantify sun 
exposure such as sunbathing, episodes of childhood sunburn, outdoor occupation, holi-
days abroad, sunscreen use, number of sunburns, number of painful sunburns or use of 
sunbeds. Outdoor occupations were associated with development of skin cancers in six 
out of eight studies [141, 19, 101, 92, 111, 95, 36, 81]. Patients with sec have reported 
heavier cumulative sun exposure than those without [114, 105, 149, 91]. 
Bouwes-Bavinck et al. (1993) looked at the risk of developing NMSe in three different 
levels of sunlight exposure (~1 0,000 hours, 10,000-20,000 hours, 20,000+ hours) - Pa-
tients in the highest sun exposure group apparently had a greater risk of see than Bee 
but 95% confidence intervals were very wide and overlapping. This result was stronger 
in multivariate analysis after adjusting for sex, age at examination, skin type and number 
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of keratotic lesions. The adjusted odds ratios comparing the highest sun exposed group 
versus the lowest one was 97.5 (only 14 cases and 59 controls; 95%CI: 6.6-1444) for 
SCC and 49.3 (95%CI: 2.8-878) for BCC [142]. This result was corroborated by Ramsay 
et al. (2000) and Rosso et al. (1996) where SCC showed a significant positive asso-
ciation with increased cumulative sun exposure whereas BCC did not reach statistical 
significance [101, 91]. One study found that in univariate analysis, patients with BCC and 
patients without skin cancers had the same cumulative exposure to sunlight [105]. 
Mithoefer et al. (2002) and Bouwes Bavinck et a/. (1993) found that, the number of 
painful or second degree sunburns increases the risk of developing both SCC and BCC 
[92, 142]. This result was stronger when sunburns occurred between the age of 12 and 
29 but histology types were not examined separately [142]. This result was corroborated 
by 2 other studies; a multicentre study where the risk of developing SCC and BCC was 
double in patients with 5 or more sunburns before the age of 20 compared with those who 
never burn [143] and in an Australian study where a 3-fold increase risk for SCC and BCC 
was reported between patients who frequently burned during their childhood and those 
who never or rarely burned [143]. Mithoefer et al. (2002) did not find any association with 
childhood sun exposure [92]. Only one study has not reported an association between 
skin cancers and sun exposure [150]. 
Location of skin malignancies 
Most studies found that skin lesions in transplant recipients are more frequent on sun-
exposed areas of the body [105, 98, 151, 101, 92, 22, 95, 116, 34, 39, 14, 120, 111, 
114, 152,32, 36, 37, 142, 93, 70, 153, 119]. The distribution of skin malignancies differs 
by histology types. SCC appear predominant on the head, neck and dorsum of hands 
whereas BCC are also frequent on the trunk and legs [111, 114, 101, 152, 32, 37, 120, 
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142, 119, 106, 154, 122]. Gupta et al. (1986) did not find any difference between the 
distribution of the body location of skin cancers in transplant recipients and the general 
population [34]. Staples et al. (1998) in their third Australian National Survey reported 
that 49% and 40% of BCC and SCC respectively occurring on the head and neck. They 
also reported a higher proportion of BCC on the trunk (21 %) than SCC (8%) [56]. 
The location of NMSC appears different between men and women. Male patients tend to 
have more lesions on the head and neck whereas women are more susceptible to have 
lesions on their trunk [119]. In transplant recipients, aggressive tumours were also more 
frequent on the head than other body sites [110, 114]. Euvrard et al. (1995) found that 
for kidney transplant recipients who were less than 40 years old at transplantation skin 
cancers on the head represent 19% of the total number of lesions (181/225 lesions in 45 
patients) whereas the older patients had 67% of their skin lesions (120/179 lesions in 43 
patients) located on the head (P:::;0.001). This group also found 70% of malignant skin 
lesions on the head of heart transplant recipients and 59% of skin lesions on other body 
locations in kidney recipients (P:::;0.001) [111]. This may reflect the older age of heart 
compared with renal transplant recipients. The location of skin malignancies reflects the 
importance of sun exposure and highlights the aetiological differences between sec and 
BCC. 
Skin, hair and eye colour 
The Fitzpatrick classification is the most commonly used to identify the skin type and is 
based on pigmentation and tanning ability. It can be described as follow: 
• Skin type I - Very fair skin or freckled, always burns, never tans 
• Skin type II - White, usually burns easily, tans with difficulty 
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• Skin type III - White to medium skin tone, sometimes burns, tans gradually 
• Skin type IV - Medium skin tone, rarely burns, always tans well 
• Skin type V - Olive to dark skin tone, very rarely burns, tans very easily 
• Skin type VI - Black, never burns 
In most studies, but not in all [122], skin type VI and sometimes type V were excluded as 
no skin cancers occurred in these groups [19, 141, 100, 155]. Euvrard et al. (1995) used 
eye colour as a better marker of skin type since transplant recipients' skin colour might be-
come darker after immunosuppressive treatments [111 , 156]. Many studies examined the 
relationship between skin type, hair and eye colour and risk of developing skin tumours in 
transplant recipients [99, 105, 141, 101, 92, 111, 102, 116, 95, 142, 144, 81, 143, 122]. 
As expected, patients with skin types I and II have a statistically significant greater risk 
of NMSe than types III and IV [99, 105, 116, 147, 143]. All 14 cases in Espana et al. 
(1995) were type II or III but no comparison with the skin type distribution in the control 
population was reported [102]. Bouwes Bavinck et al. (1993) found that patients with skin 
type I and II have a higher risk of see, but not Bee, in comparison with patients with skin 
types III or IV [142]. 
Transplant patients with light-coloured eyes are also at higher risk for skin cancers [111, 
101, 92, 143] especially of developing see rather than Bee or premalignant lesions 
[111, 101, 19]. Regarding hair colour, Lindelof et al. (2003) found people with light blond 
or red hair were at greater risk of developing skin cancer than people with dark hair [141]. 
Having red hair was also associated with increased risk of skin cancers in transplant 
recipients in another study but the sample size was very small [92], but not all studies 
report such an association [122]. Results from transplant recipients are in accordance 
with those from the general population. 
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3.9.3 Age at transplantation 
All studies but one found that patients who develop NMSC are significantly older at the 
time of transplantation than recipients without NMSC [99, 105, 98, 19, 101, 92, 116, 95, 
94, 32, 36, 29, 103, 120, 142, 157, 143, 148]. These results seem independent of the 
type of the organ transplanted and the histological type of NMSC [98, 101]. Naldi et al. 
(2000) found a nine fold increased risk in patients of 50 years or more compared with 
those less than 30 years old at the age of transplantation (95%CI: 4.3-20.5). This result 
was adjusted for age, sex, treatment types and graft organs [98]. Another study based on 
multivariate analyses adjusted for sex, skin type, eye colour, treatment type and primary 
sclerosing cholangitis found a 15% increased risk of developing skin cancer for each year 
of age older patients were at time of liver transplantation (P=0.0003) [92]. Surprisingly, 
Adami et al. (2003) did not support this finding their results were adjusted for follow-up 
time, gender and type of organ. Patients less than 40 years old were 4 times (95% CI: 
2.7 to 5.4) more likely to develop NMSC than people older than 60 years and patients 
between 40 and 60 years old were 1.5 (95% CI: 1.0 to 1.9) more likely to develop NMSC 
than the same reference group [20]. 
3.9.4 Sex 
Of the 21 studies which looked at the association between sex and skin cancers in trans-
plant recipients, nine did not report any association [105, 141, 152, 95, 94, 20, 142, 144, 
157]. Ong et al. (1999) found a significant higher risk in males in univariate analysis it 
was no longer statistically significant after adjustment for age at transplantation, follow-up 
time, skin type, occurrence of HLA-mismatching and residence [116]. Six studies found a 
significantly higher risk of skin cancer in men in univariate analysis and did not examine 
multivariate analysis [111, 101,35, 158, 146, 147]. Four studies found a significant higher 
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risk in males in univariate and multivariate analysis. Their analyses were adjusted for age 
at transplantation and: 
-follow-up time and organ type [103] 
-eye colour, hair colour, primary sclerosing cholangitis and use of ciclosporin [92] 
-organ type and different type of treatments [98] 
-creatinine at 1 year, donor type and length of immunosuppression [120] 
-not specified [122] 
Very few studies have reported on the risk of BCC and SCC for men and women sepa-
rately [99, 141, 95, 143, 101, 98, 103]. None of the studies controlled for sun exposure. 
3.9.5 Type of transplantation 
Six studies have examined the association between the risk of developing BCC and/or 
SCC and the type of transplanted organs [105, 98, 89, 111, 20, 143]. Three of them did 
not find any association between NMSC and type of organ after controlling for different 
confounding variables. Adami et al. (2003) looked at kidney versus all other organ types 
and adjusted their analyses for age at transplantation and follow-up time [20]. Naldi et 
al. (2000) and Fortina et al. (2000) looked at kidney versus heart transplant recipients 
in multivariate analysis adjusted respectively for age, sex and type of treatment and for 
age, sex, type of treatment, type of skin, sun exposure, presence of keratosis and warts 
[98, 105]. A recent multicentre case-control study reported no association between the 
type of organ and the development of either BCC or SCC [148]. 
Two Norwegian studies based on the same data found respectively a 2.8 (95% CI: 1.2-
6.7) and a 2.9 (95%CI: 1.3 - 6.2) fold increased risk of SCC in heart transplant recipients 
compared with kidney transplant recipients after controlling for age at transplantation and 
type of treatment [23, 89]. Euvrard et al. (1995) found a higher frequency of tumours in 
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heart than kidney transplant recipients without controlling for any variables [111]. 
3.9.6 Number of rejections and number of transplantations 
• Number of rejections 
All studies but one did not find any association between the number of rejections 
and the development of NMSe in transplant recipients [110, 98, 19, 101, 92, 116, 
120, 94, 159]. 
• Number of transplantations 
All studies that examined the risk of developing NMSe with increased number of 
transplantations did not report any association [101, 94, 70]. 
Patients with higher number of rejections or transplantations might actually have spent 
less time on immunosuppressive therapy and might therefore be at lower risk of skin 
cancer. 
3.9.7 Actinic keratoses (AK) 
Actinic keratoses are pre-malignant skin lesions which are caused by long-term sun ex-
posure and are considered to be a precursor lesion of see. They consist of epidermal 
dysplasia affecting one to two thirds of the epidermis and are regarded by some as in 
situ see [93]. In one Australian study, fewer than 1/1000 AKs progressed to see [71]. 
Studies on transplant recipients reported similar findings for AKs to the general popula-
tion. Thus, AKs are more common on sun-exposed areas [101, 142,95] and their number 
increases with time since transplantation [145]. A significantly higher number of AKs are 
found in skin cancer patients in particular those with see [19,149,145,160,161,81,99, 
142]. In the Netherlands, 80uwes-8avinck et al. (1993) found a strong significant associ-
ation with number of keratoses (AK and other warty keratoses) and the presence of see 
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after controlling for sex, age at physical examination and skin type. Patients with more 
than 100 keratotic skin lesions were 21 times more likely to develop skin cancers than 
patients with fewer than 50 keratoses (95%CI: 5.3-81.7). Odds ratios for patients with 
SCC and BCC were respectively 54 (95% CI: 8.2-351) and 9 (95% CI: 2.0-43.8). The 
analysis was based on 29 patients with SCC, 16 with BCC and 96 controls. This study 
looked also at risk factors associated with development of keratoses in transplant recip-
ients and did not find any association with cumulative exposure to sunlight and with the 
number of episodes of painful sunburns [142]. An Australian study found that the number 
of AKs was clearly associated with outdoor occupations and fair skin colour [160]. A re-
cent multicentre case-control study based in the Netherlands, United Kingdom, Germany, 
France and Italy confirmed the strong association between the presence and number of 
keratoses (AKs and other warty keratoses) and the development of SCC and BCC in 
transplants patients [148]. The development of keratoses (AK and other warty keratoses) 
was clearly associated with time since transplantation, age and fair skin. 
3.9.8 Viral warts and non-HPV cutaneous infections 
• Viral warts 
Viral warts are benign hyperproliferative epithelial skin lesions induced by human 
papillomavirus (HPV) and, are particularly common among transplant recipients. 
Their prevalence is very high and increases with time since transplantation [101, 
95, 35, 156, 149, 93, 151, 162]. Barr et al. (1989) found that 20% of patients with 
5 or less years of follow-up developed viral warts and 77% of patients with more 
than 5 years of follow-up (P:::;0.001) [93]. In a French study looking at 152 patients, 
the prevalence of viral warts was 16% at the time of transplant, 23% at one year, 
35% at 3 years, 45% at 5 years and 54% at 7 years [162]. Viral warts are more 
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frequent on sun-exposed areas of skin and on patients who had a higher lifetime 
exposure to sunlight [102, 149]. Skin warts are often multiple, resistant to treatment 
and recurrent [35, 93, 162, 144, 149] and are sometimes difficult to distinguish 
from other keratotic lesions such as actinic keratoses and seborrhoeic keratoses 
[93,148]. Koranda et al. (1974) noticed that nearly all patients with warts report a 
history of having had them in childhood [156]. Most studies found an association 
between the presence of warts and the development of skin cancer in transplant 
recipients [19, 151, 141, 101, 148, 122]. However, the evidence suggests that warts 
are associated with the development of SCC but not with BCC [148, 105, 36]. 
• Non-HPV infections 
Immunosuppressed patients are susceptible to many infections such as cytomegalo-
virus (CMV), Epstein-Barr virus (EBV), hepatitis Band C viruses (HBV, HCV), her-
pes simplex virus (HSV) and varicella-zoster virus (VZV) [163]. Very few studies 
have reported results on infections other than HPV and their association with the de-
velopment of skin cancers [164]. Kelly et al. (1985) tested sera for antibody against 
HSV1, CMV, EBV, VZV, Adenovirus, Influenza A and Influenza B. Mean log-titres 
were compared between 6 groups: controls patients matched for age with trans-
plant recipients, haemodialysis patients, renal transplant recipients without cancer 
up to one year post-transplant, renal transplant recipients without cancer one to two 
years post-transplant, renal transplant recipients with NMSC three to eight years 
post-transplant. Differences in means were found for CMV and EBV with higher 
mean log titre in patients who underwent renal transplantation (P:::;0.01), interpreted 
as reflecting viral reactivation leading to a rise in antibody titres. No association with 
any infections and development of NMSC was found [164]. Boyle et al. (1984) found 
that renal transplant recipients have significantly more herpes zoster infections and 
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fungal infections than a control group matched for age and sex. They did not find 
any difference for HSV. However, no analysis of patients who developed skin can-
cers was performed [149]. Koranda et al. (1974) observed a higher prevalence 
of skin infections in transplant recipients: 43% had verrucae, 35% herpes simplex, 
13% herpes zoster and 18% tinea versicolor [156]. 
Following a recent report on a possible association between polyomavirus and 
Merkel cell carcinoma [165], Ridd et al (2008) examined 85 SCC and 37 KA for 
the presence of polyomvirus DNA and found that it was rare in both groups, with no 
difference between them [166]. 
3.9.9 Immunosuppressive drug treatment 
It is extremely difficult to identify which drug or combination of drugs, if any, is associated 
with the development of skin cancers. This is due to the high variation in doses and types 
of immunosuppressive drugs and to the introduction of new treatments over time. It is 
also problematic to assess the total intensity of immunosuppression in a given individual 
for a specific drug regimen, as this may not depend exclusively on dose. Furthermore, 
improvement in techniques over time such as HLA matching and awareness of the dan-
ger of sun exposure complicates the task of evaluating the impact of immunosuppressive 
drugs on skin cancer risk, and the interpretation of results presented in the literature has 
to be made with caution [103]. 
The Introduction of cic/osporin (1981) 
Before the introduction of ciclosporin, the conventional immunosuppressive regimen was 
azathioprine and steroids (CONV). Ciclosporin was then either used alone or in combina-
tion with CONV. From 1986, triple therapy based on azathioprine, ciclosporin and steroids 
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was the preferred choice (TRIPLE). Most studies have therefore looked at the introduction 
of ciclosporin as a risk factor for the development of skin cancers in transplant reCipients. 
These studies can be classified into 3 groups: 
those which compared-
• Ciclosporin +/-steroids versus CONV [103, 150, 167, 168, 23, 169, 170, 112, 171] 
• Ciclosporin +/-steroids +/-azathioprine versus CONV [157, 103, 172, 171, 168, 23, 
169,173,174] 
• Ciclosporin +/-steroids versus TRIPLE [171, 168,23, 169] 
There is no evidence of an increased risk of NMSC due to ciclosporin (+/- steroids) treat-
ments compared with CONV [103, 167, 23, 168, 169, 170, 112, 171]. Bunney et al. 
(1990) took follow-up time into account as patients on azathioprine have been followed 
longer than ciclosporin users and found the same prevalence of skin malignancies in both 
groups [170]. The only significant positive association was from a study based only on 63 
patients taking ciclosporin and 33 patients taking azathioprine. Furthermore, the asso-
ciation was reported only for a specific time period after transplantation (37-48 months) 
[150]. 
A randomised trial of 231 patients comparing low and normal doses of ciclosporin found 
a higher number of skin cancers (p::;0.05) in the group with higher doses after controlling 
for azathioprine dose. This study also found an increased risk for KS in normal dose of 
ciclosporin users compared with those on lower doses [175]. A Turkish study reported an 
increased incidence rate for KS with ciclosporin users compared with non-users but not 
for other cancers [21]. Penn et al. (1991) reported also a higher incidence of NHL and KS 
in ciclosporin users [176]. In several studies, an earlier development of skin cancers or 
other cancers in ciclosporin users has also been reported [177,157,30,174]. However. 
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this result might be confounded by age [177]. 
Patients on TRIPLE appear at higher risk of developing NMSC than patients using ci-
closporin either alone or with steroids or those using CONV [169, 23, 168, 174, 173]. This 
result seems stronger in patients with SCC than BCC [173, 169]. Jensen et al. (1999) 
found a 3-fold increased risk of skin cancers in TRIPLE versus CONV users (95%CI: 1.4-
5.3) after controlling for age at transplantation and type of transplantation [168]. Glover et 
al. (1997) supported this result with a 3-fold increased risk for NMSC. After stratifying by 
histological types, they found that TRIPLE users where eight times more likely to develop 
SCC than patients under CONV (95%CI: 1.3-54.8) and found a non significant higher 
risk for BCC. No adjustment variables were listed (e.g. age at transplantation, sunlight 
exposure, fair complexion) [173]. In contrast, three studies did not report increased inci-
dence rates of NMSC in TRIPLE users versus bitherapy users [105, 103, 171]. Blohme 
et al. (1992) compared crude prevalence at 5 years post transplantation and did not find 
any differences [171]. In addition, Bouwes-Bavinck et al. (1996) did not find also any 
increased risk of skin cancers in TRIPLE versus CONV users after controlling for age 
and sex of the patients [103]. 
Sirolimus (Rapamycin) and tacrolimus (FK 506) 
At one year after transplantation, tacrolimus is prescribed in 59% and 29% of new kid-
ney tranplant patients in the USA and in Australia respectively [178, 179]. The Cochrane 
review comparing "tacrolimus versus ciclosporin as primary immunosuppression for kid-
ney transplant" includes 123 reports of 30 trials (4102 patients). No difference in the 
incidence of new malignancies was found between the two groups up to five years after 
transplantation. The follow-up time was probably too short to detect any differences in 
skin cancer occurrences [180]. To my knowledge, there is no meta-analysis of the im-
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pact on therapy on skin cancer among OTR. A recent randomized controlled trial based 
on 121 liver transplant recipients receiving either tacrolimus and steroids or a quadruple 
regimen (ciclosporin, azathioprine, steroids and antithymocyte globulin) reported an in-
creased number of malignancies in ciclosporin users after a 12 year follow up. However, 
results on NMSC were not detailed. A better graft survival was clearly found for patients 
under tacrolimus, but the use of antithymocyte globulin at the start of the ciclosporin regi-
men was thought to be the main reason for the higher occurrence of malignancies in this 
group [9]. Several studies have suggested a decreased risk of malignancy in patients 
using treatment based on sirolimus [181, 182, 183]. However, the short follow-up time 
does not allow reliable conclusions [183]. 
Mycopheno!ate moteti! 
To my knowledge there is no study that has looked at the association of mycophenolate 
mofetil and the development of NMSC. 
Other medications 
The monoclonal antibodies OKT3 used to treat acute rejection in heart transplant recipi-
ents has been associated with an increased risk of lymphomas [184, 185, 186] but results 
vary [187, 188]. Two studies have reported an increased risk of skin malignancy in OKT3 
users compared with never users [188, 44]. Another study in immunocompetent people 
found a higher risk of SCC and BCC in corticosteroid users compared with their age and 
sex matched controls [189]. 
Summary 
There is not enough evidence that ciclosporin increased the incidence of skin cancers 
in transplant recipients compared with the conventional therapy. However, the addition 
of ciclosporin to CONV may increase the risk of developing NMSC. The overal intensity 
of immunosuppression rather than the specific drugs used might be the most important 
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factor for development of skin cancers but it is difficult to quantify [103, 190]. In relation to 
sirolimus, the short follow up does not allow definite conclusions. Confounding variables 
such as age, follow-up time and sun exposure would also have to be taken into account 
to examine associations between medication and skin cancers. 
3.9.10 Donor characteristics 
Studies examining the association between donor characteristics and development of 
skin cancers in transplant recipients are sparse. This might be due in part to publication 
biases i.e negative results were not published, but also to issues relating to confidentiality 
and consent. 
ABO blood group 
Three studies have reported results on the risk of skin cancer according to donor ABO 
blood group in renal transplant recipients, but no associations were identified [120, 96, 17] 
Donor age 
The use of elderly donors is becoming more frequent [191]. In renal transplant recipients, 
age of donor has been associated with a greater incidence of delayed graft functions, 
chronic allograft nephropathy, increase of cardiovascular disease and therefore worse 
survival [191, 192, 193]. Two studies mentioned age of donor but did not report any as-
sociation with development of skin malignancies [120, 96]. 
Donor sex 
No association has been reported with skin malignancies [120]. 
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Living or cadaveric donor 
Controversial results have been reported. Gruber et al. (1994), Ramsay et al. (2000) and 
Roeger et al. (1992) did not find any increased risk associated with the donor/recipient 
relationship [101, 157, 169]. However Bordea et al. (2004) found that renal recipients 
with living donors are at lower risk of developing skin cancers. This result remains statis-
tically significant after controlling for age at transplantation, sex of the recipient, length of 
immunosuppression and blood creatinine levels (OR=0.34 & 95%CI (0.14-0.82); p=0.02) 
but this result might be confounded by sun exposure [120]. It could also be argued that a 
better recipient/donor match implies a lower immunosuppressive treatment and hence a 
lower risk of skin cancer however living donor are not always well-matched and therefore 
might require higher immunosuppressive drugs. 
Transmission from donor 
Infections and malignancies can be transmitted from donor to recipient. Low risk of ma-
lignancy transmission has been reported [194, 195]. Birkeland et al. (2002) reported 
0.2% prevalence of transferring a cancer and 1.3% prevalence of having a donor with 
undetected malignancy [194]. Transmission of melanoma from a donor has been re-
ported [194, 196, 197] but there is no epidemiological evidence of BCC or SCC trans-
mission from a donor. However, two recent studies suggested that a BCC and some 
KS-associated HHV8 could have originated from non-malignant cells transmitted from 
the organ donor [198, 199]. These studies examined tumours in female renal reCipients 
who received a kidney from a male donor. 
Human Leukocyte Antigens 
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Since the discovery of the HLA system in the 1950s, new HLA sequences are contin-
uously being recognised. Consequently, early HLA typing might lack class II antigen 
results. Human Leukocyte Antigens (HLA) have been examined in two different ways to 
study their association with NMSC in transplant patients. Some studies have looked at 
HLA frequencies in patients with NMSC and those without [200,201,202,203, 116,204, 
102, 152, 205, 206]; other studies have looked at the degree of mismatch between donor 
and recipient as a potential risk factor [101, 102, 152, 203, 169, 116, 23, 17, 116, 207]. 
Studies are generally quite small and only two enrolled more than 100 cases [116, 203] . 
• Frequency of HLA sequences 
Conflicting results have been published on the association between HLA frequen-
cies and BCC [200, 201,202,203, 116,204, 102] or SCC [203, 201,202, 116, 152, 
205, 169, 204, 102] or all skin cancers [201, 202, 206, 203, 208, 116, 205, 102] or 
NMSC specifically [209]. Heterogeneous control groups have also been used (ei-
ther transplant recipients without skin cancers or healthy donors from the general 
population). Moreover some studies performed multiple tests for association with-
out taking into account chance findings. A few studies corrected their P-values for 
the number of performed tests [203, 201, 206, 203, 205] or specified that their HLA 
choice was prior to analysis [203, 201]. 
HLA-A 11 frequency: Early and small studies with numbers of cases varying from 
14 to 81 tend to show a protective effect of HLA-A 11 against NMSC [201, 202, 206, 
208, 205]. Bouwes-Bavinck et al. (1991) was the only study reporting significant 
results after correcting the P-value for number of tests. Two recent studies based 
on 271 and 152 cases have respectively reported a significant positive association 
[203] and no association [116]. Espana et al. (1995), Jensen et al (1999) and 
Bouwes-Bavinck et al. found no association either [102, 23, 142]. In 2004, Bock 
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et a/. reported that patients with NMSC were twice (95% CI: 1.1 to 3.5) as likely 
to be HLA-A 11 positive compared to those without NMSCS [209]. No association 
between HLA-A 11 frequency in controls and SCC or BCC can be concluded from 
the literature. 
HLA-DR7: Czarnecki et a/. (1992) found a statistically significant higher frequency 
of HLA-DR7 in patients with skin cancers compared to controls, but no P-value 
correction was reported [208] and Bouwes-Bavinck et a/ (1997) found the same 
trend, but their result did not reach statistical significance [203]. Another study 
found a statistically significant negative association [116] and three other studies 
did not report any associations [201, 202, 23, 209]. There is no evidence either of 
differences in HLA-DR7 frequency between controls and patients with BCC or SCC. 
HLA-B27: Eight studies have reported on HLA-B27 frequency and skin cancers 
[201,202,203,208, 116, 102,205,23,209]. Only Czarnecki et al (1992) reported a 
significant positive association (not corrected). Bouwes-Bavinck et al (1991) found a 
statistically significant higher frequency in renal transplant recipients compared with 
two different control groups (healthy donors and transplant recipients). This result 
did not remain statistically significant after correction when using renal transplant 
recipients as controls. The five other studies did not report any differences . 
• Level of HLA mismatch 
Bouwes-Bavinck et al. (1991) reported a positive association between the devel-
opment of SCC and increasing level of mismatches at HLA B loci [207]. They also 
found an increased risk of SCC with DR homozygosity whereas Ong et al. (1999) 
reported similar findings in patients with all NMSC [116]. None of these findings 
were corroborated by other authors and no association between level of HLA mis-
matches and the development of skin cancers in transplant recipients for class I and 
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II were reported [101, 102, 152, 203, 169, 116, 23, 17]. 
3.9.11 Other potential risk factors 
Hormones 
There is no information on the association of hormones and development of Bee or see 
either in transplant recipients, or in immunocompetent people. To my knowledge there is 
no study on vitamin D (a steroid hormone) and the development of NMSC in transplant 
recipients. 
Body mass index 
Kasiske et al. (2004) found a decreased risk of NMSC with increasing body mass index 
[158]. This result was controlled for donor status (living or cadaveric), hepatitis virus in-
fection, education, employment, donor race, donor age, HLA mismatches, and panel of 
reactive antibodies. 
Tobacco 
Studies which looked at all skin cancers did not find any significant association with smok-
ing in transplant recipients [92, 116, 120]. Of the studies that examined the association 
between smoking and different histology types, five reported an increased risk of devel-
oping sec in transplant recipients who smoked tobacco [19, 101, 146,82, 147] and one 
did not find any association [141]. A recent multicentre case-control study did not find 
consistent associations between smoking and the development of sec or Bee [148] 
between the 6 centres (United Kingdom, Australia, the Netherlands, Germany, Italy and 
France). 
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Alcohol 
Mithoefer et al. (2002) and Bouwes-Bavinck et al. (2008) did not find any associa-
tion between skin cancer development and alcohol consumption in transplant recipients 
[92, 148]. Conversely, Xiol et al. (2001) found a significant positive association between 
skin cancers and alcohol consumption in univariate analysis (p=0.04) [94]. 
Type and time on dialysis 
Three studies which looked at the association between the time spent on dialysis, the 
type of dialysis and the risk of developing skin cancers after transplantation did not find 
any association [101, 95, 120]. A recent American study found a significant protective 
effect with increased time on dialysis before transplantation [158]. This result was con-
trolled for donor status (living or dead), hepatitis virus infection, education, employment, 
donor race, donor age, HLA mismatches, and panel reactive antibodies but not sun ex-
posure. 
Family history of skin cancer 
Ramsay et al. (2000) and Mithoefer et al. (2002) did not find any link between family 
history of skin cancer and patients who developed skin malignancies [101,92]. 
Radiation history (other than exposure to ultraviolet radiation) 
Mithoefer et al. (2002) did not find any association between skin cancer development in 
transplant recipients and radiation history [92] and Ramsay et al. (2000) did not find any 
association with arsenic exposure [101]. 
Diabetes (primary disease) 
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Gruber et al. (1994) reported that non-diabetic patients are more likely to develop skin 
cancers than diabetics (RR=2.09; P=0.001) [157]. Roeger et al. (1992) also reported a 
lower significant risk of see in diabetics [169]. This is in agreement with a recent study 
in immunocompetent people that reported lower risk of NMSe in patients with type 2 di-
abetes mellitus using insulin [210]. However, only one study controlled for sun exposure 
[169] and it should also be borne in mind that non-diabetic patients might also live longer 
post-transplantation. Transplant patients with primary disease of diabetes were also less 
likely to develop NMSe than those without diabetes [211]. 
Creatinine 
Bordea et al. (2004) found that skin cancers in kidney transplant recipients are associated 
with high creatinine level at 1 year post transplantation. This result was still significant in 
multivariate analysis after controlling for age at transplantation, sex, length of immuno-
suppressive treatment and donor relation (cadaveric or living donor) [120]. However, this 
finding might be due to the intensity of immunosuppression which is difficult to assess. 
Blood transfusion 
There is no information on the association of blood transfusion and development of Bee 
or see in transplant patients. 
Education 
Bouwes-Bavinck et al. (2008) in a multicentre case-control study did not find an associa-
tion between see development and education but found higher risk of Bee with higher 
education after adjustment for age, sex, years after transplantation and study center. 
[148]. 
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3.10 Summary 
Transplant patients are at increased risk of skin cancers, in particular sec, in comparison 
with the general population (SIR from 18 [95% CI: 17 to 20] to 253 [95% CI: 172 to 334]). 
SCC occurs significantly more frequently than BCC and consequently a reversed see to 
BCC ratio is often reported in the transplant population compared with the general popu-
lation. NMSC are often multiple and recurrent and SCC behave more aggressively. NHL 
and KS occur on average earlier than NMSC. The cumulative incidence of skin lesions 
especially SCC increases sharply after transplantation. The time from transplantation to 
development of first cutaneous lesions varies from study to study due to differences in pa-
tients' age at transplantation. The distribution of the lesions on the body is similar in the 
general and transplanted population. A higher proportion of SCCs occur on sun exposed 
areas, whereas BCC is also more common on the trunk and the limbs. UV radiation is the 
principle agent responsible for the development of skin lesions and it is therefore crucial to 
collect information on it since it might confound the association between skin cancer and 
HPV. It is however not clear if sun exposure before and/or after transplantation or early 
and/or later in life is associated with an increased risk. Tobacco might also increase the 
risk of developing SCC. Patients with skin cancers are more likely to have pre-malignant 
lesions, such as actinic keratoses and carcinoma in situ, or viral warts. There is no clear 
evidence on the oncogenic effect of a specific immunosuppressive regimen. The level of 
immunosuppression and not a specific agent might be the most important factor for the 
development of skin cancers. However, the addition of ciclosporin to eONV may increase 
the risk of developing NMSC and sirolimus might be protective. It is not clear if males are 
at higher risk of skin cancers than females. Lower risk of skin cancer in diabetic patients 
has also to be taken with caution since the role of UV exposure has not been examined 
in some of these studies. Publications on donor characteristics (gender, age. blood type 
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and rhesus status) and skin cancers are sparse and there is so far limited evidence of 
any associations. There is also not enough evidence of an association between HLA mis-
matching or any HLA frequency and the development of NMSC in transplant recipients. 
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CHAPTER 4 
Literature review: Epidemiology of human papillomavirus in relation 
to squamous cell carcinoma and basal cell carcinoma 
4.1 Introduction 
The aim of this chapter is to describe the papillomavirus family, to describe the serological 
and genotyping methods for detection of HPV and to review the epidemiological evidence 
available to date on the association between HPV and the risk of sec and Bee in both 
transplant recipients and immunocompetent patients. Case-control studies have been 
used to examine the relationship between HPV and the development of see or Bee. 
4.2 Human papillomaviruses (HPV) 
In 1933, Shope and Hurst described the first mammalian tumour virus in cottontail rabbits 
in North America [212] but it was not until the late seventies that the virus was first cloned 
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and sequenced [213] _ Papillomaviruses are small circular double-stranded DNA viruses 
with sizes around 8kb. 
Figure 4.1: A human papillomavirus (from http ://www.virology.net) 
Their genome can be divided into three components. The early (E) genes code for pro-
teins involved in the regulation of viral transcription and replication (E1 and E2) , cell pro-
liferation (E5, E6 and E7), viral life cycle (E4) . Two genes with unknown roles (E3 and E8) 
are not present in human papillomaviruses. The late (L) genes contain two genes cod ing 
the capsid proteins L 1 and L2. The long control region (LCR) or upstream regulatory 
region located between the L 1 and E6 genes contains response elements and the origin 
of replication (Figure 4.2) . 
... 
I.CR --
!I 
Figure 4.2: Example of HPV genome (HPV16) 
The L 1 gene of the open reading frame (ORF) is the most comparable gene across all 
HPVs. This nucleotide sequence is used to identify new HPV types. In 1995, at the 
International Papillomavirus Workshop in Quebec , participants decided that a new HPV 
type is identified if its L 1 ORF is distinct by more than 10% from any existing HPV type . 
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At the time of writing, one hundred and eighteen papillomaviruses have been completely 
described of which 96 are human and 22 are animal types [214]. Classification has 
been modified over the years. This report uses the recent terminology from de Villiers 
et al. (2004) and focuses on human types only. HPVs can be partitioned into 'genera' 
which in turn can be split into 'species', and can be further subdivided into 'types' (Figure 
4.3). The HPV phylogenetic tree is formed of 5 genera called alpha, beta, gamma, mu 
and nu papillomaviruses. The DNA sequence of the L 1 ORF differs by more than 40% 
between genera. Within each genus, species have in common between 60% and 70% 
of their DNA sequence of the L 1 ORF. Within species, the L 1 ORF of HPV types have 
in common between 71 % and 89% of their DNA sequence. Types are also divided into 
'subtypes' and 'variants'. Subtypes and variants have respectively 90% to 98% and more 
than 98% of their DNA sequences in common with any HPV type of the same species. 
Alpha-papillomaviruses are the biggest genus and contain mucosal and cutaneous HPV 
types. The concept of high and low risk HPV types was introduced in 1985 by Zur Hausen 
[215], based on the strength of association with cervical cancer. In 2003, Munoz et al. 
put together data from 11 case-control studies and investigated in more detail the risks 
associated with various HPV types in relationship to the development of squamous-cell 
cervical cancer [216]. As a result, viruses with high and low oncogenic risks of genital 
HPV were better defined. Types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 
and 82 are carcinogenic and to some extent types 26, 53 and 66 also. The low risk 
group includes types 6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81 and CP6108. The beta-
papillomavirus genus is composed mainly of the HPV types with skin cancers occurring 
in the context of epidermodysplasia verruciformis (EV), a rare inherited skin disease. The 
next largest genus, gamma-papillomaviruses, contains 7 cutaneous HPV types and the 
two other genera, mu- and nu-papillomavirus, are small and contain respectively 2 and 1 
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cutaneous HPV. 
Genus 
Alpha-papiJ/omavirus 
Della-
papUlomaviru5 
Epsilon-papillomavirus 
Zeta-paplllomavirus 
Bota -
papiliomavirus 
Omikron-papiliomav irus 
XI-paplllomavlru$ 
Nu-papiliomavirus 
Figure 4.3: The HPV phylogenetic tree 
High risk mucosal HPVs cause cervical cancer but infection with some other types is also 
responsible for benign lesions of cutaneous and mucosal epithelia [217] . For instance, 
common warts seen on the skin of arm , hand and leg are associated with HPV 1, 2, 4, 
7, 27 and 57 ; flat warts are usually caused by HPV 3, 10 and sometimes 2 and are more 
common in immunosuppressed patients or patients with EV. Gen ital warts (condyloma 
acuminata) , oral warts and low-grade cervical squamous intraepithel iallesions are mainly 
caused by HPV 6 and 11. 
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4.3 Life cycle of HPV, host immune response and the role of 
E6 and E7 proteins 
• Life cycle of HPV (from reviews [218, 219, 215, 220, 221]) 
Most of the knowledge on the HPV life cycle is based on mucosal HPV. Papillo-
maviruses are thought to infect the host through abrasions in the epithelium with 
hair follicles being a probably route of entry for beta types. HPV is solely localised 
within the epithelium and infects basal keratinocytes probably stem cells at a low 
copy number. 
HPV enters the cells, uncoats and its DNA enters the host nucleus. Upon infection, 
the virus takes advantage of the replication mechanism of the cell to replicate its 
genome through the control of E1, E2 and, probably, of E6 and E7 proteins. During 
replication, the infected cell divides into a daughter cell that migrates towards the 
skin surface whereas the other cell remains in the basal layer and provides a viral 
reservoir for future cell division. The infected cells in the basal layer can remain for 
several years (latent infection). 
In uninfected epithelial, basal cells detach from the basement membrane and stop 
dividing. HPV is therefore challenged to replicate in nondividing cells approaching 
terminal differentiation. HPV proteins (E6 and E7) interact with the host cells pro-
teins to delay the death of the cell and to reactive viral DNA replication in the cell. It 
is however not understood how the virus starts initiating DNA replication. 
In the upper layers of the epithelium, the viral genome is highly amplified. At that 
stage, the late genes L 1 and L2, encoding the viral capsid, are activated when 
cell approaches terminal differentiation and virions are assembled. The new virus 
particles are shed with the dead skin cells and can spread to other hosts. 
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• Host immune response (from reviews [218, 220, 222, 215]) 
HPV replication depends on continued cellular division and the virus has therefore 
to adapt to a milieu where cell division has stopped. The virus stratagem is to 
replicate its viral genome and to express viral proteins in terminally differentiating 
cell and to be invisible to the host immune system. 
Under normal circumstances, infected cell should present on their surface spe-
cial molecules, known as class I and II major histocompatibility complex (MHC) 
molecules, to initiate an immune response. Class I molecules are found on virtu-
ally all cell types of the body and present endogenous antigen to cytotoxic T-cells 
(CD8). Class II molecules, particularly associated with B-cells, dendritic cells and 
macrophages, present exogenous antigen to helper T-cells (CD4). HPV evades 
the host immune mechanism by preventing antigen presentation. As HPV are not 
lytic and none or little inflammation is present, Langerhans cells, the main antigen 
presenting cells in the skin, are therefore not activated. Consequently, the innate 
immunity might not be triggered and the adaptive immunity is delayed. 
Production of cytokines is another mechanism of the host immune system to make 
virally infected cells more susceptible to be detected by dendritic cells and, there-
fore, to launch cell-mediated immunity. However, HPV can also downregulate cy-
tokine production and the interaction of E6 and E7 HPV proteins with type 1 inter-
ferons seems also to inhibit further cell-mediated immunity. 
Failure in HPV detection may lead to persistent infection and a higher probability of 
cervical cancer. In most cases of cervical cancer, the viral genome has been inte-
grated to the host cell genome. Despite HPV ability to manipulate the host immune 
system, around 80% to 90% of genital HPV infections are controlled or cleared by 
the host immune system. Around 10% to 20% of individuals have persistent infec-
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tion. 
• E6 and E7 proteins 
The mechanism of action of high risk HPV genital types is well understood and 
seems clearly to differ from cutaneous HPV types. The E6 and E7 proteins of 
high risk mucosal types have been associated with the degradation of p53 and 
retinoblastoma (Rb) respectively and their inactivation is necessary for induction of 
cervical cancer. The interaction of E6 and E7 proteins with the host proteins in-
duce cell abnormalities, continued cell proliferation and immortalisation. This phe-
nomenon has not been observed with low risk mucosal types such as HPV6 or 
HPV11. 
The transforming potential of E2, E6 or E7 proteins has been investigated for few 
beta HPV types (mainly HPV5, HPV8 and HPV38) [223, 224, 225, 226]. In contrast 
to high-risk mucosal types, the direct degradation of p53 was not observed with 
HPV5 or HPV8 E6 proteins [223, 224, 225, 226]. Some transforming potential has 
been reported for HPV38 in studies on animals or in vitro [227, 228] and particularly 
in relation with UV irradiation [229]. Jackson et al. (2000) reported that HPV5 E6 
proteins could also degrade another pro-apoptotic protein called Bak [230] and the 
transforming potential of diverse E6 HPV proteins following UV damage was also 
reported [231, 232] (for a review, [233]). Integration into the host DNA has only 
been reported once in metastastic lesions [234]. 
4.4 Methods of detection 
Papillomaviruses are difficult to culture in vitro but have been characterised by molecular 
methods based on DNA sequence homology. Most studies of NMSC over the past 15 
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years have focused on HPV DNA detection and genotyping. Cutaneous HPV type preva-
lence varies dramatically between such studies and this is mainly due to the detection 
methods employed. In contrast with genotyping methods which can only examine current 
infection, serology can detect past and present infection and, in anogenital infections, can 
be a marker of cumulative HPV 16 exposure [235] . 
• HPV-DNA detection 
The methods for HPV-DNA detection are divided into two groups based on am-
plification and non-amplification techniques. In the 1990s, the non-amplification 
techniques (Southern blot, dot blot hybridation, in situ hybridation, filter in situ hy-
bridation) have been replaced by DNA amplification techniques mainly due to their 
lack of sensitivity and specificity. 
The amplification techniques are composed of target-amplification (polymerase chain 
reaction also called PCR), signal-amplification [second or third version of Hybrid 
Capture (DIGENE, Gaithersburg, USA) also called HC2 and HC3] and of probe-
amplification (ligase chain reaction). 
HC tests consist of the denaturation of the specimen, the hybridisation with RNA 
probes, the capture of hybrids, the reaction with its conjugate and the production of 
light signals proportional to the amount of HPV-DNA present in the specimen. HC2 
can detect HPV types 6, 11, 42, 43, 44 and 59 so-called 'low' risk types and 16, 18, 
31,33,35,39,45,51,52,56,58,59 and 68, which are 'high' risk types for cervical 
cancers. 
Performing PCR tests involves denaturing the DNA in vitro by heating, 'annealing' 
or binding the two primers complementing a specific sequence at one end of the tar-
72 
4- Literature review: Epidemiology of human papilloma virus in relation to squamous cell c.3fCinoma and basal eel carcinoma 
get sequence, replicating or 'extending' the target sequence and repeating the last 
three steps. PCR can amplify very small amounts of DNA and hence produces suf-
ficient quantity of DNA to be analysed with conventional laboratory methods. peR 
and HC have similar sensitivity and specificity but most studies have used peR 
methods. PCR is a highly sensitive technique and contamination is the main issue 
of concern, which can lead to false positive results. Amplification by peR methods 
requires Tag primers and the choice of these primers is essential. Consensus (or 
general) primers target the conserved sequence in the HPV L 1 gene and degener-
ate primers are a mixture of primers and can detect a wider range of HPV types. 
New primers have been developed over time and the most commonly used primers 
from the HPV L 1 gene are: MY09/MY11 and GP5+/GP6+. They have been com-
pared in several studies [236, 237]. PCR techniques have permitted the detection 
of novel HPV types. The frequency and the range of HPV types identified in see 
vary widely between PCR assays [238, 239]. Recently, new methods using broad 
spectrum PCR (PM-PCR) combined with a reverse hybridation system (RHA) has 
been developed for betaHPV genotyping [240] . 
• Serology 
In the early 1990s, studies used Western blots with bacterially expressed major cap-
sid protein L 1 and early genes E6 and E7 of HPV8. Due to their lack of specificity 
this technique has been replaced by enzyme-linked immunosorbent assay (ELISA) 
techniques using HPV-type specific virus-like particles (VLP). ELISA techniques 
have to determine a cut-off value for positivity. Studies have employed different 
methods for calculating this threshold. Calculations are always based on a control 
group. One method of calculation consists of excluding people with readings higher 
than the mean plus 3 standard deviations (SO) and repeating this process until no 
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readings exceed the recalculated mean + 3SD [161]. Another method excludes 
readings higher than mean plus 3 SO, recalculates the mean of the remaining read-
ings and the cut-off point is chosen at the 90th percentile of this distribution [81]. 
New technology using an antibody detection method that is based on a glutathione 
S-transferase capture enzyme-linked immunosorbent assay in combination with flu-
orescent bead technology has recently been developed. This technology, called 
Luminex, can detect antibodies of up to 100 HPV types at the same time. More 
details are given in the following chapter. 
4.5 Humoral response to HPV infection 
The evaluation of HPV as a risk factor for cervical cancer has been recently reviewed by 
the Monograph Programme of the International Agency for Research on Cancer (IARC) 
[215]. Serology is a very useful epidemiological tool for defining past and cumulative 
exposure to HPV infection and the assays are reasonably type-specific [215]. 
Serology is less sensitive than genotyping methods and among cases whose tumours 
contained HPV 16 DNA, seropositivity ranged from 25% to 73% [241]. Hence, serology 
is not useful for screening but, in epidemiological studies, it has shown to be a good tool 
to detect an association between HPV infection and cervical cancer [235, 242, 243]. In 
prospective studies of cervical intra-epithelial neoplasia (CIN) or cancer of the uterine 
cervix, cases have been found to have a higher prevalence of antibodies against certain 
HPV types (in particular HPV16), prior to diagnosis, as compared to controls with relative 
risk from 2.5 to 30. For instance, in one prospective study of antibody levels against HPV-
16, women who subsequently developed invasive cervical cancer (28 out of 99 cases 
[29%]) within 10 years of sample collection were more than twice as likely to be HPV-16 
seropositive than controls (43 out of 194 [22%]) [244]. 
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HPV-DNA and serological data in prospective studies of mucosal HPV types and cervical 
cancer are in agreement [215]. Comparable findings have been reported in prospective 
studies of other established oncogenic viruses such as human herpesvirus-8 (in relation 
to Kaposis sarcoma) and hepatitis B (in relation to hepatocellular carcinoma), in which a 
higher than expected prevalence and titre of antibodies has been identified in blood taken 
years before diagnosis of cancer [245, 244]. 
The persistence of HPV infection is necessary for progression to high grade CIN or inva-
sion, but CIN lesions can also spontaneously regress [215]. Ho et al. (2004) examined 
the natural history of HPV16 virus-like particle antibodies in 608 young women and re-
ported that detectable levels of antibodies against HPV16 are associated with persistent 
high viral load in blood and/or persistent infection [241]. The median duration of anti-
bodies against HPV16 was 3 years [241]. The median time from HPV16 infection to the 
detection of antibodies has been reported to be between 8 and 12 months [241, 246]. 
The seroprevalence of HPV tend to be lower in men than women [215]. 
4.6 Epidermodysplasia verruciformis of Lewandowsky-Lutz (EV) 
and human papillomaviruses 
EV is a rare genodermatosis, characterised by disseminated and persistent warty lesions 
on the skin and was first described in 1922 by Lewandowsky and Lutz [247]. EV patients 
develop common and plane warts, depigmented pityriasis versicolor-like lesions and red 
wart-like lesions and plaques [248, 249, 250, 251]. First lesions appear usually during 
childhood; between 30% and 50% of EV patients develop skin cancers, essentially lo-
calised to sun exposed areas, between 20 and 40 years after the occurrence of their first 
benign lesions [252, 253, 254]. 
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In the late 1960s and early 1970s small case reports (between 1 and 14 patients) us-
ing light and electon microscopy reported a large number of viral particles in EV patients' 
lesions [255, 256, 257, 258]. With the development of hybridisation methods, it was possi-
ble to differentiate between these new HPV types. The first isolated types in EV patients 
were 3 and 4 which differed clearly from the known HPV1 and HPV2 associated with 
plantar and common warts [259, 250]. Clinical appearances and tendency to malignan-
cies were soon related to different HPV types. HPV3 was harboured in flat wart lesions 
with very rare progression to malignancies whereas HPV4 (nowadays called HPV5) was 
more likely to be present in very flat verrucous reddish lesions or plaques with oncogenic 
potential [260,249,248,250,261,251]. 
Early detection techniques identified new types only in EV patients and a few immuno-
suppressed people [214, 262, 263, 264, 265, 266, 267]. As a result, these new HPV 
types were called "EV-HPV types". With the development of new extremely sensitive 
techniques, such as PCR and the use of degenerate primers, a wide range of HPV types, 
included EV-types, are now found not only in EV patients but also in hairs, lesions and 
normal skin of immunocompetent and immunosuppressed people of patients with psori-
asis [268, 145, 269, 270, 271, 272, 273, 274, 275, 276, 277, 117, 278, 279, 280, 239]. 
Consequently, some authors have questioned the terminology 'EV-HPV types' since their 
presence is not restricted to EV patients [281]. 
Today the so-called EV-types are within the beta papillomvairus genus and include: 5, 
8, 9, 12, 14, 15, 17, 19-25, 36-38, 47, 80 and 93 [282, 214, 262, 263, 264, 265, 266]. 
Multiple HPV infections are extremely common in EV-patients [283, 263, 252] and types 
5, 8, 14, 17, 20 and 47 have been suggested to be oncogenic [262, 260, 283, 284, 285]. 
Recently, Oell'Oste et al. (2008) examined 4 EV patients (at least 3 Italian patients) and 
reported higher titers for 16 betaHPV and to a less extent to 9 gammaHPV compared to 
76 
4- Literature rlNiew: Epidemiology of human papiflomavirus in relation to squamous cell carcinoma and basal cell caronoma 
54 sex and age-matched German controls [286]. HPV-DNA of type 5 was found in the 
skin cancer of one patient and up to 18 beta-HPV genotypes were found in eyebrow hairs 
and skin samples. 
EV-HPV particles have been rarely found in premalignant and malignant lesions [262, 
258,266, 287]. Integration into the host DNA has only been reported once in metastastic 
lesions [234] and recently, two mutated genes EVER1 and EVER2 have been associated 
with EV [288, 289]. 
However, the rarity of EV does not favour epidemiological studies and no definite conclu-
sion on the association between HPV and development of see can be assessed. 
4.7 Current epidemiological evidence for the risk of sec and 
Bee from HPV 
4.7.1 Using genotyping methods 
HPV-DNA prevalence varies widely from study to study in part due to a number of factors 
including the immunosuppressed status of the patient, the choice of sample (hairs, skin 
swabs, peri-Iesional samples, biopsy of lesions or normal skin, unique or multiple sam-
ples per patient), the use of different peR methods (nested, specific or degenerate), the 
choice of primers and the number of HPV types tested. Forslund et al. (2004) reported 
higher HPV positivity in samples from the top of both healthy skin and skin cancer than 
inside the tumour [290]. It is also important to note that most studies were based on small 
numbers and there is no study that looked at both immunocompetent and immunosup-
pressed patients with more than 50 people . 
• Case-control studies (Appendix A) 
A systematic review was performed through a Pubmed search using synonyms for 
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relevant words on studies reporting on HPV genotyping and sec, and published 
up to October 2008 [search terms: BCC, SCC, DNA, HPV, genotyping, skin can-
cer, cutaneous, non-melanoma, transplant, general population, immunocompetent]. 
supplemented by searches of references in identified papers, by hand searches of 
relevant journals. No restriction was placed on language of publication. No attempt 
was made to identify unpublished studies or to obtain unpublished data from pub-
lished studies. All published case-controls reporting on the association between 
SCC and/or BCC and HPV-DNA positivity were included in this review. 
Fourteen case-control studies have considered the presence of HPV-DNA in pa-
tients with NMSC and patients without. Eleven studies have been undertaken in 
immunocompetent patients [291,292,147,278,293,294,295,296,153,297,298] 
and three in both immunocompetent individuals and renal transplant recipients 
[268, 145, 299]. The presence of HPV-DNA was examined in plucked hairs from 
eyebrows, scalp, arm and leg [291, 292, 147, 145, 299, 297], or skin biopsies 
[278, 268, 276, 153, 298] or skin swabs [295]. Most studies were based on primers 
from the L 1 gene but E7 gene [297, 292, 147] and E 1 gene [278, 298] were also 
used. Two studies using primers from the E7 gene seemed to be based on the 
same data and found similar results [292,147]. 
In 2000, Boxman et al. undertook the first case-control study with 51 BeC, 25 
SCC and 89 controls and found no statistically significant association between the 
presence of EV-HPV DNA in plucked hairs from eyebrow, scalp, arm and legs and 
the development of SCC (unadjusted OR: 2.0 and 95%CI: 0.5 to 80.0) [291]. eases 
were matched for age and sunscreen allocation, and primers were from the L 1 
region. No association was reported between the development of BCC and EV-
HPV DNA positivity. 
78 
4- Literature review: Epidemiology of human papilloma virus in relation to squamous cell carcinoma and basal ceO carcmom.3 
Three and four years later, two studies carried out in Leiden looked at the presence 
of HPV-DNA (5, 8, 15, 20, 24, 38; plus 2 and 16 in [292]) in plucked hairs in 155 
and 156 individuals with SCC and 371 and 320 controls respectively [147, 292]. 
They used primers from the same region of E7 and got similar results. Individuals 
who were positive to any beta-HPV DNA were twice as likely to have SCC than the 
beta-HPV DNA negative people (unadjusted OR and 95% CI: 1.4 to 3.2 and 1.3 to 
3.2 respectively). The result was still statistically significant after adjustment for age 
and sex [292] and age, sex, skin type, sun exposure and painful sunburns [147]. 
Only HPV 5, 8, 20 were found to be associated with the development of sec after 
controlling for these variables. No association between HPV 16 or HPV 2 and see 
was reported [292]. 
Two case-control studies examined skin biopsies [278, 268] and used primers from 
E1 and L 1 genes respectively. Iftner et al. (2003) looked at mucosal types (16, 
31, 33, 35 and 51) and beta-types (5, 8, 12, 17, 19, 22, and 36) and Harwood et 
al. (2004) examined skin biopsies for the presence of all HPV-DNA types. Iftner 
et al. (2003) examined the HPV-DNA prevalence in 72 patients with SCC and 106 
controls. The risk of SCC was thirty times higher in patients who were positive 
for any HPV types compared with those who were negative after controlling for 
age, sex and location of skin lesions (95%CI: 10.9 to 83.0) [278]. Harwood et 
al. (2004) examined 39 immunocompetent individuals (57 samples) and 38 renal 
transplant patients (67 samples) with and without NMSC and reported a statistically 
significant association between beta-HPV positive (OR: 6.4; 95%CI: 1.8 to 22.9) 
and the development of NMSC after controlling for transplant status, sex and either 
location on the body from which the sample came (sun exposed or not) or number 
of samples per individuals. A non-statistically significant positive association was 
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reported between positive for any HPV types and the development of NMSC and 
a non-statistically significant negative association was noted between cutaneous 
HPV types specifically, and the development of NMSC [268]. 
In a case-control study involving 54 patients with xeroderma pigmentosum, skin 
biopsies of 40 SCC were 3 times more likely to be HPV-DNA positive to any types 
(95%CI: 0.6 to 37.7) or to beta types (95% CI: 0.5 to 34.2) compared to those from 
9 samples from healthy skin [294]. There was no difference between BCC and 
healthy skin biopsies. 
In 2006, Struijk et al. looked again at HPV-DNA using primers from the E7 gene for 
type 5, 8, 15, 16, 20, 24 and 38 using plucked hairs from 64 cases and 58 tumour-
free individuals and they reported negative non-significant associations for each of 
the HPV type examined [297]. Using skin biopsies, Andersson et al. (2008) and 
Forlsund et al. (2007) reported higher odd ratios in patients with SCC compared to 
those without lesions for detection of HPV-DNA of any types (OR: 2.1; 95% CI: 1.0 
to 4.2) and in particular for beta types of species 2 (OR: 4.4; 1.9 to 10.1) [293, 153]. 
No association with HPV-DNA of beta types from species 1 was identified, and BCC 
was not related to the presence of HPV-DNA. Asgari et al. (2008) examined 72 SCC 
and 121 benign lesions and found no difference in presence of beta HPV-DNA after 
adjusting for sex, age, location of lesions, previous sunburns and smoking [296]. In 
a case-control study looking at 101 SCC and 101 BCC, the proportion of SCC with 
HPV-DNA was compared to BCC [298]. No difference was found for infection to any 
betaHPV but, SCC were more likely to have HPV-DNA of betaHPV types of species 
1 . 
In summary, very few studies gave informative results with large CI and, overall, 
there is no consistent association between the presence of HPV DNA and SCC. 
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• HPV-DNA prevalence (Appendices B and C) 
- Prevalence of HPV-DNA in skin and hair follicles from patients with SCC or BCC 
(Appendix B) 
Among immunocompetent people with see, the prevalence of HPV-DNA positivity 
varies from 19% to 84% in any samples and from 13% to 83% in patients [300, 301, 
277,238,117,276,302,303,304,160,278,297,153,296, 293, 298], wheffias 
in renal transplant recipients with see the prevalence in samples varies between 
50% and 91 % and in patients between 50% and 84% [305, 301, 306, 277, 238, 
279,276, 302, 145,307, 303]. Studies examined mainly skin biopsies and only four 
used plucked hairs [291, 292, 147, 297]. Only 2 studies had more than 100 cases 
and reported that 71 % and 84% respectively of patients with see were HPV-DNA 
positive [147, 298]. 
A lower prevalence has generally been reported in patients with Bee. A study us-
ing plucked hairs reported that 61 % of immunocompetent patients with Bee were 
beta HPV-DNA positive [291]. Studies using skin biopsies found from 8% to 78% 
HPV-DNA positive samples in immunocompetent patients [278, 301,277,303, 160, 
290,280, 308, 293, 153] and 0% to 83% of samples from renal transplant patients 
[305, 301, 277, 279, 145, 303, 269, 280, 308, 239]. Between 21% and 78% of 
immunocompetent patients [291, 277, 117, 280, 298] compared to 75% of renal 
transplant recipients were found to be HPV-DNA positive [277]. 
- Presence of HPV-DNA in normal skin, psoriasis, peri-Iesional samples, Bowen s 
disease and actinic keratoses, viral warts and patients with other conditions (Ap-
pendix C). 
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The prevalence of HPV-ONA in normal skin samples of immunocompetent people 
varies between 13% to 54% [309, 302, 308, 268, 278, 276, 275, 296, 293] and in 
renal transplant recipients it ranges between 11 % and 87% [302, 308, 279, 268, 
145, 269, 276]. The prevalence increases when normal skin biopsies come from 
patients with psoriasis or connective tissue diseases [274, 271,276,310,311]. 
Highest HPV-ONA prevalence has been reported in viral warts where more than 
three quarters of patients' tested samples are HPV-ONA positive [302, 279, 276, 
278, 270, 269, 239, 308]. All viral warts are expected to be HPV-ONA positive and 
lower prevalence indicates a lower sensitivity of the methodology used or might be 
due to misdiagnosis. More than three quarters of samples from patients with psoria-
sis have also been reported to be HPV-ONA positive [272, 273, 274, 269, 275, 311]. 
Biopsies from AK and/or BO have also shown a high prevalence of HPV-ONA rang-
ing from 11 % to 70% in immunocompetent patients [302, 308, 278, 280, 290, 277, 
117,278,312,313, 153,293,295] and between 0% and 88% in renal transplant 
recipients [302, 308, 279, 145, 280, 239, 277]. High proportions have also been 
reported in peri-Iesional samples [309, 290, 30, 280, 296], in skin swabs [281] and 
hair follicles of patients with or without NMSC [307, 299, 291, 160,308,314]. 
- HPV types 
No HPV-ONA from predominant types has been consistently found in samples. 
Beta types seem however to have a higher HPV-ONA prevalence than other types 
[239, 238, 308, 314, 310, 293, 296]. PCR is such a sensitive tool that new HPV 
types are found in many studies [279,301,276,291,305,239,307,145,310,281]. 
Multiple HPV-ONA types are commonly found in a single sample [280, 277, 291]. 
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- HPV-DNA cutaneous type prevalence from 3 continents 
One study has been undertaken in several countries to compare prevalence. In 
2000, Antonsson et al. studied HPV-DNA in skin swab samples of immunocompe-
tent people from Bangladesh, Japan, Ethiopia, Sweden and Zambia. Respectively 
68% (34/50), 54% (26/48), 52% (26/50), 70% (35/50), 42% (21/50) were found 
positive to any HPV-DNA. Eighty eight HPV types and putative types were found 
of which 22 were new. Thirty nine percent of the samples (53/137) had multiple 
infections. Respectively, 12, 9, 9, 18 and 2 types were exclusively found in these 
countries. HPV-5 was the only single type to be detected in the five countries and 
was present in 6.5% (16/248) of all tested samples [315]. 
4.7.2 Using serological methods 
A systematic review was performed through a Pubmed search using synonyms for rel-
evant words on studies reporting on HPV genotyping and see, and published up to 
October 2008 [search terms: Bee, see, serology, antibodies, HPV,skin cancer, cuta-
neous, non-melanoma, transplant, general population, immunocompetent, VLP, Luminex, 
ELISA], supplemented by searches of references in identified papers, by hand searches 
of relevant journals. No restriction was placed on language of publication. No attempt 
was made to identify unpublished studies or to obtain unpublished data from published 
studies. All published case-controls reporting on the association between see and/or 
Bee and antibodies against HPV were included in this review. 
Twelve case-control studies have looked at the association between HPV and NMSC 
using serological methods [316, 317, 318,161,271,306,146,81,147,153,297,319]. 
All studies but one examined immunocompetent patients only. The common HPV types 
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investigated were HPV1, HPV5, HPV8, HPV9, HPV15, HPV16, HPV20, HPV23, HPV24, 
HPV36 and HPV38. One study also examined more alpha HPV types (HPV6, HPV10, 
HPV32 and HPV57) [153]. Most studies based on ELISA used IgG-specific ELISA with 
VLP composed of the major L 1 capsid protein of the specific HPV type and most recent 
studies used the Luminex technology looking at antibodies against L 1 capsid protein of 
HPV types. 
Figures 4.4 and 4.5 show results of all case-control studies that used serology for all 
betaHPV types tested and 2 alpha types HPV1 and HPV16. Figures include results 
on L 1 protein. Cases are respectively patients with SCC (Figure 4.4) or BCC (Figure 
4.5) and controls are those without the disease. Heterogeneity was observed between 
studies and very wide 95% CI were also found. The number of positive sera varies 
markedly between studies for both cases and controls, suggesting that methods detecting 
serological response might vary with respect to sensitivity. For example, studies have 
shown that 4% to 73% of sera from patients with SCC harbour antibodies against HPV8 
(Figure 4.4). Only four studies controlled for crucial confounding factors such as UV 
radiation [161, 146, 81, 153] and these studies suggest an association between HPV5 
and SCC. Only one study has examined antibodies against E6 protein of HPV types 
[297]. They reported non-statistically significant at 5% level negative associations with 
SCC and all examined HPV types (HPV8, 15, 20, 24, 38 and 16). 
From this review there is no consistent evidence that immunocompetent patients with an-
tibodies against any single HPV types examined have a higher risk of developing see 
or BCC than controls. Patients with antibodies against HPV8 were associated with pres-
ence of SCC in some studies but this result was not corroborated in a recent study with 
larger number of patients [319]. This largest study has only find a statistically significant 
(at 5% level) association between SCC and HPV 5. Significant findings were actually 
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associated with studies with less power suggesting evidence of publication bias. Overall 
HPV5 might be associated with the presence of see but more studies are needed to 
clarify the association. A recent study from Andersson (2008) [153] looked also at other 
alpha types (HPV6, 10, 32 and 57) but did not find any association with SCC. 
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First author, Year Country 
Laborato t:f~m.~r % _ 
Method feclimqu~ ~Is PositIVe OR (95%CI) OR & 95%CI 
BETA Gf:NU5 
traV-5 avre, 2000 France/Poland A ELISA 6/119 0/5 NA 
Feltkamp, 2003 The Nethe~ands A ELISA 160/333 1/0.3 2.6 (0.2-31.9)* 
Karagas, 2006 USA A Luminex 2521461 7/11 1.7 (1.0-3.1)est 
-B 1.8 (1.0-3.1 ) •••• 
Andersson, 2008 Sweden A Luminex 721121 19/13 1.6 (0.7-3.7)···· ... 1 
HPV·8 
Steger, 1990 Germany A Western blot 11/445 73/20 10.7 (2.5-63.2) .. 1 • 
Stark,1998 Germany A ELISA 14/210 71/8 30.3 (7.4-142.5) ... • t Stark,1998 The Nethe~ands A-Tx ELISA 30/89 27/23 1.3 (0.4-3.5) ... 
Bouwes-Bavinck, 2000 The Nethe~ands A ELISA 13/82 69/45 3.1 (0.7-13.3)·· 
Feltkamp, 2003 The Netherlands A ELISA 160/333 4/0.3 14.7 (1.6-135.0)· t 
Masini, 2003 Italy A ELISA 46/84 57/32 3.2 (1.3-7.9)··· • Karagas, 2006 USA A Luminex 2521461 16115 1.1 (0.7-1.7)est -
--
B 1.2 (0.8-1.8)···· 
Struijk, 2006 Australia A ELISA 64/58 2213 7.8 (1.7-73.4). • I 
B 9.3 (1.9-45.6)· 
Andersson, 2008 Sweden A Luminex 721121 29/26 1.2 (0.6-2.4)····· .. 1 
HPV·9 
Karagas, 2006 USA A Luminex 2521461 9/9 1.0 (0.6-1.8)est 
B 1.0 (0.6-1.8)"··· 
Andersson, 2008 Sweden A Luminex 721121 21/12 1.5 (0.7-3.2)"···· •• 1 
HPV·15 
Feltkamp, 2003 The Netherlands A ELISA 160/333 4/2 1.8 (0.6-5.6)·· 
Masini, 2003 Italy A ELISA 46/84 35/48 0.4 (0.2-0.9)··· • Karagas, 2006 USA A Luminex 2521461 10/9 1.2 (0.7-2.0)est ,-I-
B 1.3 (0.8-2.3)···· 
Struijk, 2006 Australia A ELISA 64/58 16/5 3.4 (0.8-20.0) ... 
B 3.8 (0.9-15.8)* 
Andersson, 2008 Sweden A Luminex 721121 18/17 1.1 (0.5-2.6) .. 1 .. 
HPV-20 
r-
Feltkamp, 2003 The Netherlands A ELISA 160/333 5/2 2.2 (0.8-6.7)·· 
Karagas, 2006 USA A Luminex 2521461 10/6 1.7 (0.9-3.1)esl -
-B 1.7 (0.9-3.0)···· 
Struijk, 2006 Australia A ELISA 64/58 810 NA 
B NA 
Andersson, 2008 Sweden A Luminex 721121 13/13 0.9 (0.3-2.4)···· ... , 
HPV·23 
Masini, 2003 Italy A ELISA 46/84 15112 1.0 (0.3-3.3)··· 
HPV-24 
-Feltkamp, 2003 The Netherlands A ELISA 160/333 13n 1.5 (0.8-2.9)·· ... -
Karagas, 2006 USA A Luminex 2521461 7/6 1.1 (0.6-2.2).'1 
-B 1.2 (0.6-2.2)···· 
Struijk, 2006 Australia A ELISA 64/58 13n 1.9 (0.5-9.2)est 
B 2.6 (0.7-9.7)·· 
Andersson, 2008 Sweden A Luminex 721121 17/11 1.7 (0.6-4.2)····· •• , 
HPV-36 
Masini, 2003 Italy A ELISA 46/84 20/8 2.8 (0.8-10.0)*" 
Karagas, 2006 USA A Luminex 2521461 4/6 0.8 (0.3-1.6)est 
B 0.8 (0.4-1.8)*'" 
Andersson, 2008 Sweden A Luminex 721121 m 0.9 (0.2-3.2)···· ... 1 
HPV-38 
3.0 (1.1-8.4)" Feltkamp, 2003 The Netherlands A ELISA 160/333 6/3 • 
Karagas, 2006 USA A Luminex 2521461 13/11 1.3 (0.8-2.1)est -
--
B 1.3 (0.8-2.1 ) •••• 
Struijk, 2006 Australia A ELISA 64/58 210 NA 
B NA 
Andersson, 2008 Sweden A Luminex 721121 25/18 1.5 (0.7-3.2)*·· .... 1 --
ALPHA GENUS 
~V-16 tark,1998, Germany A ELISA 14/210 312 1.7 (0.7-3.7) 
Feltkamp, 2003 The Netherlands A ELISA 160/333 17110 1.5 (0.4-5.6)*' 
Struijk, 2006 Australia A ELISA 64/58 612 3.8 (0.4-190.3)"1 
B 7.9 (0.8-81.7)* 
Andersson, 2008 Sweden A Luminex 721121 11/10 1.1 (0.4-3.2)····· esl 
MUGENUS traV-1 avre, 2000 France/Poland A ELISA 6/119 33/19 2.1 (0.2-15.5) 
Andersson, 2008 Sweden A Luminex 721121 21/18 1.2 (0.5-2.6)··· .... 1 
I I I I I 1 1 .J 
~~IAbletients fri 0, :1: con l~nfe8~~al tive to.thls HPV Iv o 0.5 2 4 8 16 32 64 iPnb'-~&llPalive In aI/ art'Aryses 
e nd ew colour and sun eXllOSure . 
of lRefla\!! ~ro'eSSlonal or recreatIonal sun exposure and eye cofour 
~~~r.~ly~·i!ye oofour, sunburn history and location of lesion 
Figure 4.4: Studies of cutaneous squamous cell carcinoma in relation to the detection of antibod-
ies against L 1 protein of some beta, alpha and mu HPV types. 
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s~UdJr' Year 
o ntrv Method tee nlQue 
~~J.:G~~US 
Favre et al. 2000 A EliSA Fr~ncelPOland 
Felt am~ et al. 2003 A EliSA The Ne e~ands 
K'U~ias et al. 2006 A Luminex 
B 
HPV-8 
SteRar at al. 1990 A Wastern blot 
G rm~ny St~ a al. 1998 A EliSA 
rma~ St~rk at I. 1998 A·Tx EliSA 
he Netl~rlands B~~as- avinck et al. 2000 A EliSA 
Netherlanr F~tkam~ et a . 2003 A EliSA 
he Ne he~ands 
K'U~ias et al. 2006 A Luminax 
B 
Wieland et al. 2000 Germany A EliSA 
HPV·9 
K'U~ias et al. 2006 A Luminex 
B 
H~V.15 ~tk~~ at al. 2003 A EliSA he e herlands 
Wialand at al. 2000 A EliSA ~ermand 'U~i s at al. 2006 A Luminax 
B 
H~V'20 ~hk~~ at al. 2003 A EliSA e e erlands 
K'U~ias at al. 2006 A 
B 
Luminex 
HPV-23 
NONE 
H~V'~4 
alt am~ et al. 2003 The Neth rlands A EliSA 
K'U~ias et al. 2006 A Luminex 
B 
HPy.~6 
A ELISA Wle and at al. 2000 
~erma:;r 'U~i s et al. 2006 A Luminex 
B 
H~V.38 ~tkam~ at al. 2003 he Ne erlands A EliSA 
~tf§lias at al. 2006 A Luminex 
B 
ALPHA GENUS 
H~V'16 EliSA ~tkam~ at al. 2003 A he Ne erlands 
~ialand at al. 2000 A ELISA 
rmany 
MU GENUS 
H~V'1 A EliSA !f=vre at al. ~2000) 
rancelPola d 
Number 
Casesl 
controls 
34/119 
N: 291/333 
S.:141/333 
525/461 
60/445 
14/210 
18/89 
19/82 
N: 291/333 
S.:141/333 
525/461 
40/200 
525/461 
N: 291/333 
S.:141/333 
40/200 
525/461 
N: 291/333 
S.:141/333 
525/461 
N: 291/333 
S.:141/333 
525/461 
40/200 
525/461 
N: 291/333 
S.:141/333 
525/461 
N: 291/333 
S.:141/333 
40/200 
34/119 
Positive 
315 
1/0.3 
010.3 
717 
40/20 
35/8 
22123 
32145 
210.3 
5/0.3 
11115 
18/16 
6/9 
212 
3/2 
515 
7/9 
5/2 
6/2 
6/6 
11n 
1217 
4/6 
13/13 
3/6 
213 
3/3 
8/11 
212 
4/2 
5/11 
29/19 
OR (95% CIl 
0.6 (0.01-5.0) 
3.7 (0.5-38.4)" 
NA 
1.0 (0.6-1.7) ... 
1.0 (0.6-1.7)···· 
2.7 (1.4-4.9) 
30.3 (7.4-142.5) ... 
1.0 (0.2-3.6) 
0.7 (0.2-2.4)" 
9.2 (1.1-78.2)·· 
17.3 (2.1-143)"· 
0.7 (0.5-1.0) ... 
0.7 (0.5-1.0)···· 
1.1 (0.4-2.9) 
0.7 (0.4-1.1)est 
0.7 (0.4-1.2)···· 
1.2 (0.4-3.6)"· 
1.5 (0.4-5.3)·· 
1.1 (0.1-5.7) 
0.8 (0.5-1.3)est 
0.8 (0.5-1.3)···· 
3.2 (1.3-7.9)*· 
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Figure 4.5: Studies of cutaneous basal cell carcinoma in relation to the detection of antibodies 
against L 1 protein of some beta, alpha and mu HPV types. 
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4.8 Association between HPV prevalence, UV exposure, sex 
and age 
Harwood et al. (2004) did not have enough statistical power to draw conclusions on the 
association of HPV-DNA positivity and sun exposure [268]. Struijk et al. (2003) and 
Forlsund et al. (2008) reported a higher EV HPV-DNA prevalence in males than in fe-
males and did not find any association with sun exposure [292, 293]. De Jong-Tieben 
et al. (2000), however, noticed a higher EV-HPV DNA prevalence in samples on sun 
exposed areas compared with those from non exposed locations. This result was only 
found in patients with skin cancers [160]. Two studies have reported an association be-
tween HPV-DNA positivity and sun exposure [147, 160]. Sunburn episodes between 13 
and 20 years was associated with higher EV-HPV DNA prevalence compared with people 
who never had any and lifetime sun exposure was inversely associated with HPV-DNA 
prevalence [147]. EV-HPV DNA prevalence was also found to be higher in plucked hairs 
of patients with any outdoor occupation (mainly indoor occupations versus in and outdoor 
occupation (OR: 1.82; 95%CI: 1.20 to 2.76) versus mainly outdoor occupation (OR: 2.53; 
95%CI: 1.52 to 4.23). These results were not controlled for any other factors [160]. 
HPV-DNA prevalence has been found to increase with increasing age in some studies 
[281, 160, 292, 320] but not all [147, 319, 153, 316, 318] . The largest previous study of 
HPV seroprevalence in the immunocompetent population reported on age and sex distri-
butions of alpha, beta, gamma, nu and mu HPV types among 1797 German adults and 
children [320]. Overall, detection of antibodies against nu and mu types was evident in 
childhood whereas seroprevalence to alpha types was higher in women after puberty; 
seroprevalence to beta and gamma types was found to increase with age. Other studies 
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have reported only on beta HPV seroprevalence and risk factors among immunocompe-
tent individuals [147, 319,153,146,316,318]. Termorshuizen et al (2004) reported no 
association in 313 controls patients between seropositivity to any of 6 beta HPV types 
(HPV5, 8, 15, 20, 24 or 38) and age, sex, skin type, lifetime sun exposure and painful 
sunburns at different age periods [147]. Karagas et al (2006) also reported that seropos-
itivity to any of 8 beta types (HPV 5, 8, 9, 15,20, 24, 36 or 38) in 461 immunocompetent 
patients without skin cancer did not differ in terms of age, level of education, smoking 
status, skin phototype and number of sunburns but noted higher beta seroprevalence in 
men compared to women [319]. Andersson et al (2008) looked at 434 immunocompe-
tent patients with and without skin cancer (basal and squamous cell carcinoma) and also 
found no relationship between age, sex, skin type, smoking and previous sunburn and 
seropositivity to any beta types (HPV 5, 8, 9, 10, 15, 20, 24, 36 and 38) [153]. Only 
Feltkamp et al (2003) found a statistically significant (at 5% level) association between 
unadjusted seroprevalence of HPV24 and increasing age and male sex in immunocom-
petent patients [146]. Psoriasis patients treated with psoralen and UV-A (PUVA) have 
also been found to have high seropositivity [318]. 
4.9 Summary 
Case reports on patients with the rare inherited skin disease EV suggested that specific 
HPV types such as 5 and 8 might be involved in the development of skin cancers in EV 
patients. As a result, these HPV types were called EV-types. It is however not possible to 
make definite conclusions on the basis of these earlier reports in such a rare condition. 
Furthermore, following the improvement of HPV-DNA detection methods such as PCR, 
EV-HPV DNA (now termed beta HPV) types were not only found in EV patients. Many 
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HPV types appear to be ubiquitous and persistent in normal skin, hair follicles, psoriasis 
and other hyperproliferative skin lesions. Higher HPV-DNA prevalence has been sug-
gested in immunosuppressed people compared to immunocompetent ones, but data are 
sparse and studies are based on small numbers. 
The interaction between the immune system and HPV is complex and not fully under-
stood. The oncogenic mechanism of the E6 and E7 proteins of HPV high risk genital 
types is well known but the same properties have not been established for other HPV 
types of relevance to skin cancers. Even if EV-associated SCC suggest a role for HPV, 
there is no integration of viral DNA into the host genome. It would therefore imply that if 
HPV plays a role in skin carcinogenesis it is via a different and complex mechanism and 
interaction with the mutagenic effects of UV radiation has been suggested. 
Most studies have used HPV-DNA detection methods to examine the association with 
NMSC. Due to the high sensitivity of PCR methods and the ubiquity of HPV, new types 
were often detected. The prevalence varied widely between samples within the same pa-
tient depending on its type (i.e hair or skin), its layer (before or after tape stripping) or its 
body location (sun exposed or not). To avoid these limitations, some recent studies have 
been looking at serology as a different tool to investigate the association between HPV 
and the development of SCC or BCC. In the earlier studies, only a few HPV types were 
examined and all but one of the studies was undertaken in immunocompetent people. 
Patients who are HPV5 and/or HPV8 seropositive might be at higher risk of developing 
SCC but more studies are needed to be done to confirm this finding and to look at serol-
ogy for more HPV types. The prevalence of many HPVs seems to increase with age and 
might be associated with sun exposure. It is therefore very important to collect informa-
tion on UV exposure and other possible confounding variables to better understand the 
association between HPV, NMSC and sun exposure. 
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CHAPTER 5 
Methods, subjects and laboratory techniques 
5.1 Introduction 
This chapter describes the two case-control studies and the cohort study that will form 
the basis of this thesis. Design of the studies, questionnaires, the definition of case 
and control status, specimen collection and storage are presented. The last part of this 
chapter describes multiplex serology. 
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5.2 A prospective pilot study nested in the Oxford compo-
nent of the European Prospective Investigation into Can-
cer and Nutrition (EPIC·Oxford) 
5.2.1 Aim of the study 
The aim of this pilot study was to examine the relationship between antibodies against 
HPV-L 1 antigens for 38 HPV types in relation to SCC in apparently immunocompetent 
patients with plasma collected before or after the diagnosis of their skin tumour. We used 
biological samples and data from the Oxford component of the European Prospective 
Investigation into Cancer and Nutrition (EPIC-Oxford). 
5.2.2 Methods 
• EPIC-Oxford 
Between 1993 and 1999, 65,429 people aged 20 years and above and living in 
the UK were recruited into the Oxford component of the European Prospective In-
vestigation into Cancer and Nutrition (for further details of the study see [321] and 
[322]). Recruitment was through collaborating general practitioners, vegetarian and 
vegan societies, health-food magazines and from friends and relatives of the par-
ticipants. Data were obtained via questionnaire on demographic, diet and other 
lifestyle factors, but no information on sun exposure or skin type was available. For 
about 19,500 volunteers, a blood sample was taken, sent through the mail to the 
laboratory, where plasma was separated, aliquoted and stored in liquid nitrogen. 
All participants are followed up for mortality and cancer incidence by record linkage 
with the National Health Service Central Register. Ethical approval was granted by 
92 
5- Methods, subjects and laboratory technIQues 
the Royal College of General Practitioners Clinical Research Ethics Committee, the 
Central Oxford Research Ethics Committee and local research ethics committees. 
All cases and controls for this pilot study were identified from within the EPIC-Oxford 
cohort. 
• Definition of cases and controls 
All cases and controls were of Caucasian origin. Cases with a diagnosis of cuta-
neous SCC were identified from within the cohort using codes for cancer site (C44) 
and morphology (8070/3, 8071/3, 807413, 8076/3), based on the 10th revision of 
the International Classification of Diseases for Oncology (ICD-1 0). Thirty-nine peo-
ple who had plasma collected prior to the diagnosis of their first reported SCC were 
identified (they were not all eligible cases from EPIC). Of these, four had previously 
had a cutaneous basal cell carcinoma diagnosed and two others had a BCC di-
agnosed after recruitment and blood collection, but prior to the diagnosis of SCC. 
These 39 individuals will be referred to as the 'incident' cases. In addition, 15 in-
dividuals who had a cutaneous SCC diagnosed prior to recruitment and blood col-
lection were also included. These individuals are referred to as 'prevalent' cases. 
Of these, one had a BCC diagnosed following recruitment and two had been diag-
nosed with BCC prior to recruitment. One incident and two prevalent cases had 
another cancer type diagnosed prior to recruitment (one prostate, one cervix and 
one thyroid cancer respectively). Four incident cases had other cancers detected 
following recruitment and the development of their first SCC (two with lung cancer, 
one with prostate cancer and one with both cancers of the pancreas and digestive 
organs). 
The control group includes 80 persons who had not had a diagnosis of SCC reg-
istered with the National Health Service Central Register either before or after re-
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cruitment. They were randomly selected from among other study participants for 
whom a plasma sample was available. Information on medication and medical his-
tory available from the questionnaire revealed that none of the participants reported 
being on immunosuppressive therapy, or having ever received an organ transplant. 
Three controls developed breast cancer following recruitment. 
5.3 The Oxford and London case-control studies 
5.3.1 Aim of the studies 
Two case-control studies based at Barts and London NHS Trust and at the Oxford Rad-
cliffe Hospitals were carried out to investigate the seroepidemiology of HPV among OTR, 
to detect potential confounders for the association between see and HPV, to examine 
the HPV seroprevalence by ethnicity and by different immunological status and finally, to 
examine the role of HPV and other factors in the development of NMSe and particularly 
see. In London, patients have access to a dedicated dermatology clinic at their routine 
visit at the transplant centre whereas in Oxford patients are referred to a dermatologist if 
transplant clinicians or GPs detect a suspicious skin lesion. Using questionnaire data, the 
impact of dedicated skin clinics on the level of awareness of the danger of skin cancers 
incurred by organ transplant patients and on the use of adequate protections against UV 
exposure will also be examined_ 
5.3.2 Retrospective power calculation 
Preliminary data on which to base a power calculation were not available when I started 
the thesis. 119 prevalent see and 425 controls (around 1:4 case-control ratio) were actu-
ally recruited. The number of cases in an unmatched case-control study with a significant 
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level of 5% and a power of 95% for 1:4 case-control ratio is (Figure 5.1): 
Proportion of exposed 
in control group 
5% 
10% 
15% 
20% 
25% 
30% 
Relative risk 
1.5 2 2.5 3 4 
1503 467 248 163 93 
811 256 138 92 54 
585 188 103 69 41 
476 155 86 59 36 
415 138 77 53 33 
378 128 73 50 32 
Figure 5.1: Retrospective power calculation 
5.3.3 Methods 
A flow chart of the recruitment process is shown in Figure 5.2. Case-control studies 
within two cohorts of organ transplant recipients from London and Oxford were con-
ducted. Transplant recipients from Barts and London NHS Trust were recruited between 
October 2002 and August 2006. To increase the power of the study, a case-control study 
from the Oxford Radcliffe Hospitals was set up and conducted between May 2005 and 
August 2006. 
In London, all patients have access to a dedicated dermatology clinic following their usual 
visit to the transplant centre and undergo routine dermatological examinations, at which 
all benign and malignant lesions are recorded and treated if necessary. Patients were 
recruited at routine clinic visits and completed a specialist nurse-led questionnaire and 
were examined by a dermatologist. In Oxford patients are referred to a dermatologist 
if a suspicious skin lesion is present, but are not otherwise under routine surveillance. 
Therefore, transplant recipients attending the Oxford Transplant Centre were invited by 
mail to take part in the study and to complete a questionnaire. At the next clinic visit. 
this questionnaire was checked and finalised by a dermatologist who also conducted 
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an examination of the participants' skin, recording all benign and malignant cutaneous 
lesions. Treatments were initiated where indicated and educational information relating 
to the risks of skin cancer in transplant recipients was also provided. In both centres, 
a blood sample was taken and serum, buffy coat and red blood cells were separated, 
aliquoted and frozen at -80°C. 
5.3.4 Questionnaire, data entering and storage 
• Questionnaires 
A copy of the questionnaire is included in Appendix D. The same questionnaire 
was used in both centres to collect information on (i) social and demographic de-
tails (age, sex, height, weight, ethnicity, marital status, educational level, area of 
residence, country of birth) (ii) smoking and alcohol history; (iii) medical history 
(skin and/or other cancers, psoriasis); (iv) exposure to ultraviolet (UV) radiation 
(outdoor occupation and hobbies, sun exposure before and after transplantation, 
sun exposure currently, number of moles and freckles before and after transplan-
tation, history of sunburn in childhood, protective measures against UV radiation, 
time spent abroad); (v) history of HPV-related viral infection (cutaneous and genital 
warts and history of abnormal cervical smear in women); (vi) transplantation and 
dialysis (number of transplantations, dates, type of dialysis, time spent on dialysis 
before and after transplantation, primary diagnosis); (vii) gynaecological and re-
productive history for women (age at menopause, number of pregnancies, use of 
hormonal contraception, hormone replacement therapy, surgical removal of uterus). 
Since it is not clear how cutaneous HPV are transmitted, the questionnaire also in-
cluded some questions on possible risk factors for infection (e.g. shared bedroom 
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or bed as a child, number of siblings and number in household, as surrogates for 
crowding and proximity). All information on transplantation, medications and skin 
cancers was cross-checked against information held in the renal-centre database 
and medical records. 
• Data entering and storage 
All data were entered using the database FoxPro version 2.6 and a quality con-
trol for data was performed on 30% of the dataset. Less than 1 % of errors was 
found. Personal identifying information was kept separately from the database and 
an identifier number was given to each patient, so that anonymity was maintained 
throughout. 
5.3.5 Specimen and storage 
Transplant patients were asked to donate 8ml of venous blood at their routine blood test 
and plucked hairs were also collected. A blood specimen was collected into EDTA tubes, 
centrifuged and the serum, buffy coat and red blood cells were separated and frozen at 
-800 C. Hair samples for HPV DNA testing were stored in envelopes and frozen at -80 0 C. 
Anonymous samples (sera for the case-control studies and plasma for the EPIC-Oxford) 
were shipped on dry ice to the laboratory of Infection and Cancer Program (F020, DKFZ) 
in Heidelberg, Germany for HPV testing. All assays were performed by a single person 
(KMM). All laboratory investigators were blind to the case or control status of the patients. 
5.3.6 Definition of cases and controls 
Only malignant lesions with confirmed pathological verification of diagnosis were In-
cluded. Patients were classifed as cases if review of histological records revealed evi-
dence of SCC with or without other non-melanoma skin cancers. Of the 145 patients with 
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SCC, 70 (48%) had SCC with or without in-situ carcinoma of the skin (CIS), 66 (46%) had 
SCC with a history of BCC and 9 (6%) had SCC with a history of other non-melanoma 
skin cancers (porocarcinoma, Merkel cell carcinoma, eccrine nodular carcinoma or tric-
holemmal carcinoma) and with or without BCC. Controls were patients without confirmed 
diagnosis of skin cancer or CIS. In the course of the study, 20 patients from the London 
group developed their first SCC and were excluded from the control group. 
Patients with blood taken prior to development of their first lesions were classified as 
'incident' cases and those with sera taken after the development of their first lesion were 
classified as 'prevalent' cases. 
The different case groups examined are: 
- Case 1: Any squamous cell carcinoma 
- Case 2: Basal cell carcinoma only 
- Case 3: Prevalent squamous cell carcinoma 
- Case 4: Incident squamous cell carcinoma 
- Case 5: Prevalent basal cell carcinoma only 
- Case 6: Incident basal cell carcinoma only 
Patient cases 1 and 2 were selected to examine the risk factors associated with the 
development of SCC or BCC only based on the questionnaire data. Patient cases 1 
to 5 were used to investigate the association between squamous cell carcinoma, basal 
cell carcinoma and HPV seropositivity. The case group 6 which includes only 5 patients 
was not analysed thoroughly. Final numbers of cases and controls by centre, ethnicity, 
availability of blood specimen and/or completed questionnaire are summarised in Figure 
5.2. 
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5.4 Immunocompetent (Ie) and dialysis patients from London 
Patients with end-stage renal disease on dialysis, at increased risk of infections and 
cancers probably due to abnormalities of the immune system, and immunocompetent 
patients were also included to compare seroprevalence across different immune status 
(OTR, IC and dialysis patients). Caucasians and non-Caucasians immunocompetent pa-
tients without a history of skin cancer were enrolled from ophthalmology, plastic surgery 
or phlebotomy departments. A short questionnaire on basic socio-demographic details 
(sex, date of birth and ethnicity) and skin cancer history was completed and a blood 
sample was obtained and frozen at -80 0 C. No information on refusal rates for IC was 
available. In Oxford, data from EPIC-Oxford that used the same laboratory methodol-
ogy to assess HPV serostatus were used to compare seroprevalence between OTR 
and IC individuals (Section 5.2). In order to evaluate the influence of renal failure pre-
transplantation on HPV seroprevalence, stored sera from Caucasian and non-Caucasian 
dialysis patients from London with no history of transplantation, were also included. De-
tailed skin cancer history was not available for these patients, although it was known that 
none had previously attended the dermatology department for treatment of skin cancer. 
Basic socio-demographic details (sex, date of birth and ethnicity) were provided from the 
hospital renal database. Table 5.1 shows the number of patients that are included in each 
analysis. 
5.5 Multiplex serology 
HPV antibody detection was by multiplex serology, an antibody detection method that is 
based on a glutathione S-transferase capture enzyme-linked immunosorbent assay, as 
previously described [323, 324], in combination with fluorescent bead technology [325, 
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326]. All antigens were expressed in E.coli as double fusion of full-length viral proteins 
with a N-terminal glutathione S-transferase domain and a C-terminal peptide consisting 
of the last 11 amino acids from the large T antigen of simian virus 40 [323]. 
The expression constructs for the L 1 proteins of HPV types 16 and 18 have been de-
scribed elsewhere [324]. Expression constructs for the full length L 1 proteins of HPV 
types 1 a, 2a, 3, 4, 5b, 8, 9, 10, 11, 15, 17, 20, 23, 24, 36, 38, 41, 48, 49, 50, 57, 60, 
63, 65, 75, 76, 77, 92, 93, and 95 were generated using the same methods and are 
described in detail elsewhere [324, 320]. Finally, expression constructs for L 1 of HPV 
types 7 (amplified HPV nucleotides 5798-7312 in GenBank accession number X74463), 
13 (5742-7238, X62843), 27b (5704-7191, AB211993), 96 (5856-7391, AY382779), 101 
(5034-6578, OQ080081), and 103 (4945-6489, OQ080078) were newly generated all us-
ing EcoRI before the start and Sail at the end of the L 1 open reading frame as cloning en-
zymes. Sequence variations to the published sequences present already in the parental 
clones were found for HPV-27b (T6230e (F to S); T6465C; A6765G; T6894C) and HPV-
103 (A5774T (E to V); A6293G (0 to G)). Genomic clones for HPV types 93 and 96 
have not been published yet. HPV-93 (FAIMVS6) (0. Forslund, unpublished data) was 
recently isolated from an actinic keratosis on the dorsum of the hand of an 82-year-old 
male and HPV-96 (FA47) (0. Forslund, unpublished data) from an see in situ on the up-
per chest of a 75 year old male [280]. HPV101 and HPV103 were recently isolated from 
cervico-vaginal cells of two women in their 30s [327]. Surprisingly, phylogenetic analyses 
revealed that these two types cluster together with the gamma- and pi-PV groups usually 
associated with skin HPV. 
Glutathione-casein was coupled to internally fluorescence-labelled polystyrene beads 
(Luminex, Austin, TX), and fusion proteins were affinity-purified on the beads directly 
in a one-step procedure. Beads with glutathione S-transferase alone were prepared for 
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background determination. Binding of the antigens (i.e. the glutathione S-transferase 
fusion proteins) to various bead sets was verified with a monoclonal antibody against the 
common C-terminal peptide [323]. The differently labelled bead sets carrying different 
antigens were then mixed and incubated in 96-well plates with human plasma diluted 
1 :100 in blocking buffer, as described previously [326]. The analyses were performed 
blinded with respect to the case or control status of the samples. Antibodies bound to the 
beads via the viral antigens were then stained with biotinylated anti-human immunoglob-
ulin and fluorescent reporter conjugate streptavidinR-phycoerythrin (Molecular Probes, 
Eugene, OR). Antibodies bound to antigens on beads were quantified in the Luminex an-
alyzer, which also identified the internal bead colour and thus the antigen carried by the 
bead. Antibody quantity was determined as the median R-phycoerythrin fluorescence 
intensity (MFI) from at least 100 beads of the same internal colour after subtraction of 
background reactivity (glutathione S-transferase alone). 
5.6 Sensitivity and specificity of the assay 
HPV type cut-off values were based on a reference panel of 164 sera with antibody 
prevalence defined in a previous study [320] and reanalyzed in this study. The cut-offs 
were chosen in a way that produces high specificity. For all HPV types but HPV6 analyzed 
here, MFI cut-offs to define seropositivity for all antigens were set to 200 MFI [320]. To 
reduce the influence of borderline seropositive sera, a stringent (doubled) cut-off of 400 
MFI was applied to HPV6. Data analysis using geometric mean MFI values instead of 
cut-off values did not materially change the results. 
For assays of antibodies to sexually transmitted genital HPV cut-off definition can be 
based on the seroreactivity in groups of virgins [328] while for the cutaneous types, which 
is the vast majority of HPV types analysed here the definition of a mostly uninfected and 
101 
5- Me'hoas ScC;ecs analaborarory rechmques 
thus mostly seronegative group is not possible. In the absence of defined reference sera 
that could be used as international standards, any cut-off definition has an arbitrary com-
ponent and seroprevalence values obtained by different laboratories in general should 
only be compared with caution. Here, all antigens were identically constructed L 1 fusion 
proteins expressed in the same bacterial expression system. Thus, given the uniformity 
of the antigens the use of a uniform cut-off appears justified. To avoid false-positivity 
by low-level cross-reactivity and thus to increase type specificity of the seroprevalence 
values a cut-off well above background levels was chosen. Thus, the chosen cut-off is 
rather stringent and probably underestimates the true seroprevalence of cutaneous HPV 
infections [320]. 
One of the limitations of the evaluation of the performance of the assay is that it is currently 
the 'gold standard' for cutaneous HPV types. Direct comparison of GST L 1 fusion protein-
and VLP-based ELISA (VLP: virus-like particle) with 105 human sera has been performed 
for HPV 16 and 18, and showed a good correlation of 0.7 [324]. Of 46 monospecific 
monoclonal antibodies detecting conformational epitopes on VLP of 9 mucosal types all 
reacted with the GST-L 1 fusion protein of the same type [329] demonstrating the ability 
of GST-L 1 to bind type-specific antibodies. Based on these observations, it is reasonable 
to assume similar properties for the other HPV types investigated here. Cross-reactivity 
cannot be entirely ruled out and thus unspecific antibody reactions. Like VLP, GST-fusion 
proteins present conformational and neutral ising epitopes but display a higher amount of 
linear/cross-reacting epitopes than VLP [329]. Thus, under the condition that only highly 
purified, intact VLP preparations are used as antigens, VLP-based assays may yield a 
higher ratio of specific to unspecific reactions than with GST-L 1-based serology. 
It should also be born in mind that this HPV test is not used as a screening tool but only 
as a measure of an exposure for epidemiological studies. Despite a lower sensitivity. 
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serology has shown to be a good tool in epidemiologic studies to detect an association 
between HPV infection and cervical cancer [235,242,243] but not for screening. 
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N =233 
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- refused to take part 
- deceased 
- back on dialysis 
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- other 
EXCLUSIONS 
- incomplete or uncertain skin cancer history 
- genital see 
- history of in-situ carcinoma of the skin (only) 
- history of other skin cancers 1 
FINAL NUMBERS 
(Patients with see / Bee (only) / without skin cancer) 
Non-Caucasian 
with questionnaire only N=12 
(Patients with sce / Bec (only) I without skin cancer) (0, 0, 12) 
with blood sample only N = 57 
(Patients with sec / Bec (only) I without skin cancer) (1,0,56) 
with both specimen and questionnaire 
N= 110 (Patients with sec / Bee (only) I without skin cancer) 
(0, 0, 110) 
N number; see: Squamous cell carcinoma; Bee: Basal cel carcinoma 
N= 722 
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-9 
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-14 
-10 
N= 584 
(921241468) 
5 < 
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N= 21 
(2,0, 19) 
N =333 
(87, 22, 224) 
I Exclusions of 19 patients with other skin cancers (9 patients with a history of malignant melanoma (with or without seC), 8 patients with a history of Kaposi's 
Sarcoma (with or without See). 1 patient with poro carcinoma and Bee, and 1 patient with lentigo maligna) 
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CHAPTER 6 
Risk factors associated with the presence of antibodies against 
human papillomavirus 
6.1 Introduction 
Transmission and prevalence of high risk mucosal HPV types associated with genital 
warts, abnormal smears or cervical cancer have been studied intensively. It is, however, 
unknown how most other human papillomaviruses (HPV) are transmitted and distributed 
in the population and what factors are associated with HPV seropositivity - all important 
factors in understanding and interpreting the significance of the association between HPV 
seroepidemiology and NMSC risk. This chapter reports on HPV seroprevalence among 
Caucasian control OTR of the London and Oxford case-control studies and on the associ-
ation between human papillomavirus and risk factors established from the questionnaire. 
Finally, an examination of the sero-epidemiology of HPV among different ethnic groups 
and among people of different immunological status is presented. 
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6.2 Statistical methods 
All analyses considering HPV and the association with various risk factors from the ques-
tionnaire were restricted to Caucasian patients without skin cancers (NMSC are rare in 
non-Caucasian population and our ultimate aim is to examine the association between 
SCC and HPV and, therefore, to detect potential confounding factors). The association 
between HPV, ethnicity and immunological status was examined separately. 
To assess the relationship between seropositivity to a single HPV type and various risk 
factors measured by questionnaire, conditional (on centre) logistic regression adjusted for 
sex, age at recruitment (less than 44, 45-59, 60 or more) and time since transplantation 
(less than 5 years, 5 to 9 years, 10 or more years) was applied. Conditional logistic re-
gression on centre was used to deal with the potential for bias due to confounding by cen-
ter. Age and sex were included in the model due to their strong established association 
with mucosal types. The adjustment for time since transplantation was decided following 
results on univariate analysis showing a possible decline in antibodies production within 
the first 5 years of transplantation (Table 6.5 for crude proportions). Seropositivity to multi-
ple HPV types can be looked at a count data (seronegative to all HPV types, seropositive 
to one HPV type, seropositive to two HPV types ... ). The association between multiple 
HPV seropositivity and risk factors can therefore be analysed using negative binomial 
regression adjusted for the same factors (over-dispersion was observed when Poisson 
models were fitted). 
Skin type was defined using Fitzpatrick classification scale as follows (I) never tans. al-
ways burns, (II) rarely tans, usually burns, (III) usually tans, can burn, (IV) always tans, 
rarely burns, (V) Asian, Middle Eastern and (VI) African/Afro-Caribbean. Ethnicity was 
defined as Caucasian (those who identified themselves as 'White and were usually in-
dividuals of European descent) and non-Caucasian (those who identified themselves as 
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'Asian, 'Far Eastern, 'Black or 'other and were usually individuals of non-European de-
scent). 
To compare single HPV seroprevalence between immunocompetent, dialysis and trans-
plant patients from London and between OTR and IC patients from Oxford, logistic re-
gression adjusted for age «45, 45 to 59, 2:60 for London and <55, 55 to 64, 2:65 for 
Oxford) and sex was used. To assess the association between multiple HPV seropos-
itivity and immunological status, negative binomial regression adjusted for age and sex 
was used with further adjusment for centre where appropriate. Sensitivity analysis was 
performed to compare HPV seroprevalence among IC, dialysis and transplant patients 
with kidney graft only. 
Where results are presented in the form of plots, black squares indicate the point esti-
mates and horizontal lines represent 95% confidence intervals (CI). To deal with multiple 
significant tests the level of statistical significance was set to 1 % and when a sufficient 
number of patients was available, agreement of results across centre or population was 
used to detect genuine associations. Missing value categories were added to adjust-
ment variables with incomplete information in order to retain all the observations in the 
analyses. Likelihood ratio tests were used to assess heterogeneity and trend tests. All 
P-values are two-sided. Statistical analyses were carried out using STATA 9 (StataCorp, 
2005). 
6.3 Descriptive statistics 
In total, seroprevalence data from 1225 individuals were available. They comprised 425 
Caucasian and 201 non-Caucasian OTR (5 patients [0.8%] from London with a solid 
organ graft other than kidney) with a blood sample and a completed questionnaire, but 
without skin cancer. Information from 182 Caucasian and 50 non-Caucasian IC patients 
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without skin cancer, and 222 Caucasian and 145 non-Caucasian dialysis patients were 
also included. 
Table 6.1 shows the distribution of OTR by sex, time since transplantation, age at re-
cruitment and ethnicity for each centre. There was no statistically significant difference 
at 5% level in distribution between the two centres in terms of sex, age at recruitment 
and time since transplantation, but, 35 patients (16%) in Oxford were non-Caucasians 
compared to 166 (41 %) in London. Of the 201 non-Caucasian patients, 53% identified 
themselves as Asian (54% versus 46% in London and Oxford respectively), 31% as Black 
(31 % versus 31 % respectively), 9% as Far Eastern (8% versus 14% respectively) and 7% 
as other ethnic group (7% versus 9% respectively). In terms of country of birth, 97% of 
Caucasian OTR were born in Europe and 80% of non-Caucasians were born outside Eu-
rope (42% Indian subcontinent, 29% Africa, 13% Caribbean, 10% Far East, 4% Middle 
East and 2% Other). Caucasian patients tended to have been transplanted for longer 
than non-Caucasians (P=0.002). 
6.4 Multiple HPV seropositivity among Caucasian OTR 
Figure 6.1 shows the count ratio of seropositivity to multiple types of one genus by 
seropositivity to multiple types of another genus. Those individuals seroreactive to mul-
tiple types of one genus were more likely to be seroreactive to multiple types of another 
genus. There was no difference in terms of age at recruitment, time since transplanta-
tion, sex or skin type between patients HPV seronegative to any types and those being 
seropositive to at least one HPV type (Table 6.2). 
To explore further the relationship between each of the HPV types, double seropositivity 
was examined i.e the proportion of patients who were seropositive to one HPV type and 
also to another type based on the laboratory cut-off definitions. Table 6.3 shows the 
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results. For instance of the 39 patients who were seropositive to HPV5 79% (31 patients) 
were also seropositive to HPV8. 
Clear patterns were observed within and between genera: 
• alpha types: 
The proportion of people with double HPV seropositivity was lower between al-
pha types and any other types compared to other genera. Patients who were 
seropositive to HPV6 had lower seroprevalence for other alpha types. Higher dou-
ble seropositivity (64%) was observed between HPV 13 and HPV6, which are both 
members of the same species (10). 
• beta types: 
A high proportion of patients who were seropositive to a single beta HPV type (other 
than HPV 93) were also seropositive to HPV 8, 9, 15, 17, 38 or 49 (dotted area on 
Table 6.3). Patients who were seropositive to HPV24 or HPV36 from species 1 or 
to HPV75 or HPV76 from species 3 were also seropositive to most beta HPV types 
but also gamma and mu types. Between half and a third of patients seropositive to 
gamma types (not HPV4) or to HPV63 (mu genus) or to HPV1 01 or HPV1 03 (other 
types) were also more likely to be seropositive to HPV15, 17, 38 or 49. Seroposi-
tivity to HPV93 was distinct from the other types with very low seroprevalence . 
• gamma types: 
Between 46% and 79% of patients seropositive to a single beta or gamma HPV type 
were also seropositive to HPV 65 or HPV 95. In particular patients seropositive to 
gamma HPV types were more likely to be seropositive to gamma HPV types from 
the species 1 (HPV4, HPV65 or HPV95). These results are highlighted in the dotted 
area on Table 6.3. 
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• other types: 
Around three quarters of patients seropositive to HPV 103 were also seropositive 
to gamma HPV types from species 1 and between half and a third to HPV9, 15, 17, 
38, 49, 75, 76 and 92. 
These findings are summarised in the Table 6.4. Seropositivity to beta types was mainly 
explained by seropositivity to HPV8, 9, 15, 17, 38 and/or 49 and for gamma types by 
species 1. Of the 425 Caucasian OTR, 237 (56%) were seropositive to any beta types, 
205 patients (48%) were seropositive to HPV8, 9, 15, 17, 38 and/or 49 and only 32 
patients (8%) were seropositive to any of the other 10 betaHPV types. Regarding the 
gamma types, 200 patients (47%) were seropositive to any gammaHPV types, 178 (41 %) 
were seropositive to HPV4, 65 and/or 95 (species 1) and 22 patients (5%) were seropos-
itive to any of the three other types. 
6.5 Risk factors associated with HPV based on questionnaire 
data among Caucasian OTR 
• Seropositivity to individual HPV type 
Table 6.5 summarises results on seropositivity for a single HPV type among Cau-
casian control OTR by centre, sex, time since transplantation, age at recruitment 
and skin type. The prevalence of 8/34 HPV types differed significantly (P~0.05) 
between centres. In both centres, higher seroprevalence was observed for HPV6 
(33% and 26% for London and Oxford respectively), HPV8 (24% and 18%), HPV15 
(26% and 29%), HPV17 (24% and 21 %), HPV38 (23% and 21 %), HPV49 (19% 
and 21 %), HPV4 (27% and 23%), HPV65 (30% and 25%), HPV95 (22% and 20%), 
HPV1 (33% and 24%) and HPV63 (28% and 17%). Seroprevalence was statistically 
111 
6- Risk factors associated with the presence of al1tibodles against human paplf'omaVlfu5 
significantly higher at the 1 % level in London compared to Oxford for 3 cutaneous 
types; HPV 27 (21 % versus 12% respectively), HPV 63 (28% versus 17%) and 
HPV 101 (10% versus 3%), and for 1 mucosal type, HPV 13 (13% versus 5%). As 
expected, higher HPV seroprevalence was observed in women for HPV16 (25% 
in female versus 10% in male) and seroprevalence for mucosal HPV types (16, 6 
and 13) decreased with increasing age (P-trend<0.01). Seropositivity to types be-
taHPV15, 38 and to a less extent betaHPV5, 8, gamma75 and 76 seemed to drop 
after transplantation and then increased and stabilised. Apart from an increase in 
seroprevalence of HPV4 with time since transplantation (P-trend= 0.01) and a de-
crease in seroprevalence of HPV65 with increasing age (P-trend<0.001), no clear 
association was found with time since transplantation for any of the other HPV types 
examined. Similarly, no association was found between HPV seroprevalence and 
skin phototype. 
Table 6.6 summarises associations for all other factors that were found to be statis-
tically significant at least at the 1 % level between risk factors from the questionnaire 
and single HPV seropositivity. Analyses were not performed by centre as figures 
were too small. Overall, given the large amount of available data from the question-
naire, very few variables were associated with single HPV seropositivity. Seroposi-
tivity to HPV6 was highly associated with a history of genital warts, increased with 
number of children (P-trend= 0.001), was higher in current users of oral contracep-
tive and was higher in past and current smokers as compared to never-smokers 
(P-value never versus ever smokers= 0.004). Self reported abnormal smear test 
was statistically significantly associated with mucosal H PV types 6 and 16. Mu-
cosal type HPV13 seropositivity was also associated with a history of genital warts 
(P:::;0.001). A self-report of history of abnormal smears was also associated with 
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seropositivity to betaHPV 15, 17, 38, 76 and 92. A history of herpes zoster was 
inversely associated to seropositivity to betaHPV 24 and 96. Variables related to 
UV exposure did not show any links with seropositivity except for HPV16 which was 
associated with sunbathing and outdoor hobbies. Patients with self-reported history 
of warts were 3 times more likely to be seropositive to alphaHPV 13 (95%CI: 1.2 
to 9.2; P=O.01) and betaHPV 5 (95%CI: 1.1 to 9.8; P=O.02) with a large number 
of transplant patients reporting such history (68%). A history of psoriasis (n= 23 
patients) was not associated with any of the 34 HPV types examined. No other dis-
tinguishing epidemiological features of transplant recipients with antibodies against 
any of the 34 HPV types examined were identified. All results are available in Ap-
pendix E1. 
• Multiple seropositivity 
Figure 6.2 is a graphical representation of selected risk factors associated with the 
presence of antibodies against multiple HPV types by genus. Multiple HPV seropos-
itivity was more frequent in patients from London as compared to Oxford for alpha 
mucosal types and for other types (nu, mu and 2 undefined types). Young women, 
current smokers and female patients reporting a history of having had an abnor-
mal cervical smear test and/or genital warts were more likely to be seroreactive 
to multiple mucosal HPV types. Women with a self-reported history of abnormal 
cervical smear were also more likely to be seropositive to more beta HPV types 
than those without such a history (CR: 2.3; 95% CI: 1.2 to 4.5; P=O.01) and mul-
tiple seropositivity to beta types seemed to be higher in patients with longer time 
since transplantation (P-trend=O.02). Ultraviolet radiation exposure history was not 
associated with seropositivity to a single HPV type but patients who reported us-
ing a sunbed and sunbathing were twice as likely to have more gamma serotypes 
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than those who did not (P-trend=0.007). No other distinguishing epidemiological 
features of OTR with antibodies against multiple HPV seropositivity were evident. 
All results are available in Appendices E2, E3 and E4. 
6.6 Human papillomavirus and ethnicity among OTR 
Table 6.7 shows the odds ratios for being seropositive to each single HPV type in non-
Caucasian versus Caucasian OTR after controlling for age at recruitment, sex, time since 
transplantation and centre. The prevalence of L 1 antibodies against HPV 5 (Odd ratios 
[OR]: 2.0 and 95% CI: 1.2 to 3.4; P=0.01), HPV 93 (OR: 2.6; 95% CI: 1.2 to 5.6; P=0.01) 
and HPV 101 (OR: 1.9; 95% CI: 1.1 to 3.3; P=0.02) were higher among non-Caucasian 
than Caucasian patients whereas for HPV 1 seroprevalence was lower in non-Caucasian 
patients compared to Caucasians (OR: 0.5; 95% CI: 0.3 to 0.7; P<0.001). Although the 
low seroprevalence did not allow for separate examination of results by centre, HPV1 
seroprevalence was similar between Caucasian and non-Caucasian OTR from Oxford 
(24% versus 26%), but only 35 non-Caucasian OTR were recruited in Oxford. 
Table 6.9 (part F) summarises results on seropositivity to multiple HPV types by ethnicity 
and centre. There was no difference at the 1 % level of significance between Caucasian 
and non-Caucasian OTR regarding multiple HPV seropositivity for any types, alpha, beta, 
gamma or other types (nu, mu and 2 not defined types). 
Among non-Caucasian patients, there was no statistically significant difference for any 
of the 34 HPV types, nor with antibodies against multiple seropositivity, between the 
117 OTR with skin type V (Asian/Middle Eastern) and the 62 patients with skin type 
VI (Africa! Afro-Caribbean) at the 1 % level of significance (Appendix E5). Restricting 
analysis among the non-Caucasians to 106 Asians versus 62 Black patients showed 
higher seropositivity for mucosal types (especially HPV7, HPV16 and HPV13) and also 
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for betaHPV types of the species 2 among Black patients compared to Asians (Appendix 
E6). 
6.7 Human papillomavirus by immunological status and com-
parison with the published literature 
In Table 6.8, seroprevalence of the 34 HPV types examined in the OTR are compared 
to those from IC patients and dialysis patients recruited for comparison and with those 
from the published literature. In order to exclude possible methodological variables, only 
studies using an identical methodology and performed in the same laboratory as our own 
study were included [320, 1, 330]. The mean age at recruitment varied widely between 
these studies with older patients from Italy and EPIC-Oxford study [1, 330]. There were 
also differences in the sex ratio (number of male/number of female) between studies 
ranging from 0.6 to 1.6. Across countries, the most notable finding was the higher sero-
prevalence of many HPV types detected in Italy as compared to either Germany or the 
UK. The only consistent finding across ethnicity groups and across centres was a lower 
HPV4 seroprevalence among OTR compared to IC or dialysis patients. Otherwise, HPV 
seroprevalence differed little for most types across the different studies and centres, after 
adjustment for age and sex. For multiple HPV seropositivity, there was also no statisti-
cal difference at the 1 % level of significance between ethnic groups or by immunological 
status (Table 6.9). Seropositivity to any HPV types ranged between 81 % and 94%_ Differ-
ences identified among OTR relating to ethnicity were corroborated for HPV93 (dialysis 
patients - OR: 3.4; 95% CI: 1.4 to 8.5; IC: OR not available and 0% in Caucasians versus 
10% in non-Caucasians) and HPV1 (dialysis OR: 0.5; 95%CI: 0.3 to 0.8; IC: OR: 0.5; 
95% CI: 0.2 to 1.0), but not for HPV5, HPV101 or other HPV types among dialysis and IC 
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patients from London_ Exclusion of non-renal transplant patients (n= 5) did not materially 
change results. 
As for transplant patients, those individuals seropositive to multiple types of one genus 
were more likely to be seroreactive to multiple types of another genus independently of 
immunological status or ethnicity (Appendices E7 and E8)_ 
6.8 Discussion 
Little is known of the seroepidemiology of HPV, with the exception of those mucosal 
types associated with cancer of the uterine cervix [215]_ We report here on risk factors 
associated with HPV seropositivity for 3 mucosal and 31 cutaneous HPV types across 5 
genera among 425 Caucasian and 201 non-Caucasian OTR without skin cancer and we 
compare HPV seroprevalence between populations with different immunological status 
and consider ethnic variations. 
Eighty six percent of Caucasian transplant recipients without skin cancers in this study 
were seroreactive to at least one HPV type, identical to previous results from a UK study 
among Caucasian immunocompetent people (86%) [1] (Chapter 7), illustrating the ubiq-
uity of HPV [281]. Findings for mucosal HPV types were in line with results from previous 
studies [215, 320] and provide internal validation for the multiplex technology used in this 
study. 
We observed differences in HPV seroprevalence between OTR from 2 geographically 
close centres (Oxford and London) perhaps reflecting the importance of variations in en-
vironmental exposure or even clinical practice such as close proximity in clinics_ Individ-
uals seropositive to multiple types of one genus were also more likely to be seroreactive 
to multiple types of another genus, possibly suggesting similar modes of transmission or 
cross-reactivity of the assay. This result was not explained by a higher susceptibility of 
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OTR to get multiple seropositivity since the same pattern was observed among Ie and 
dialysis patients. 
Associations with time since transplantation and seropositivity to certain beta or gamma 
types were not linear but might reflect a decline in antibody production following inten-
sive immunosuppressive treatments in the first years following transplantation. However, 
this remains speculative and would require prospective HPV serology studies for con-
firmation. In contrast, in Caucasians, we observed that most HPV seroprevalence did 
not differ substantially, after controlling for age and sex, between IC individuals, dialysis 
patients without a history of transplantation and OTR from London or between IC and 
transplanted individuals from Oxford suggesting apparently low disturbance in production 
of antibodies by immunological status. The only notable exception was a lower HPV4 
seroprevalence among OTR compared to dialysis or IC patients independent of centre 
or ethnicity. Unfortunately, we do not have complete information on the type of dialy-
sis (continuous ambulatory peritoneal dialysis or haemodialysis) to explore whether this 
specifically affected seroprevalence. No association was observed between the pres-
ence of psoriasiS and any of the 34 HPV types examined. Despite the small number 
of patients, this result is consistent with a recent study on beta HPV-DNA and psoriasis 
[331]. There is limited statistical power to examine associations with all of the HPV types, 
in part because the prevalence of some is low. Further limitations may arise because 
details of risk factors were examined using self-reported information. 
The largest previous study of HPV seroprevalence in the immunocompetent population 
reported on age and sex distributions of alpha, beta, gamma, nu and mu HPV types 
among 1797 German adults and children [320]. Overall, detection of antibodies against 
nu and mu types was evident in childhood whereas seroprevalence to alpha types was 
higher in women after puberty; seroprevalence to beta and gamma types was found to in-
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crease with age. We did not find an association between age and presence of antibodies 
against gamma and beta types in either the transplant population or the immunocompe-
tent group. Other studies have reported only on beta HPV seroprevalence and risk factors 
among immunocompetent individuals [147, 319, 153, 146, 316, 318]. Termorshuizen et 
al (2004) reported no association in 313 controls patients between seropositivity to any 
of 6 beta HPV types (HPV5, 8, 15, 20, 24 or 38) and age, sex, skin type, lifetime sun 
exposure and painful sunburns at different age periods [147]. Karagas et al (2006) also 
reported that seropositivity to any of 8 beta types (HPV 5, 8, 9, 15, 20, 24, 36 or 38) in 
461 immunocompetent patients without skin cancer did not differ in terms of age, level 
of education, smoking status, skin phototype and number of sunburns but noted higher 
beta seroprevalence in men compared to women [319]. Andersson et al (2008) looked at 
434 immunocompetent patients with and without skin cancer (basal and squamous cell 
carcinoma) and also found no relationship between age, sex, skin type, smoking and pre-
vious sunburn and seropositivity to any beta types (HPV 5, 8, 9, 10, 15,20, 24, 36 and 38) 
[153]. Only Feltkamp et al (2003) found a statistical significant association between unad-
justed seroprevalence of HPV24 and increasing age and male sex in immunocompetent 
patients [146]. 
No previously reported studies have investigated the association between the preva-
lence of HPV antibodies by ethnicity. Consistently across immunological status, we 
observed statistically significant differences between Caucasians and non-Caucasians: 
betaHPV 93 was higher in non-Caucasians, whereas muHPV type 1 seroprevalence was 
lower. As most Caucasians were born in Europe and non-Caucasians outside Europe we 
were not able to distinguish if the observed differences were confounded by birth coun-
try. There were some limitations to our analyses on ethnicity as diverse groups (Asian, 
Black [African and Afro-Caribbean], Far Eastern or other) with different birth country were 
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all pooled in the 'non-Caucasian' category. Although this essentially equates to non-
European, this is inevitably somewhat crude grouping and more detailed geographical 
studies are essential to examine further the HPV seroprevalence among different ethnic-
ities. 
In summary, findings on the association between various risk factors and mucosal HPV 
types were an internal validation of the methodological approach used in this study. Sig-
nificant differences in HPV seroprevalence were identified between study centres and 
according to ethnicity, but no other distinguishing epidemiological feature of transplant 
patients with antibodies against any of the 34 individuals or multiple HPV types examined 
were identified. Interpretation of future HPV and cancer association studies will require 
a better understanding of HPV seroepidemiology and further research is now needed to 
clarify the risk factors and the natural history of these viruses. 
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Caucasian patients Non-Caucasian patients 
Oxford London Oxford London 
N=182 N=243 N=35 N=166 
no (%) no (%) no (%} no (0/0) 
sex 
male 110 (60) 150 (62) 19 (54) 96 (58) 
female 72 (40) 93 (38) 16 (46) 70 (42) 
P-het. 0.8 1 0.61 
age at recruitment (years) 
<45 80 (44) 107 (44) 16 (46) 69 (46) 
45-59 64 (35) 94 (39) 11 (31) 70 (31) 
60 or more 38 (21) 42 (17) 8 (23) 27 (23) 
P-trend 0.6 1 0.81 
time since transplantation (years) 
<5 70 (38) 80 (33) 14 (40) 82 (49) 
5 to 9 52 (29) 61 (25) 12 (34) 35 (21) 
10 or more 60 (33) 102 (42) 9 (26) 49 (30) 
P-trend 0.08 1 0.71 
N Total number; no: number 
1 P-values between Oxford and London are based on logistic regression adjusted for each other 
Both centres 
Caucasian Non-Caucasian 
N=425 N=201 
no (%) 
260 (61) 
165 (39) 
187 (44) 
158 (37) 
80 (19) 
150 (35) 
113 (27) 
162 (38) 
no (%) 
115 (57) 
86 (43) 
0.6 2 
85 (42) 
81 (40) 
35 (17) 
0.8 2 
96 (48) 
47 (23) 
58 (29) 
0.0022 
2 P-values between Caucasian and non-Caucasian are based on conditional (on centre) logistic regression adjusted for each other 
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6- RIsk factors associated WIth the presence of anbbodJes agamsl human papl'&>n", ........ < 
neg 1 2 3 4+ 
184140 49 23 29 
Seropositivity to ALPHA types 
.···f 
.-1,' f" " 
neg 1 2 3/4 5+ 
188 76 48 42 71 
Seropositivity to BETA types 
".+" 
t·/!! 
• 
neg 1 2 3 4+ 
Seropositivity to ALPHA types 
•. ··f 
. ..-I .. !.! 
neg 1 2 3 4+ 
• 
neg 1 2 3 4+ 
225 92 38 33 37 
Seropositivity to GAMMA types 
neg 1 2 3 4+ 
Seropositivity to GAMMA types 
.. +A 
fA .. 
neg 1 2 3/4 5+ 
Seropositivity to BET A types 
··-If' 
IA 
neg 1 2 3/4 5+ 
neg 1 2 3+ 
233107 53 32 
Seropositivity to OTHER types 
.. r1 
•. , T 
neg 1 2 3+ 
Seropositivity to OTHER types 
neg 1 2 3+ 
Seropositivity to OTHER types 
ri 
neg 1 2 3 4+ 
Seropositivity to ALPHA types Seropositivity to BETA types Seropos itivi ty to GAMMA types 
• Count ratios (CR) were calculated using negative binomial regress ion and adjusted for age at recruitment 
time since transplantation, sex and centre 
CI : confidence Interval ; n: number 
Other types: HPV types from nu, mu genera and HPV101 and 103 
All P·values for trend <0.001 
Figure 6.1: Count ratios (CR) (and 95%CI) of the expected number of seropositivity from one 
genus by the number of seropositivity of another genus among Caucasian control 
transplant patients (n=425) 
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6- Risk factors assoaated WIth the presence of an/ibodJes aga nst human papiIom.].YliS 
Seronegative to Seropositive to at 
all HPV types least one HPV type total 
N= 59 N= 366 N= 425 
sex 
male 25 (42) 140 (38) 165 (39) 
female 34 (58) 226 (62) 260 (61) 
P-het. 0.5 
age at recruitment 
<45 24 (41) 163 (45) 187 (44) 
45 to 59 20 (34) 138 (38) 158 (37) 
~60 15 (25) 65 (18) 80 (19) 
P-trend 0.3 
time since transplantation 
<5 24 (41) 126 (34) 150 (35) 
5 to 9 11 (19) 102 (28) 113 (27) 
~10 24 (41) 138 (38) 162 (38) 
P-trend 1.0 
N: number; HPV: Human papillomavirus; Het. : heterogeneity 
P-value using conditional (on centre) logistic regression adjusted for each other 
Table 6.2: Age, sex and time since transplantation distribution in seropositive compared to 
seronegative to any HPV types among Oxford and London Caucasian without skin 
cancer 
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6- Risk factors associated WT/h the presence of anbbod,es agalllst human pap"llorr.a s 
Seropositivity to 
None beta type 
HPV 8, 9, 15, 17, 38 and/or 49 
Any of 10 other beta types 
All 
N=425 
188 (44%) 
205 (48%) 
32 (8%) 
None gamma type 225 (53%) 
HPV 4, 65 and/or 95 (gamma, species 1) 178 (41%) 
Any of 3 other gamma types (HPV 48, 50 and/or 60) 22 (5%) 
Oxford 
N=182 
85 (47%) 
87 (35%) 
10(5%) 
114(63%) 
68 (37%) 
9 (5%) 
London 
N=243 
103 (42%) 
118(28%) 
22 (9%) 
135 (55%) 
110(45%) 
13 (5%) 
Table 6.4: HPV seroprevalence by most frequent beta and gamma HPV types. 
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23 
38 
49 
75 
76 
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4 
65 
95 
48 
50 
60 
41 
1 
63 
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All 
N=426 
% POS 
8% 
14% 
17% 
8% 
1&% 
30% 
10% 
S% 
21% 
14% 
11 % 
12% 
3"1, 
16% 
27% 
24% 
10% 
22% 
20% 
12% 
10% 
12% 
16% 
26% 
28% 
21% 
1&'10 
8'10 
4'10 
11 "1. 
29"1. 
23"1. 
7-,. 
&'10 
London 
N=243 
"I. POS 
9% 
17% 
21% 
9% 
16% 
33% 
13% 
11 % 
24% 
16% 
11 % 
15% 
5% 
19% 
26% 
25% 
12% 
23% 
19% 
14% 
12% 
15% 
15% 
27% 
30% 
22% 
16% 
8% 
5% 
13% 
33% 
28% 
10% 
70/. 
CENTRE 
Oxford 
N=182 
"I. POS 
8% 
11 % 
12% 
7% 
15% 
26% 
5% 
7% 
18% 
12% 
12% 
8% 
1% 
11 % 
29% 
21 % 
7% 
21 % 
21 % 
9% 
7% 
8% 
14% 
23% 
25% 
20% 
15% 
7% 
4% 
8% 
24% 
17% 
3% 
4% 
P-va/ue' 
0.9 
O.OS 
0.01 
0.4 
0.& 
0.1 
0.01 
0.2 
0.2 
0.3 
0.8 
0.03 
0.0 
0.03 
0.6 
0.3 
0.07 
0.8 
0.6 
0.2 
0.1 
0.04 
O.S 
0.6 
0.2 
0.& 
0.7 
0.8 
0.& 
0.0& 
0.04 
0.01 
<0.001 
0.2 
Male 
N=2&0 
% POS 
8% 
13% 
15% 
7% 
10% 
29% 
8% 
10% 
21 % 
15% 
11 % 
11 % 
2% 
15% 
27% 
21 % 
9% 
22% 
18% 
12% 
9% 
12% 
13% 
27% 
27% 
19% 
15% 
6% 
3% 
11 % 
26% 
21% 
6% 
6% 
SEX 
Female 
N=1&6 
'Io POS 
9% 
16% 
21 % 
12% 
25% 
32% 
13% 
7% 
22% 
13% 
12% 
13% 
4% 
15% 
28% 
27% 
10% 
23% 
22% 
12% 
11 % 
13% 
16% 
23% 
30% 
25% 
16% 
10% 
7% 
11 % 
34% 
27% 
9'1. 
6% 
P-value' 
Q7 
Q6 
Q1 
Q1 
<QO~ 
Q6 
Q~ 
0.3 
O.S 
0.4 
0.9 
0.7 
0.6 
1.0 
0.9 
0.2 
0.8 
0.9 
0.4 
0.9 
0.& 
0.8 
0.6 
0.4 
0.4 
0.2 
0.7 
0.07 
0.08 
1.0 
0.1 
0.2 
0.2 
1.0 
AGE AT RECRUITMENT (years) 
<45 4 5-59 ~ 6 0 
N=187 N=168 N=80 
% POS % POS % POS 
9% 
18% 
24% 
11 % 
22% 
36% 
16% 
10% 
26% 
15% 
13% 
13% 
2% 
17% 
27% 
24% 
9% 
22% 
22% 
12% 
9% 
12% 
13% 
28% 
35% 
24% 
19% 
8% 
4% 
11 % 
31% 
27% 
6% 
6% 
8% 
12% 
12% 
6% 
11 % 
28% 
4% 
9% 
18% 
12% 
8% 
10% 
3% 
15% 
31 % 
23% 
9% 
23% 
18% 
12% 
11 % 
13% 
16% 
27% 
25% 
16% 
13% 
9% 
6% 
11% 
30% 
20% 
6% 
8% 
8% 
11 % 
13% 
6% 
10% 
20% 
8% 
8% 
18% 
18% 
13% 
13% 
4% 
14% 
20% 
24% 
11 % 
21 % 
18% 
11 % 
9% 
11 % 
15% 
16% 
19% 
25% 
14% 
4% 
4% 
11 % 
23% 
20% 
10% 
4% 
P-value 
trend' 
0.& 
0.1 
0.01 
O.OS 
<0.001 
0.01 
<0.001 
0.6 
0.0& 
0.8 
0.7 
0.8 
0.6 
0.& 
0.6 
0.9 
0.& 
0.9 
0.2 
1.0 
0.9 
1.0 
0.& 
0.09 
<0.001 
0.7 
0.2 
0.3 
0.8 
0.9 
0.2 
0.1 
0.4 
0.8 
TIME SINCE TRANSPLANTATION (years) 
<5 5 to 9 ~10 
N=160 N=113 
% POS % POS 
10% 
11 % 
14% 
6% 
16% 
31% 
9% 
5% 
16% 
11% 
8% 
8% 
2% 
13% 
18% 
19% 
5% 
14% 
14% 
7% 
5% 
8% 
9% 
17% 
22% 
17% 
13% 
7% 
4% 
11 % 
25% 
16% 
6% 
4% 
7% 
18% 
21 % 
11% 
15% 
24% 
10% 
11 % 
24% 
14% 
16% 
12% 
3% 
19% 
40% 
34% 
13% 
30% 
21% 
14% 
12% 
13% 
20% 
30% 
34% 
25% 
21 % 
7% 
5% 
11 % 
27% 
28% 
7% 
8% 
N=1&2 
% POS 
8% 
15% 
17% 
9% 
16% 
33% 
11 % 
12% 
25% 
18% 
10% 
15% 
4% 
15% 
27% 
21% 
11 % 
25% 
24% 
15% 
13% 
15% 
16% 
30% 
30% 
23% 
14% 
8% 
4% 
10% 
35% 
26% 
8% 
7% 
P-value 
trend ' 
0.6 
1.6 
2.6 
3.6 
4.6 
6.6 
&.6 
0.0& 
0.1 
0.1 
0.6 
0.1 
0.6 
0.7 
0.07 
0.8 
0.1 
0.03 
0.02 
0.03 
0.03 
0.07 
0.1 
0.01 
0.2 
0.3 
1.0 
0.8 
1.0 
0.7 
0.1 
0.07 
0.8 
0.3 
SKIN TYPE 
1111 III IIV 
N=133 
'Io POS 
6% 
14% 
20% 
8% 
14% 
29% 
13% 
N=273 
% POS P-va/ue ' 
10% 0.2 
14% 1.0 
16% 0.& 
8% 0.7 
16% 0.3 
31 % 0.4 
9% 0.& 
9% 9% 0.9 
21 % 21% 0.9 
12% 15% 0.4 
9% 11 % 0.6 
10% 11 % 0.6 
3% 3% 0.8 
14% 15% 0.6 
23% 29% 0.4 '?> 
21% 25% 0.3 ~ 
8% 11 % 0.3 iii' 
19% 24% 0.3 ~ 
iil 
20% 19% 1.0 ~ 
'" 9% 13% 0.2 8 
1\> ' 
8% 11 % 0.3 it 
14% 12% 0.8 ~ 
S 
12% 16% 0.4 So 
(1) 
23% 26% 0.& 'tl 
25% 28% 0.3 ~ 
20% 22% 0.& ~ 
Q. 
., 15% 15% 0.9 
' S 
5% 9% 0.1 & 
4% 4% Q7 a --~----~--~~~ 
12% 10% 0.8 ~ 
31% 29% 0.9 ~ 
24% 23% 0.8 ~ 
7% 8% 0.4 ~ 
HPV Human paplnomavlrus , POS number seroposltJve paoents. N number, NO Not defi ned Skin type was defined as (I) rarely tans, usually bums' (II) usually tans, can bum' (III) always tans rarely bums ' (IV) always tans, never bums ' . 
7% 6% 0.8 J 
Het heterogeneity tesL 
• Analyses were based on uncondluonal logls!Jc regression adlus ted for sex, time since transplantatJon and age at recrui tment' Analyses were based on cond,uonal on centre logistiC regression adlusted for sex, Ome since transplantallon nnd ago -
t recruitmenl P-values are based on tests for heterogeneity calculated by li kelihood ratio tests and tests for trend were obtamed by treallng categoncal vanable as a contJnuous vanable In the model ~ 
Some figures do not add up to 425 due to missing data P-va.lues were highlighted If less or equal than 0.01 
Warts 
Previous cancer 
Outdoor hobbies (after 
transplantation) 
Sunburn (before 
transplantation) 
Sunbath/sunbed 
Number of children 
Tobacco 
Number of 
transpantation 
Organ type 
(not kidney) 
Ever used oral 
contraceptive 
Ever used hormone 
replacement therapy 
Herpes Zoster 
Abnormal smear 
Genital warts 
Hair color (red or 
blonde) 
type 
species 
genus 
6· Risk factors associated wIth the presence of an/dJodJes agamst human paptIoma, s 
+ 
+ 
0 I 0 [T]0 J + + + + + 
0 
0 0 
3 2 27 7 16 6 13 5 8 20 24 36 93 9 15 17 23 38 49 75 76 92 96 4 65 95 48 50 60 41 1 63 101 10 
2 4 8 9 10 1 2 3 4 5 2 3 4 1 2 
ALPHA BETA GAMMA NU MU NA 
N: number: HPV: Human papillomavirus; NA: not available; Analyses were adjusted for age at recru itment, sex, time 
since transplantation and conditional on centre. 
Positive association , PSO.001 Negative association, PS0 001 
t Positive association, 0.001 <PsO.01 - Negative association, 0.001 <PSO 01 
Table 6.6: Summary of risk factors from the questionnaire associated with single HPV seroposi -
tivity among Caucasian control transplant patients (N=425) 
126 
~ 
I\) 
---.J 
~ 
c: (ti 
0') 
~ 
~ :IJ CD _ . 
(") C/) 
-g : ~ 
CD III 
::J (") 
............ 
C/) 0 
:E en 
;:::.' III 
:TC/) 
o C/) 
c 0 
...... (") 
C/) 0) ' 
'A ...... 
_ . CD 
::J a. 
£ :E 
::J.::+ 
(") :T 
~ 3 
...... c ~ -o =!". 
3-0 
OCD 
x I 
...... -U Q < 
a.C/) 
III CD 
::J ~ 
0.0 
-0 
'0 o C/) 
::J ;:::;: 
a. <' 0;:::;: 
::J,< 
III 
3 
o 
::J 
co 
o 
III 
C 
(") 
III 
C/) 
III 
::J 
...... 
~ 
III 
::J 
C/) 
-0 
III 
::J 
...... 
Risk factors 
Number 
Centre 
London 
Oxford 
Sex 
~ raw~2. 
243 5-</H ref 
'82 6518 0.7 (0.5-1 .0) 
Male 260 60/6 ref 
Female 165 57119 U (1 .1-1.8) 
Age at recruitment 
q4 '87 52/,9 ref 
CR & 9S%CI 
Alpha mucosal 
(3 types) 
P.0.02 
-P.O.O' 
44-59 156 61/5 0.6 (0.5-0.9) __ 
60 or more eo 70/6 0.5 (0.4-0.8) . -----
TIme since transplantation P< 0.00' 
<5 '50 57/1' ref 
5 to 9 113 65111 0.8 (0.6-12) 
10 or more '62 561'2 1.0 (0.7-1 .4) 
skin type' 
10r2 
30r4 
50r6 
Tobacco' 
61/'3 ref 135 
269 561'0 1.1 (0.8-1 .5) 
'79 64/1' 0.9 (0.6-1 .2) 
Never 202 63/'0 ref 
Past 56 53/'2 1.3 (0.8-1 .9) 
CUrYent 139 55/11 1.4 (1 .0-1 9) 
Alcohol consumption' 
1 or more '42 6319 ref 
less than 1 157 81/11 1.2 (0.8-1 .6) 
fonner 17 35/12 1.4 (0.8-2 .6) 
never 69 5-</10 1.3 (0.9-1 .9) 
Parity 
None 
lor 2 
3 Of more 
Sunburn 
never 
1 t03 
'57 61/'5 ref 
167 59/8 1 1 (0.8-1.5) 
75 57/8 1.4 (0.9-2 1) 
79 561'0 ref 
155 56113 1 1 (0.8-1.7) 
4 Of more 165 61/9 1.1(0.7-1.6) 
Sunburn before 18 
never 187 56/11 ref 
1 to 2 I IS 64112 1.0 (0 .7-1 4) 
3 Of more 92 591'0 1.1 (0.7-1.5) 
Sunbed use and sun bathing 
never ,30 58110 ref 
.. ,her 211 IlOJ9 1 0 (0.7-1 4) 
both S3 S512, 12 (0.8-18) 
Genita l warts 
neve' ~..: f52Ja ref 
P. 0 5 
.. er 21 11/44 2.5 (1.7-3.7) 
--Abnormal smear' P< 0 001 
"0 !o"ll14 ref 
.... 34137 1 9 (1 2-29) I _ 
Ever used HRT' P.O._ 
SAl ref 
.... , 1 1 (08-21) 
0.7 
O.S 2 4 
~ ~~b+ 
CR & 9S%CI 
Alpha cutaneous 
(4 types) 
6511. ref 
70fT 0.8 (0.6-1.0) 
68/8 ref 
65116 1.3 (0.9-1.7) 
P. O.' 
8111 7 ref 
7218 0.6 (0.5-0.9) __ 
71/6 0.6 (0.4-1.0) 
69/8 ref 
62115 1.3 (0.9-1.9) 
69112 1.1 (0.8-1 .5) 
65112 ref 
69110 0.9 (0.7-1.3) 
72/11 0.8 (0.6-12) 
68112 ref 
64110 1.0 (0.7-1.6) 
70/6 0.9 (0.6-1 .3) 
67111 ref 
70110 0.9 (0.6-1 .3) 
P.0.007 
65112 1.0 (0.5-2.1) ,., 
67fT 1.0 (0.6-1.5) 
P.1.0 
64116 ref 
70/6 0.7 (0.5-1 .1) 
7217 0.8 (0.5-1 .3) _ I 
66114 ref 
69112 0.9 (0.6-1.4) 
6817 0.9 (0.6-1.4) 
65111 ref 
66/12 1.0 (0.7-1 .5) 
m4 0.6 (0.4-' .0) 
62/12 ref 
7318 0.7 (0.5-1.0) 
66115 0.9 (0.6-1 .5) 
7019 ref 
35121 2.1 (1 ~ 4) 
72111 ref 
5-<120 1 4 (0.9-24) 
87114 ref 
68111 1 8 (0.9-36) 
P. 0 2 
P.0.7 
P.0.06 
P.04 
P.0.003 
P.0.2 
P·Ol 
0.5 
• 
2 
_ _ _ _ _ _ .t r~t .......... ,",I'M;. tran.."taton end c.enh ,-.tI.,.. .pCWOpn.~) 
4 
~ ~~~2+ 
42139 ref 
47136 0.8 (0.6-1.1 ) 
.3137 ref 
46139 1.1 (0.8-1.4) 
.3137 ref 
46f31 0.9 (0.7-1.3) 
«139 0.9 (0.6-1.4) 
51133 ref 
CR & 9S%CI 
Beta 
(16 types) 
P.0.7 
35/44 1.9 (1.3-2.8) 
--45138 1.6 (1.1-2.3) - +--
P.0.02 
47135 ref 
43138 1.1 (0.8-1.5) 
42/36 1.3 (0.9-1.8) 
P.05 
43135 ref 
48/43 0.7 (0.4-12) of(_t_ ....... -+-
45/40 0.9 (0.6-1.4) 
P.0.5 
44139 ref 
45138 1.0 (0.7-1.4) 
24/41 1.2 (0.5-2.7) I -
48130 0.7 (0.5-1 .2) --4_ ....... "'-
41139 ref 
48/37 0.8 (0.6-12) 
43139 1.1 (0.7-1 .9) 
431., ref 
46f34 0.9 (0.6-1.5) 
43/40 1.0 (0.6-1 .6) 
•• '''0 ref 
4.135 0.9 (0.6-1.3) 
45/39 1 1 (0.7-1.7) 
47J3.t rer 
.5f3B 12 (0.8-1.7) 
38145 1.5 (0.9-2 .6) 
45/36 ref 
32184 , .7 (0.9-32) 
53/33 ref 
29/54 2.3 (12~ 5) 
45137 ref 
46/41 12 (0.6-2.3) 
P.0.6 
P.08 
P.0.9 
P.O.l 
P.OI 
P.O.Ol 
P. 0.7 
0.5 2 
J c.,-0Qff .. • '. rr..."a... ... ~ r.j_~",,,-
"'P!+ ~:41.'!:. ~~~.Ij1r.~~ =0:::.;. and pe~~ btI.ng .. f09C"I ..... to 2 or mot. HPV t)'~. of 1M~"'" 
4 
U~2+ 
49126 ref 
56124 0.9 (0.7-1.2) 
5-</23 ref 
52/29 1.1 (0.8-1 .5) 
49130 ref 
54/23 0.8 (0.6-1 .1) 
59119 0.7 (0.5-1 .0) 
61/19 ref 
43/32 1.5 (1.0-2.2) 
52127 1.4 (1.0-1.9) 
56m ref 
52124 1.1 (0.8-1 .5) 
56120 1.1 (0.7-1.5) 
47128 ref 
64116 0.6 (0.4-1.0) 
6'/23 0.8 (0.6-1 .1) 
57/23 ref 
51/25 1.1 (0.8-1.5) 
CR & 9S%CI 
Gamma 
(6 types) 
P.0.06 
41/41 1.3 (0.6-2.6) _____ nnrnn_n __ n-
64119 0.8 (0.5-1.3) _ 
P.0.6 
47129 ref 
61/22 0.7 (0.5-1.0) 
53120 0.8 (0.5-1 .3) _ I 
58120 ref 
52128 1.2 (0.8-1 .8) 
55/23 1.1 (0.7-1.7) 
5Om! ref 
58/24 0 .8 (0.5-1 1) 
58122 0.7 (0.5-1 1) 
56117 ref 
55/26 1.3 (0.9-1 .8) 
43/38 1.9 (1.2-3 1) 
5-<125 ref 
50125 1 1 (06-2.0) 
56/25 ref 
46f34 1.4 (08-2.5) 
57125 ref 
46132 1 9 (1 1-3 4) 
P. 0 2 
P.0.007 
P.0.7 
P.0.2 
P, 003 
O.S 
• 
• 
2 4 
CR & 9S%CI 
Other 
~ ~~~2+ (S types) 
49/25 ref 
62/14 0.6 (0.5-0.8) __ 
P<O.ool 
591' 8 ref 
46122 1.3 (1.0-1.7) 
51/21 ref 
57120 0.9 (0.7-12) 
59/'8 0.8 (0.6-1.2) 
61115 ref 
50122 1.3 (0.9-1 .8) 
52/23 1.3 (1.0-1 .8) 
53/21 ref 
57120 1.0 (0.7-1.3) 
6Q12O 1.0 (0.7-1.4) 
5'/25 ref 
62/17 0.7 (0.4-1 .0) 
561, 8 0.7 (0.5-1.0) 
56122 ref 
56122 1.0(0.7-1.4) 
P. 009 
P. I 0 
p . 0.06 
59/24 0.8 (0.4-1 .6)~(--4:'-1f-
551'0 0.8 (0.5-1 .2) -_t-~·-
S4/24 ref 
57117 0 .7 (0.5-1.0) 
55120 0.9 (0.6-1.3) 
4./24 re f 
52123 0.9 (0.6-1 .3) 
64118 0.7(0.5-1.0) 
51/21 ref 
56/23 1 1 (0 8-1 .6) 
601'5 0.9 (0.8-1 3) 
57118 ref 
57119 1 1 (08-1.5) 
45131 1 .6 (10-2 4) 
54120 rof 
57119 12 (0 7,20) 
46122 ref 
54131 12 (0.8-20) 
53120 r.f 
4Yl1 lQ (1.2-3 3) 
P.0.5 
p. 007 
P. 01 
P.04 
r.OOl 
O.S 2 4 
'?> 
~ 
iii' 
~ 
iil 
! 
a 
! 
s 
~ 
~ 
~ 
Q. 
!!:: 
'" i 
1 
i 
J 
~ 
c:r HPV BOTH CENTRES OXFORD LONDON (b 
~ Caucasian Non-Caucasian Caucasian Non-Caucasian Caucasian Non-Caucasian 
" 
VI OR* of Caucasian 
'. :l no POS (%) no POS (%) no POS (%) no POS (%) no POS (%) no POS (%) 
~' I c species type vs non-Caucasian P*-value 
ct) "1J <II N=425 N=201 N=182 N=35 N=243 N=166 ~< Ol 95% CI (J) 2 3 36 (8%) 13 (6%) 0.7 (0.4-1.4) 0.3 15 (8%) 1 (3%) 21 (9%) 12 (7%) 
~ (J) 2 61 (14%) 25 (12%) 0.8 (0.5-1.3) 0.4 20 (11%) 6 (17%) 41 (17%) 19 (11%) _ . ct) 4 - ...... ::ro IV 27 73 (17%) 29 (14%) 0.7 (0.5-1.2) 0.2 22 (12%) 6 (17%) 51 (21%) 23 (14%) 0"0 oJ: 8 7 36 (8%) 22 (11%) 1.3 (0.7-2.4) 0.3 13 (7%) 7 (20%) 23 (9%) 15 (9%) c ...... a. 
_ct) 
(J) < IV 9 16 67 (16%) 30 (15%) 0.9 (0.6-1 .5) 0.7 27 (15%) 6 (17%) 40 (16%) 24 (14%) 
A" 0> 6 128 (30%) 50 (25%) 0.7 (0.5-1 .1) 0.08 47 (26%) 7 (20%) 81 (33%) 43 (26%) - ' ct) 10 :::l :::l 13 42 (10%) 24 (12%) 1.1 (0.6-1 .9) 0.8 10 (5%) 6 (17%) 32 (13%) 18 (11%) n n 
0> ct) 5 39 (9%) 34 (17%) 2.0 (1 .2-3.4) 0.01 12 (7%) 7 (20%) 27 (11%) 27 (16%) :::l 
nCT 8 91 (21 %) 45 (22%) 1.0 (0.7-1 .6) 0.9 33 (18%) 7 (20%) 58 (24%) 38 (23%) ct)'< 
...... 20 61 (14%) 24 (12%) 0.8 (0.5-1.4) 0.4 22 (12%) 6 (17%) 39 (16%) 18(11%) 
----ct) 1 
0> - 24 47(11%) 16 (8%) 0.8 (0.4-1.4) 0.4 21 (12%) 5 (14%) 26 (11%) 11 (7%) n ::r 
...... :::l 36 50 (12%) 15 (7%) 0.6 (0.3-1 .1) 0.07 14 (8%) 5 (14%) 36 (15%) 10(6%) o _. 
(J) Q. 93 12 (3%) 19 (9%) 2.6 (1 .2-5.6) 0.01 1 (1 %) 2 (6%) 11 (5%) 17 (10%) (J) - <r> '< 
n 9 65 (15%) 32 (16%) 1.0 (0.6-1 .5) 0.9 20 (11%) 7 (20%) 45 (19%) 25 (15%) ~ ...... ct)"'-" IV 15 116 (27%) 47 (23%) 0.9 (0.6-1.4) 0.7 52 (29%) 13 (37%) 64 (26%) 34 (20%) I\) :::lO 
-
,.. 
ex> -0> <II 2 17 100 (24%) 46 (23%) 0.9 (0.6-1.4) 0.7 39 (21%) 8 (23%) 61 (25%) 38 (23%) 1il ...... C ..0 n 
ct) n 0 
0> 23 41 (10%) 25 (12%) 1.2 (0.7-2.1) 0.5 12 (7%) 4 (11 %) 29 (12%) 21 (13%) iil 
(J) 38 95 (22%) 46 (23%) 1.1 (0.7-1 .6) 0.8 39 (21%) 10 (29%) 56 (23%) 36 (22%) i 0> 49 84 (20%) 33 (16%) 0.9 (0.6-1.4) 0.7 38(21%) 10(29%) 46 (19%) 23 (14%) :::l III 
< 3 75 50 (12%) 26 (13%) 1.1 (0.6-1 .8) 0.8 17 (9%) 6 (17%) 33 (14%) 20 (12%) ~ 
ct) 76 42 (10%) 27 (13%) 1.4 (0.8-2.3) 0.3 13 (7%) 6 (17%) 29 (12%) 21 (13%) ~ ...... s (J) 
c 4 92 52 (12%) 30 (15%) 1.2 (0.7-2.0) 0.5 15 (8%) 8 (23%) 37 (15%) 22 (13%) s (J) Q) 
5 96 62 (15%) 29 (14%) 1.0 (0.6-1 .7) 0.9 26 (14%) 8 (23%) 36 (15%) 21 (13%) ~ :::l 
0 4 108 (25%) 37 (18%) 0.7 (0.4-1.1) 0.08 42 (23%) 10 (29%) 66 (27%) 27 (16%) Q) 
:::l 1 65 119 (28%) 51 (25%) 0.8 (0.6-1 .3) 0.4 45 (25%) 10 (29%) 74 (30%) 41 (25%) ~ , 
0 IV Q. E 95 91 (21 %) 36 (18%) 0.8 (0.5-1 .3) 0.3 37 (20%) 6 (17%) 54 (22%) 30 (18%) 0> E ~ c 2 48 66 (16%) 34 (17%) 1.1 (0.7-1.7) 0.8 27 (15%) 5 (14%) 39 (16%) 29 (17%) i n IV 0> en 3 50 32 (8%) 18 (9%) 1.1 (0.6-2.2) 0.7 13 (7%) 4 (11 %) 19 (8%) 14 (8%) (J) m 
0> 4 60 19 (4%) 16 (8%) 1.7 (0.8-3.4) 0.2 7 (4%) 3 (9%) 12 (5%) 13 (8%) ~ 
:::l :l 1 41 46 (11%) 33(16%) 0.2 14 (8%) 6 (17%) 32 (13%) 27 (16%) ~ c 1.4 (0.8-2.3) 
- 1 124 (29%) 34 (17%) 0.5 (0.3-0.7) <0.001 43 (24%) 9 (26%) 81 (33%) 25 (15%) ...... ::J 1 0> 
:::l E 2 63 98 (23%) 38 (19%) 0.7 (0.5-1.1) 0.1 31 (17%) 6 (17%) 67 (28%) 32 (19%) (J) 
"0 ; 101 30 (7%) 30 (15%) 1.9 (1 .1-3.3) 0.02 5 (3%) 5 (1 4%) 25 (10%) 25 (15%) 
oJ: 0> (5 103 26 (6%) 12 (6%) 0.9 (0.4-1 .9) 0.8 8 (4%) 4 (11 %) 18 (7%) 8 (5%) :::l 
- • P-values were calculated uSing conditional (on centre) logistic regression were adjusted for sex, time since transplantation and age at recruitment. 
"0 
0> HPV Human papiliomavirus; OR ' Odds ratio ; CI : confidence interval; no POS: number seropositive patients 
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MIchael frl Waterboer Casabonne frl a/. (2007) & Casabonne 
a/. (2008) et a/. (2008) present study et a/. (2007) 
country Germany __ Italy UK 
city All Rome Oxford & London Oxford 
ethnicity NA NA CaucasIan Caucasian Caucasian 
number 1610 77 (73) 182 425 
IC IC IC Tx Subject (all adtJts) (v.rthoul.Ion (v.rthout olon (v.rthout olon 
cancer) cancer) cancer) 
Age at NA 75% older 57 (15) 47 [13] 
recruitmen than 64 23 to 91 19 to 83 
Ratio sex NA 1.5 (51/33) 1.0 (92190) 1.6 (261/165) 
III 
III 
III II 
" 
u 8. P-het c 8. i!:' ., % eosltJve % eosllive % eosihve % eosltive (a) ~ III 
2 I 3 6 12 10 8 0.4 
4 2 5 16 10 14 0.3 
.. 27 11 17 0.08 
..c. 8 I 7 7 8 0.6 Q. ;;; 9 16 8 18 19 16 0.1 
10 11
6
3 
30 
8 10 0.7 
5 6 29 16 9 0.03 
8 12 43 15 21 0.09 
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CHAPTER 7 
Human papillomavirus in relation to cutaneous squamous and 
basal cell carcinoma 
7.1 Introduction 
This chapter summarises results from the pilot prospective study nested in the Oxford 
component of the European Prospective Investigation into Cancer and Nutrition (EPIC-
Oxford) in Section 7.2 and from the Oxford and London case-control studies among trans-
plant patients in Section 7.3. It includes reports on the association between SCC and 
BCC in relation to various risk factors from questionnaire data and also on the relation-
ship between antibodies against HPV-L 1 antigens for 38 HPV types (34 types in the 
London and Oxford studies) with sera collected prior to and after diagnosis of the first 
SCC or BCC. The chapter ends with a discussion. 
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7.2 A prospective pilot study nested in the Oxford compo-
nent of the European Prospective Investigation into Can-
cer and Nutrition (EPIC-Oxford) 
7.2.1 Statistical methods 
Fisher exact tests and unpaired Student t-tests were used to compare response propor-
tions and means. To examine the association between incident SCC and seropositivity 
to each HPV type, logistic regression was used to derive odds ratios (OR) and their 95% 
confidence intervals (CI) adjusted for age at recruitment «55, 55-64, ~65+), sex and re-
gion of cancer registry categorised as Oxfordshire and other since most individuals were 
registered in Oxfordshire. When fewer than 5 patients were seropositive to an HPV type, 
P-values were derived using Fisher's exact. 
To examine the association between multiple HPV seropositivity and SCC, negative bi-
nomial regression adjusted for the same factors was used since over-dispersion was ob-
served when Poisson models were fitted and ORs were also derived using logistic regres-
sion based on categorical data (seronegative to all, seropositive to 1 type, seropositive to 
2 or more types). 
A small number of patients already had prevalent SCC, descriptive statistics (number 
and percentage) relating to associations between seropositivity to a single HPV type and 
disease among these patients were also examined. 
Missing value categories were added to adjustment variables with incomplete information 
in order to retain all the observations in the analysis. Likelihood ratio tests were used to 
assess heterogeneity tests. All P-values are derived from two-sided tests of statistical 
significance. Statistical analyses were carried out using STATA 9 (StataCorp. 2005). 
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7.2.2 Results 
Table 7.1 shows the distribution by age, sex, and other descriptive variables for incident 
see and controls. There were no statistically significant differences in the distribution of 
any of the variables between the incident see and the control group. The mean follow-up 
time was similar (9 years) for incident see (So: 1.0 years) and the control group (SO: 
2.0 years) (P=0.2). Among controls, there were no statistically significant associations 
between any HPV type or genus, with age, sex or location of residence at recruitment 
(Table 7.2). 
In Table 7.3, the association between each HPV type and incident see was examined. 
Seroprevalence data were also reported in patients with prevalent see. There were no 
statistically significant differences in the seroprevalence of antibodies against any of the 
38 HPV types examined between incident see and controls. Among prevalent sec, 
the prevalence of antibodies against HPV was generally higher for the majority of the 
38 types examined compared to the incident see or to the control group. For betaHPV 
types specifically, the prevalence of antibodies was higher among prevalent SCC than 
among incident see for 10 of 16 types examined (63%). However, the numbers of sce 
examined were small and differences were not statistically significant. For HPV-8 (which 
has been linked to see in previous studies), the seroprevalence of antibodies was 20% 
(16/80) in controls, 23% (9/39) among incident see (OR 1.1, 95% el 0.4-3.0; P=1.0) 
and 40% (6/15) among prevalent see (P-value for controls versus prevalent SCC=0.2). 
Among the incident see only, the seroprevalence of some beta types was higher for 
individuals who were diagnosed close to the time of blood collection. For example, the 
seroprevalence of antibodies against HPV-8 was 16% (5/32) among those who were di-
agnosed 18+ months after blood collection, but 57% (4/7) for those who were diagnosed 
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within 18 months of blood collection. In addition, although only 7 see had their blood 
taken less than 18 months before diagnosis, three were seropositive to HPV-38 (43%) 
and four were seropositive for HPV types 9 and 17 (57%). 
In Table 7.4 the association between the presence of antibodies against multiple HPV 
types (seronegative, positive to one or positive to two or more types) and the risk of 
see is shown for incident see and controls. Results using negative binomial distribution 
are reported in Table 7.5. Antibodies against any HPV types were frequently detected: 
67% of the incident see were found seropositive to at least two HPV types compared 
to 66% of the controls; the differences were not statistically significant. For beta types, 
the equivalent seroprevalence was 44% in incident see and 38% in controls; again, the 
differences were not statistically significant. 
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Controls Incident SCC 
N=80 N=39 
Sex 
male 42 (53%) 24 (62%) 
female 38 (47%) 15 (38%) 
Age at recruitment (years) 
<55 17 (21%) 7 (18%) 
55- 33 (41%) 16 (41%) 
65+ 30 (38%) 16(41%) 
mean (SO) 61.5 (7.2) 61.7 (7.0) 
range 42 to 76 48 to 76 
Region of residence 
Oxfordshire 46 (58%) 21 (54%) 
other 34 (43%) 18 (46%) 
Follow-up time (years) 
mean (SO) 9.0 (2.0) 9.4(1.0) 
range o to 11 6 to 12 
Age at diagnosis (years) 
mean (SO) 66.6 (8.2) 
range NA 48 to 85 
Time from blood collection to 
diagnosis of cancer (years) 
mean (SO) NA 4.6 (2.6) 
ran~e 1 mth to 10 
SD: Standard deviation; N: number; NA: Not available; mth: month. 
SCC: squamous cell carcinoma 
Prevalent SCC 
N=15 
5 (33%) 
10 (67%) 
3 (20%) 
5 (33%) 
7 (47%) 
62.0 (8.3) 
43 to 75 
11 (73%) 
4 (27%) 
8.7(2.0) 
2 to 10 
58.2 (9.1) 
39 to 71 
-4.2 (4.5) 
-15 to -0.2 
Table 7.1: Descriptive statistics of the controls and of incident and prevalent cutaneous squamous 
by age at recruitment, sex, region of residence, age at diagnosis, follow-up time and 
time from blood collection to diagnosis of first see 
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Controls Prevalent 
Incident SCC SCC 
HPV N=80 N=39 N=15 
III NoPOS No P~S ::s 
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2 8 (10) 3 (8) 1.0 1 (7) 
4 27 10 (13) 3 (8) 0.5 3 (20) 
'" ~ 57 6 (8) 0(0) Q. 0.2 0(0) 
ii 
7 18 5 (6) 3 (8) 0.7 4 (27) 
8 7 5 (6) 1 (3) 0.7 1 (7) 
9 16 8 (10) 3 (8) 1.0 3 (20) 
10 
11 13 (16) 7 (18) 1.2 (0.4-3.4) 0.7 1 (7) 
13 7 (9) 4 (10) 0.7 1 (7) 
5 16 (20) 5 (13) 0.5 (0.2-1.6) 0.3 1 (7) 
8 16 (20) 9 (23) 1.1 (0.4-2.9) 0.8 6 (40) 
1 
20 17 (21) 9 (23) 1.1 (0.4-2.7) 0.9 3 (20) 
24 16 (20) 5 (13) 0.5 (0.2-1.6) 0.3 2 (13) 
36 13 (16) 6 (15) 0.8 (0.3-2.5) 0.8 1 (7) 
93 3 (4) 2 (5) 0.7 0(0) 
9 16 (20) 8 (21) 1.0 (0.4-2.7) 1.0 4 (27) 
!! 15 15 (19) 4 (10) 0.3 3 (20) 
CII 
..c 2 17 12 (15) 8 (21) 1.5 (0.5-4.0) 0.5 2 (13) 
23 9 (11) 1 (3) 0.7 3 (20) 
38 14 (18) 10(26) 1.5 (0.6-3.9) 0.4 5 (33) 
49 16 (20) 8 (21) 0.8 (0.2-2.4) 0.6 4 (27) 
3 75 10 (13) 3 (8) 0.5 3 (20) 
76 14 (18) 4 (10) 0.4 3 (20) 
4 92 9 (11) 4 (10) 1.0 4 (27) 
5 1 96 14 (18) 6 (15) 0.8 (0.3-2.3) 0.7 4 (27) 
4 25 (31) 16(41) 1.6 (0.7-3.5) 0.3 4 (27) 
1 65 18 (23) 8 (21) 0.8 (0.3-2.2) 0.7 5 (33) 
'" 16 (20) 8 (21) 1.0 (0.4-2.6) E 95 1.0 3 (20) 
E 
1 48 15 (19) 4 (10) 0.3 2 (13) 
'" 
2 til 
3 50 7 (9) 3 (8) 0.6 3 (20) 
4 1 60 3 (4) 0(0) 0.5 0(0) 
:::J 1 41 11 (14) 2 (5) 0.2 1 (7) c: 
E I 
1 I 1 18 (23) 8 (21) 0.9 (0.3-2.3) 0.8 4 (27) 
2 63 12 (15) 5 (13) 0.8 (0.2-2.4) 0.7 3 (20) 
0 1 101 2 (3) 0(0) 1.0 1 (7) 
z 103 5 (6) 2 (5) 0.6 1 (7) 
1 Adjusted for age at recruitment «55,55-,65+), sex and region of residence (Oxfordshire, other). 
No POS: number of HPV seropositive plasma samples; ND: Not defined 
N: number; OR: odds ratio; CI: confidence interval 
*: When the number of HPV seropositive patient was less than 5, P-value was derived using Fisher's exact test 
Table 7.3: Antibodies against capsid L 1 protein of 38 human papillomavirus (HPV) types among 
controls, incident and prevalent see 
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Controls 
N= 80 
Seropositive No POS 
against 1 (%) 
Alpha-cutaneous 
0 46 (58) 
1 20 (25) 
2 or more 14 (18) 
Alpha-mucosal 
0 58 (73) 
1 15 (19) 
2 or more 7 (9) 
Beta 
0 34 (43) 
1 16 (20) 
2 or more 30 (38) 
Beta1 
0 48 (60) 
1 14 (18) 
2 or more 18 (23) 
Beta2 
0 50 (63) 
1 16 (20) 
2 or more 14 (18) 
Beta3 
0 60 (75) 
1 6 (8) 
2 or more 14 (18) 
Gamma 
0 39 (49) 
1 21 (26) 
2 or more 20 (25) 
Gamma1 
0 47 (59) 
1 16 (20) 
2 or more 17 (21) 
Nu 
0 69 (86) 
1 11 (14) 
Mu 
0 58 (73) 
1 14 (18) 
2 8 (10) 
ND 
0 74 (93) 
1 5 (6) 
2 or more 1 (1) 
Any HPV 
0 11 (14) 
16 (20) 
2 or more 53 ~66~ 
NoPOS 
(%) 
23 (59) 
11 (28) 
5 (13) 
26 (67) 
10(26) 
3 (8) 
18 (46) 
4 (10) 
17 (44) 
23 (59) 
8 (21) 
8 (21) 
23 (59) 
9 (23) 
7 (18) 
29 (74) 
6 (15) 
4 (10) 
20(51) 
11 (28) 
8 (21) 
21 (54) 
10(26) 
8 (21) 
37 (95) 
2 (5) 
30 (77) 
5 (13) 
4 (10) 
37 (95) 
2 (5) 
0(0) 
8 (21) 
5 (13) 
26 (67) 
Incident see 
N=39 
7- Human paC,fOrr a virus in relation to cutaneous squamous and basal cell carcinoma 
OR2(95% CI) p 3 
ref 
1.1 (0.5-2.8) 
0.7 (0.2-2.3) 0.7 
ref 
1.6 (0.6-4.2) 
1.0 (0.2-4.1) 0.7 
ref 
0.5 (0.1 to 1.7) 
1.0 (0.4 to 2.5) 1.0 
ref 
1.2 (0.4-3.2) 
0.8 (0.3-2.3) 0.8 
ref 
1.2 (0.5-3.2) 
1.1 (0.4-3.0) 0.8 
ref 
1.9 (0.6-6.6) 
0.6 (0.2-1.9) 0.6 
ref 
1.0 (0.4 to 2.7) 
0.8 (0.3 to 2.2) 0.7 
ref 
1.3 (0.5-3.5) 
1.0 (0.4-2.8) 0.8 
ref 
0.3 (0.03 to 1.6) 0.2 
ref 
0.7 (0.2 to 2.3) 
0.9 (0.2 to 3.7) 0.8 
ref 
0.7 (0.1 to 4.7) 
NA 0.7 
ref 
0.4 (0.1 to 1.9) 
0.7 (0.2 to 2.1) 0.7 
'Alpha genus types: 2.3.7,10,11,13,16,18,27,57,77; Beta genus types: 
5,8,9,15,17,20,23,24,36,38,49,75,76,92,93,96; Gamma genus types: 4, 48, 50, 
60. 65. 95; Nu genus type: 41; Mu genus types: 1. 63 ; new types: 101. 103 
2 Adjusted for age at recruitment «55, 55-, 65+), sex and region of residence 
(Oxfordshire. other). 
3 P-value for linear trend. 
No pas: number of HPV seropositive plasma samples; SCC: squamous cell 
carcinoma 
N: number; OR: odds ratio; CI: confidence interval; ND: Not defined; HPV: 
human papilloma virus 
Beta 1 , 2 or 3: Positive to HPV types from species 1, 2 or 3 respectively of 
genus beta. Gamma1: Positive to HPV types from species 1 of genus gamma. 
Table 7.4: Antibodies against capsid L 1 protein of multiple human papillomavirus (HPV) types 
among controls and incident see (using logistiC regression) 
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Squamous cell carcinoma 
Control incident SCC prevalent SCC N=39 N=15 
°loneg I °loneg I 
010 neg I 010 pos %pos to 2 %pos to 2 
HPV to 2 or more or more CR1 (95% CI) P-value or more CR1 (95% CI) P-value 
alpha - mucosal 73/9 67/8 1.0 (0.5-2.1) 0.9 53/7 1.4 (0.5-3.6) 
alpha - cutaneous 58/18 59/13 0.8 (0.5-1.4) 0.5 73/13 0.7 (0.3-1.7) 
beta 43/38 46/44 0.9 (0.5-1.6) 0.7 33/40 1.4 (0.5-3.6) 
gamma 49/25 51/21 0.9 (0.5-1.6) 0.8 40/27 1.0 (0.5-2.2) 
nu, mu and NO 63/12 72/10 0.7 (0.4-1.3) 0.3 53/7 1.2 (0.5-3.0) 
HPV: Human papillomavirus; SCC: squamous cell carcinoma; N: number; CR: Count ratio; CI: confidence interval. 
Neg: seronegative: Pos: seropositive 
1 Using negative binomial regression adjusted for sex, age at recruitment, time since transplantation, skin type and centre (where 
appropriate)_ 
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7- Human papillomavirus in relation to cutaneous squamous and basal cell carcinoma 
7.3 The London and Oxford case-control studies 
7.3.1 Statistical methods 
Since non-melanoma skin cancers occur mainly in Caucasian populations, analyses look-
ing at the association between HPV seropositivity or risk factor from the questionnaire 
and SCC / BCC were restricted to Caucasian patients_ Analyses examining the asso-
ciation between seropositivity to HPV16 and a self-reported history of abnormal smear 
test and between seropositivity to HPV6 and self-reported history of genital warts were 
not restricted to Caucasian patients. Odds ratios (OR) were estimated to measure the 
association between SCC and risk factors from the questionnaire using conditional on 
centre logistic regression adjusted for sex, age at recruitment (::;44, 45-59, 2:60), time 
since transplantation (::;5 years, 5 to 9 years, 2: 10 years) and skin type (I and II, III and 
IV). Conditional logistic regression on centre was used to deal with the potential for bias 
due to confounding by center. Age, sex and time since transplantation were included 
in the model due to their association with both the outcome and the exposure variable, 
HPV. Skin type was included in the model as it is strongly associated with the outcome 
variable. 
As the number of patients who answered the questionnaire differed from the ones who 
gave specimens (Figure 5.2), the figures in tables do not always compare directly be-
tween analyses involving HPV results and those based on questionnaire only. Where 
results are presented in the form of plots, black circles indicate the odds ratios and hori-
zontallines represent 95% confidence intervals (CI). 
To examine the relationship between seropositivity to a single HPV type or multiple HPV 
seropositivity (seronegative to all, seropositive to 1 type, seropositive to 2 or more) in 
cases (SCC and BCC only), odds ratios were estimated using conditional logistic regres-
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sion on centre and adjusted for sex, age at recruitment (:S44, 45-59, 2:60), time since 
transplantation (:S5 years, 5 to 9 years, 2: 1 0 years) and skin type (I and II, III and IV). 
Multiple HPV seropositivity was also examined by species within genus. Negative bi-
nomial distribution (using multiple seropositivity as continuous variables) was also used 
with adjustment for the same factors as over-dispersion was observed in Poisson models. 
All analyses were also performed for each centre separately using unconditional logistic 
regression adjusted for the same factors. Five sensitivity analyses were performed to 
explore further the association between HPV and prevalent SCC i) with CIS included as 
SCC; ii) restricted to SCC only; iii) restricted to patients transplanted for 5 years or more; 
iv) restricted to SCC diagnosed four years before recruitment. 
Descriptive statistics (number and percentage) were reported when figures were too low 
to derive adjusted estimates «5 patients). To deal with multiple significance tests, agree-
ment between results of the 2 centres was used to detect genuine associations and the 
level of statistical Significance was set to 1 %. Missing value categories were added to 
adjustment variables with incomplete information in order to retain all the observations 
in the analysis. Likelihood ratio tests were used to assess heterogeneity and trend tests 
(obtained by treating the categorical variable as a continuous variable in the model). All 
P-values were two-sided. Statistical analyses were carried out using STATA 9 (StataCorp, 
2005). 
7.3.2 Results for risk factors based on questionnaire data 
• Baseline characteristics of participants 
The characteristics of study populations are shown in Table 7.6 and Figure 7.1. 
There was no statistically significant difference between London and Oxford in 
terms of sex, age at recruitment, time since transplantation and skin type (more 
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details in Chapter 8). The mean time between transplantation and the development 
of the first skin cancer was 11.9 years [SO: 7.3 years] for sce and 10.0 years [SO: 
6.7 years] for BCC. The median time between diagnosis of prevalent sce and re-
cruitment was -4 years [1025= -2years and 1075= -7years]. Patients with sec had 
an average of 5.2 lesions [SO: 8.5] and those with BCC had 3.5 lesions [SO: 4.2]. 
As expected, BCC were more often detected on non sun-exposed skin only (25%) 
than SCC (12%) (P= 0.01). For SCC, the main body sites involved were the head 
(39%), hand/wrist (28%), arms (12%) whereas for Bee, lesions tended to occur 
on the head (58%), the back (19%) and on the chest/shoulder (8%). In contrast to 
SCC, BCC were uncommon on hands (2%). 
• Risk factors from the questionnaire in relation to see 
Figures 7.2 and 7.3 show the odds ratios for OTR with SCC (140 patients) compared 
to controls (454 patients) for various risk factors examined using data from the ques-
tionnaire. Men were more likely to develop sec than women (p=0.02) and odds 
ratios for SCC also increased with increasing age at recruitment (P-trend<0.001) 
and with time since transplantation (P-trend<0.001). Patients with sec were 13 
times (95% CI: 6.3 to 28.1) more likely than controls to have been transplanted 
more than 10 years prior to recruitment. Patients with skin type I and II were also 
more likely to develop SCC than those with skin type III and IV (P<0.001). A his-
tory of actinic keratoses (AK) or cutaneous warts was positively associated with the 
development of SCC. Transplant data variables and self-reported history of non-
cutaneous cancer, psoriasis, genital warts or herpes loster was not associated 
with the development of SCC; nor were any of the data for women relating to sexual 
and reproductive factors. Being born first compared to being born second or third 
142 
7- Human papilloma virus in relation to cutaneous squamous and basal cell can::moma 
or higher order was associated with increased odds of developing sec (P-value for 
trend= 0.02). A self report of being married or currently living with a partner was 
associated with an increased risk of SCC (OR: 2.1, 95% CI: 1.2 to 3.6: P= 0.01). 
Current smokers appeared less likely to develop sec than controls but this finding 
was driven by data from only one centre (London). There was no Significant asso-
ciation between SCC and types of academic qualification, eye or hair colour, birth 
country, body mass index, physical activity or markers of crowding and proximity 
after controlling for age, sex, time since transplantation, skin type and centre. Re-
garding UV radiation exposure, the number of sunburns before the age of 18 years 
was positively associated with SCC (P-value for trend<0.002; 3 or more burns ver-
sus never: OR: 3.3, 95% CI: 1.8 to 6.2). Cases with SCC were more likely to have 
had holidays in sunny countries after transplantation but no clear dose-relationship 
was detected (P-trend=0.08). Patients with SCC and controls did not differ in terms 
of other markers of UV exposure. Conditional on centre logistic regression with all 
potential confounding variables in the model (sex, age at recruitment [less than 44, 
45-59,60 or more], time since transplantation [less than 5 years, 5 to 9 years, 10 
or more years], skin type [I and II, III and IV], number of sunburns before the age 
of 18 [none, 1 to 2, 3 or more], birth order [1,2, 3 or more] and currently living with 
partner or being married [yes, no]) did not produce any material difference to any of 
the results (Table 7.7). 
• Risk factors from the questionnaire in relation to BGG 
Figures 7.4 and 7.5 show the odds ratios for OTR with Bee only (33 patients) 
compared to controls (454 patients) for various risk factors examined using data 
from the questionnaire. Men were more likely to develop BCe only than women 
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and the age at recruitment was positively associated with the occurrence of BCC. 
Patients transplanted more than 10 years ago prior to recruitment were 6 times 
more likely to develop BCC compared to those transplanted for 5 years or less (95% 
CI: 1.9 to 17.8). Patients with skin type I and II were also more likely to develop BCC 
only than those with skin type III and IV. 
No association was found between a history of actinic keratoses and warts and 
the presence of BCC only; nor were any of the data for women relating to sexual 
or reproductive factors, transplant data (i.e organ type, donor relationship), cancer 
history, psoriasis, genital warts or herpes zoster. There was also no statistically 
significant association between cases with BCC only and the type of academic 
qualification, eye or hair colour, birth country, body mass index, physical activity or 
markers of proximity. However, it should be borne in mind that only 33 patients with 
BCC only were involved in these analyses. Regarding markers of UV exposure, pa-
tients who reported going on holidays in sunny countries after transplantation were 
more likely to develop BCC only (OR: 5.7; 95% CI: 1.9 to 17.4; P=0.0004). Patients 
with BCC only and controls did not differ in terms of other markers of UV exposure. 
• Risk factors from the questionnaire in relation to see and Bee, by centre 
Tables 7.8, 7.9, 7.10, 7.11 show results restricted to each centre. All the findings 
after pooling the data were also observed in Oxford and London separately. Several 
additional factors were associated with cases in London. Patients with SCC from 
London were more likely to report a history of genital warts than controls. In Oxford, 
markers of proximity and crowding were associated with NMSC, in particular SCC 
development. Cases were 2.6 times more likely to have shared a bed or a room as 
a child than the control group (P=0.03 and P= 0.02 respectively), and were twice 
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as likely to have shared a room as a child than the control group. The association 
between smoking status and sec was stronger in London than Oxford. Numbers 
were too small to test for interaction and in particular to look into details of patients 
with Bee. 
7.3.3 Results on serological data 
• Laboratory validation: HPV16 and HPV6 in relation to history of cytological abnor-
malities and genital warts respectively 
Table 7.12 shows the odds ratio for HPV16 seropositivity associated with a self-
reported history of abnormal smear tests and for HPV6 seropositivity associated 
with self-reported history of genital warts using data from all study participants (ir-
respective of ethnic group) and for each centre separately. As expected, highly 
statistically significant associations (P~O.003) were observed after adjustment for 
confounding variables both when data were pooled and when each centre was ex-
amined separately. 
• Seropositivity to a single HPV type in relation to see and Bee 
In Table 7.13, the seroprevalence of HPV types is examined among cases and 
controls. There was no statistically significant difference at the 1 % level between 
the prevalence of antibodies against any of the HPV types between cases with 
prevalent sec and controls. The seroprevalence of antibodies against mucosal 
HPV types in all patients with prevalent sec were similar than in the control group 
but age was a strong confounder of the association (as discussed in Chapter 6) 
producing a two-fold increased risk of prevalent sec in patients seropositive to any 
of the three mucosal HPV types examined. 
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Tables 7.14 and 7.15 show results by centre. The prevalence of antibody to HPV5 
was statistically significantly higher in patients with prevalent sec from Oxford 
(P=0.02) but not in those from London (P=0.5). In London, higher seroprevalence 
were observed for several HPV types from alpha (types: 6, 13 and 16), beta (17 
and 49) and gamma (48, 50 and 60) genera in sec compared to controls but 
associations were only statistically significant at the 5% level. Across centre, the 
seroprevalence of antibodies against betaHPV types 17 and 49 was consistently 
higher among patients with prevalent or incident SCC compared to controls. 
Patients with incident SCC were all from London. A statistically significant positive 
association was observed between seropositivity to HPV 60 of the gamma genus 
and the 20 patients with incident SCC (OR: 10.8; 95% CI 2.6 to 45A; P=0.001). 
Higher seroprevalence were also observed among cases with incident SCC for al-
phaHPV 3 (15%), betaHPV 8 (35%), betaHPV 24 (25%), gammaHPV 4 and 65 
(45%) compared to controls from London. 
Among the 31 patients with BCe only, 26 were prevalent cases and 5 were incident 
ones. None of the alphaHPV types was associated with the occurrence of Bee in 
both centres. Several seroprevalence were found higher in patients with prevalent 
BCC only compared to controls: gammaHPV 4(12/26, 46% versus 25%), muHPV 
41 (6/26, 23% versus 11 %), nuHPV 63 (10/26, 38% versus 23%). Three out the 5 
cases with incident BCC only were also seropositive to HPV 63 and 101. The small 
numbers did not allow examination by centre. 
• Seropositivity to multiple HPV types in relation to see and Bee 
In Tables 7.16, 7.17 and 7.18 the relationship between the presence of antibodies 
against multiple HPV types (seronegative, positive to one or positive to 2 or more) 
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and the risk of prevalent or incident sec or Bee only is shown for cases and for 
controls among all patients and by centre. 
Multiple HPV seropositivity was common in the control group with about 70% of all 
patients without skin cancers being seropositive to 2 or more HPV types (63% in 
Oxford and 75% in London). 
Overall, there was no statistically significant difference in multiple HPV seropreva-
lence for any of the examined genera between prevalent sec and controls at the 
1 % level except for mucosal HPV types due to the strong confounding effect of age. 
The 20 London patients with incident sec were more likely to be seropositive to 
2 or more HPV types of the gamma genus (11/20; 55%) than the control group 
(64/243; 25%). Multiple seropositivity to HPV types from other genus were not 
associated with the occurrence of incident sec compared to those without the tu-
mour. Higher multiple seroprevalence was observed among patients with prevalent 
or incident sec but result among cases with prevalent see was not corroborated 
by the Oxford data. Patients with Bee only were also more likely to have multiple 
seropositivity than controls for nuHPV, muHPV and the 2 not-defined types. 
• Fully adjusted results and sensitivity analyses for prevalent see 
Table 7.19 shows results of the sensitivity analyses on the association between 
prevalent sec and seropositivity to each HPV type after excluding or including CIS 
or other skin cancer in the case group. Stronger positive associations were found 
between prevalent sec only (with or without CIS) and HPV16 (P=0.02), HPV6 
(P<0.001), HPV5 (P= 0.03) and HPV 4 (P=0.05). Overall, analyses looking at the 
association between HPV and see with different case status did not produce any 
material differences in results. 
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Results on further sensitivity analyses and fully adjusted model for factors from the 
questionnaire that were found associated with sce are shown in Table 7.20. Fully 
adjusted (for sex, age at recruitment [less than 44, 45-59,60 or more], time since 
transplantation [less than 5 years, 5 to 9 years, 10 or more years], skin type [I and II, 
III and IV], number of sunburns before the age of 18 [none, 1 to 2, 3 or more], birth 
order [1,2, 3 or more] and currently living with partner or being married [yes, no]) 
conditional on centre logistic regression did not produce any material difference nor 
did the sensitivity analyses restricted to patients who were transplanted for 5 years 
or more or the restricted analyses to patients with diagnosis within 4 years of blood 
collection. Self-history of viral warts was not included in the fully adjusted model as 
it might be on the pathway of HPV and sce. 
• HPV seropositivity in non-Caucasian and Caucasian patients with prevalent SCC 
who gave blood only (but did not provide a questionnaire) 
- Caucasian patients: 
Of the 3 Caucasian patients who only gave blood, 1 patient had prevalent sec 
and 2 others had prevalent sec and BCe. Seropositivity was as follows: 
- patient 1: HPV types 3,2, 27, 16,6,5, 9, 17,38,4 
- patient 2: H PV types 95 
- patient 3: HPV types: 6, 63 
- Non-Caucasian patients: 
Two non-Caucasian patients who only gave blood were diagnosed with sec 
in these studies. Seropositivity was as follows: 
- patient 1: H PV types 15 
148 
7- Human papilloma virus in relation 10 cutaneous squamous and basal cell caronoma 
- patient 2: HPV types 13, 5, 8, 23, 49, 92, 48, 60, 41 and 101 
7.4 Discussion 
The prospective pilot study was the first to report on the seroprevalence of antibodies 
against HPV-L 1 in relation to cutaneous squamous cell carcinoma in apparently immuno-
competent individuals in which blood was taken prior to the diagnosis of the tumour and 
the two case-control studies are the first studies conducted in a population of OTR that 
has examined the relationship between antibodies against HPV-L 1 in relation to the risk 
of cutaneous SCC and BCC. 
However, these 3 studies had a number of limitations. Firstly, the pilot study includes only 
small numbers of cases, although it may be possible in the future to include other cen-
tres within the EPIC study. Secondly, cases in the pilot study were identified via linkage to 
Cancer Registry records and it is well recognised that there is substantial under-reporting 
of non-melanoma skin cancers in the United Kingdom, in part, because these lesions are 
rarely life threatening [332]. We were, therefore, unlikely to have identified all available 
cases and may also have missed skin cancer diagnoses among the controls. We had no 
information on the severity of SCC, nor did we have details of the occurrence of multiple 
tumours in the same individual. Thirdly, information on important confounders, such as 
sun exposure and skin type, was not available for the pilot study, although we do know 
that all participants were of Caucasian origin. Despite the fact that OTR are at a greatly 
increased risk of SCC compared to the general population, the 2 case-control studies 
have limited power to examine associations with all the different HPV types, in part be-
cause the prevalence of some is low. Consequently, some associations might not have 
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reached statistical significance. However, the study was conducted in two separate cen-
tres that were nonetheless in close geographical proximity, both to increase numbers and 
to compare and validate findings across centres. 
In accordance with all of the published literature, patients with see were more likely to be 
older, to have fairer skin, to have been transplanted for a longer period of time and to have 
had a history of AKs than controls. We also found that men were more likely to have see 
than women, a finding that has also been identified in some other studies [98], but not in 
all [141]. While the risk of see is thought to increase with lifetime cumulative sun expo-
sure [333], a higher number of sunburns before the age of 18 has also been associated 
with see in Australia [334] and a moderate association was also observed in a recent 
multi-centre study [148]. The increased odds of having see in patients being married or 
living with a partner is likely to be a screening effect a partner may identify lesions not 
seen by the patient themselves [335, 336]. To our knowledge, the association between 
birth order and the presence of cutaneous see has not been reported elsewhere. The 
possibility of a chance finding is reduced by the fact that the trend was observed in both 
centres. Birth order has also been inversely associated with allergic disease or eczema 
[337, 338] in some studies. In this context, it is hypothesised that individuals born first 
lack early exposure to infectious agents and are therefore more susceptible to develop 
certain conditions than their siblings [339]. However, its significance in this context re-
mains highly speculative. 
Very few patients developed Bee only and figures were too small to examine thoroughly 
potential risk factors from the questionnaire. However, our findings were in line with pub-
lished literature with higher occurrence of Bee only in men, older patients, individuals 
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with fairer skin, with increasing time after transplantation and with increasing age. The 
only marker of UV exposure that was found to be associated with the presence of BCC 
only was a history of sunny holidays abroad after transplantation. This result indicates 
that intermittent sun exposure might increase the risk of Bee as it has been suggested 
in the published literature [66, 67]. No association was found with any other risk factors 
from the questionnaire. 
In line with previous DNA prevalence studies [281, 340], the seropositivity to any HPV 
types was high with only 14% of OTR and Ie patients without skin cancer being seroneg-
ative to all of the 34 and 38 HPV types tested respectively (more details in Chapter 6). As 
expected, we found a statistically significant (and well-established) association between 
self-reported history of cervical cytological abnormalities and/or genital warts and HPV16 
or HPV6 respectively. This was present in both centres and validated the methodology 
used for HPV serological detection. HPV is an established cause of cervical cancer 
and cases have been found to have both a higher prevalence and titre of antibodies 
against certain HPV types (such as HPV-16), prior to diagnosis, as compared to controls 
[243,245,244]. In one prospective study of antibody levels against HPV-16, women who 
subsequently developed cervical cancers up to 10 years after blood collection were more 
than twice as likely to be HPV-16 seropositive than controls [243]. Comparable findings 
have been reported in prospective studies of other established oncogenic viruses such 
as human herpesvirus-8 (in relation to Kaposi's sarcoma) and hepatitis B (in relation to 
hepatocellular carcinoma). in which a higher than expected prevalence and titre of anti-
bodies has been identified in blood taken years before diagnosis of cancer [245,244]. 
Thus, results reported here for the incident and prevalent sce differ from those found for 
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other known oncogenic infections, as we found no consistent relationship between the 
presence of antibodies against single and multiple HPV types and prevalent or incident 
sec, even, after adjustment for multiple confounding factors. For prevalent SCC among 
OTR patients, only associations between seropositivity to mucosal HPV types (single or 
multiple) and the presence of sec were observed. Younger patients tend to have higher 
seropositivity to mucosal HPV types, as a group, than those older (Chapter 6). More-
over, independently of HPV, younger people have a lower risk of sce than older people. 
Hence, age is a strong positive confounder of the association between HPV seropreva-
lence of mucosal types and sec suggesting that the association observed can probably 
be accounted for by a strong unmeasured (or inadequately measured) confounder such 
as UV exposure. Higher seroprevalence in patients with incident SCC from the pilot study 
observed for some beta types where blood samples were obtained closer to diagnosis 
might indicate that either these patients already have skin cancer prior to blood collec-
tion and should have been grouped with the fifteen prevalent cases or that the antibody 
levels against some beta types rises closer to diagnosis. Consequently, the pilot study 
suggests that, if HPV was involved in the carcinogenic process, this is reflected in an an-
tibody response very close to the time of diagnosis of sec, or that the antibody response 
does not fully reflect oncogenic viral activity. We cannot distinguish whether the antibody 
response observed in prevalent sec was a consequence of tumour development or re-
flects a causal association. Higher seroprevalence for several HPV types (i.e HPV4 or 63) 
were found in patients with Bee compared to controls but there was no clear association 
between antibodies to a single or multiple HPV types as only 31 patients develop BCe 
only. Larger studies are needed to detect genuine associations. 
Until recently only antibodies against HPV-L 1 types 5, 8, 9, 15, 20, 23, 24, 36 and 38 
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of the beta genus, HPV 16 of the alpha genus and HPV1 of the mu genus have been 
examined in the context of skin cancer (reviewed in Chapter 4) [316, 318, 71, 271,146, 
81, 319, 297, 153,330]. With the introduction of Luminex technology, antibodies against 
up to 100 HPV types can now be tested simultaneously [319, 153, 330]. Andersson et 
al (2008) did not report any differences in seropositivity between 72 immunocompetent 
individuals with sec and 121 controls for any of the 14 HPV types they examined (HPV 
types: 1, 5, 6, 8, 9, 10, 15, 16, 20, 24, 32, 36, 38, and 57) [153] whereas Karagas et 
al (2006) examined 16 HPV types (HPV types: 1, 2, 3, 5, 6, 8, 9, 10, 15, 16, 20, 24, 
32, 36, 38, 57) in 252 immunocompetent patients with sec and 461 controls and found 
a two-fold increase risk of sec in patients who were seropositive to HPV5 compared 
to those who were seronegative [319]. In a small study also using Luminex technology, 
Waterboer et al (2008) re-tested sera from 43 immunocompetent patients with sce from 
Italy and from 77 controls for antibodies against 31 HPV types and found an association 
between prevalence of antibodies against HPV-L 1 15, 17 and 38 (beta genus species 2) 
and also with HPV-L 1 50 (gamma genus) and the presence of SCC [330]. These find-
ings were consistent with a study in which HPV-DNA from the beta genus of species 2 
predominated in sec compared to healthy skin samples [293]. In summary, there is no 
consistent associations in the published literature. 
The natural history of cutaneous HPV types is not well understood [320] and the con-
cordance between HPV-DNA in skin biopsies [153] or in plucked hairs [297] and antibody 
detection has been low. In comparison with the clear results relating HPV 16 and 6 to self-
reported histories of cervical cytological abnormalities or genital warts, the role of any of 
the 34 (and 38) HPV types examined in relation to SCC remains unclear. HPV might only 
be latently present in the skin [311]. The prevalence of antibodies against different HPV-
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L 1 antigens varies from study to study and any association might be a consequence of 
increased viral replication following cell proliferation in patients with cutaneous see (this 
may also explain associations identified for other proliferative skin lesions, such as pso-
riasis, burns and wound healing) [271]. Low HPV-DNA copy numbers in tumour cells 
[341] and the lack of HPV integration to the host-DNA [234] would also support this the-
ory. It is possible that the increased risk of see observed in OTR is simply a result of 
immunosuppression impairing the normal capacity to repair UV-damaged DNA_ On the 
other hand, inhibition of UV-induced apoptosis leading to increased capacity for cells to 
accumulate UV-induced mutations has been shown in one study to be a general effect of 
multiple HPV types [230] such that diverse HPV types may playa contributing role, rather 
than there existing specific high-risk HPV types as shown for cervical cancer. Equally, 
few sero-epidemiological studies have used the recently developed multiplexed and high 
throughput technologies such as Luminex and new HPV types or combinations of types 
[330] might still be found to be associated with see development in the future_ 
In conclusion, our serological data do not support a role for any of the 38 HPV types 
examined in the aetiology of cutaneous see. Further research is needed to clarify the 
association between see, Bee and HPV and to allow direct comparison between sero-
epidemiological, HPV DNA detection [342] and functional studies. In particular, large 
prospective studies, with recording of possible confounding variables, are necessary to 
elucidate any genuine associations. 
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N: number; BCC: basal cell carcinoma· OR: odds ratio; CI: confidence interval; Ref: reference group. Some figures c:lo not add 
up to total due to missing data. " Adjusied for age at recruitment, sex, time since transplantation, sliin type anCl strabfied by centres ""P-values for heterogeneIty 
Figure 7.4: Potential risk factors from the questionnaire and their association with BCC only 
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7- Human paptl/omavirus in relation to cutaneous squamous and basal cell caJDnoma 
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Figure 7.5: Potential risk factors from the questionnaire and their association with BCC only (con-
tinued) 
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7- Human papilloma virus in relavon to cutaneous squamous and basal cell carcmoma 
Controls SCC 
risk factors n (%) n (%) OR* (95%CI) N=454 N=140 
Sex 
female 171 (38) 44 (31) ref 
male 283 (62) 96 (69) 1.6 (1.0-2.7) 
P-value het. 0.06 
Age at recruitment 
<45 192 (42) 12 (9) ref 
45-59 175 (39) 56 (40) 5_0 (2.4-10.3) 
60 or more 87 (19) 72 (51) 15.9 (7.3-34.4) 
P-value trend P<0.001 
Time since transplantation 
<5 186 (41) 9 (6) ref 
5t09 107(24) 24(17) 5.5 (2.3-13.2) 
10 or more 161 (35) 107 (76) 17.6 (8.0-38.8) 
P-value trend P<0.001 
Skin type 
III or IV 137(31) 79 (57) ref 
lor II 312(69) 60 (43) 2.7 (1.7-4.5) 
P-value het. P<0.001 
Sunburn before 18 
never 93 (21) 54(39) ref 
1 to 2 177 (39) 39 (28) 1.8 (1.0-3.4) 
3 or more 183 (40) 45 (33) 3.2 (1.7-6.1) 
P-value trend P<0.001 
Birth order 
1st 179(40) 66 (47) ref 
2nd 142(31) 40 (29) 0.7 (0.4-1.3) 
3rd or more 132 (29) 33 (24) 0.5 (0.3-0.9) 
P-value trend 0.03 
Partner 
no 144(32) 24(17) ref 
yes 310(68) 116(83) 1.9(1.1-3.4) 
P-value het. 0.03 
* P-values were calculated using logistic regression and 
adjusted for all factors in the table 
N: total number; n: number; Het.: Heterogeneity test; SCC: 
Squamous cell carcinoma; BCC: Basal cell carcinoma; CI: 
confidence interval; OR: Odds ratio 
Table 7.7: Fully adjusted analyses for risk factors associated with SCC among Caucasian trans-
plant patients 
161 
...... 
0'> 
I\.') 
~ 
0-(i) 
~ 
Q:) 
'. 
o-u 
~o 
'<-co 
tll ::l 3 =. 
o tll 
::l ~ 
<0 -. (J) 
(")7' 
tll -C tll (") Sl 
tll 0 (J) ~ 
_.(J) tll _ 
::l ~ 
_0 
ii3 3 
::l -(J) :::r 
\jCO 
tll.D 
::l C 
-co 
\j(J) 
tll = .~o 
co ::l 
::l ::l 
-tll (J) -. 
~ro 
'<tll 
(") ::l 
coo. 
::l -
- :::r ro ~. 
.., 
tll 
(J) 
(J) 
o Q. 
tll 
-o· 
::l 
~ 
.::4: 
:::r 
(f) 
(") 
(") 
tll 
::l 
a. 
ro (") 
(") 
Controls SCC Bec only Controls SCC BCC only 
OXFORD LONDON 
risk factors n (%) n (%) OR* (95%CI) n (%) n (%) n (%) OR· (95%CI) n (%) N=183 N=51 N=9 N=271 N=89 N=24 
Sex 
female 72 (39) 16 (31) ref 15 (63) 99 (37) 28 (31) ref 6 (24) 
male 111 (61) 35 (69) 1.4 (0.6 to 3.2) 9 (38) 172 (63) 61 (69) 1.8 (1.0 to 3.3) 18 (75) 
P-value het. 0.4 0.06 
Age at recruitment 
<45 78 (43) 3 (6) ref 2 (8) 114(42) 9 (10) ref 5 (21) 
45-59 68 (37) 19 (37) 5.8 (1.6-21.7) 10(42) 107 (37) 37 (42) 4.4 (1.98-10.1) 11 (46) 
60 or more 37 (20) 29 (57) 22.2 (5.9-83.7) 12 (50) 50 (18) 43 (48) 9.6 (4.1-22.8) 8 (33) 
P-value trend <0.001 <0.001 
Time since transplantation 
<5 70 (38) 4 (8) ref 3 (13) 116 (43) 5 (6) ref 3 (13) 
5 to 9 49 (27) 5 (10) 2.3 (0.5-10.1) 3 (13) 58 (21) 19 (21) 7.4 (2.5-21.8) 6 (25) 
10ormore 64 (35) 42 (82) 15.0 (4.6-49.1) 18 (75) 97 (36) 65 (73) 13.1 (4.9-35.1) 15 (63) 
P-value trend <0.001 <0.001 
Skin type 
I to II 136 (75) 30 (59) ref 14 (58) 92 (34) 58 (66) ref 12 (50) 
III to IV 45 (25) 21 (41) 2.3 (1.0 to 5.2) 10 (42) 176 (66) 30 (34) 3.4 (1.9 to 6.1) 12 (50) 
P-value het. 0.05 <0.001 
* P-values were calculated using logistic regression and adjusted for sex, time since transplantation, age at recruitment and skin type. 
N: total number; n: number; Het.: Heterogeneity test; SCC: Squamous cell carcinoma; BCC: Basal cell carcinoma; CI: confidence interval; OR: Odds ratio 
Fitzpatrick classification scale as follows (I) never tans, always burns, (II) rarely tans, usually burns, (III) usually tans, can burn and (IV) always tans, rarely burns 
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7- Human papillomavirus in relation to cutaneous squamous and basal cell carcinoma 
Controls sec BCC only Controls sec BCC only 
OXFORD LONDON 
risk factors number(%) number(%) OR*(95%CI) number(%) number(%) number(%) number(%) N=183 N=51 N=9 N=271 N=89 ORO (95%CI) N=24 
rB~t:I.~e.~tlI.lt:l.B2~r/Qt:I. 
Organ type 
kidney 171 (93) 51 (100) 9(100) 263(97) 83(93) ref 23(96) 
other 12(7) 0(0) 0(0) 8(3) 6(7) 1.0 (0.~3.6) 1 (4) 
P-valuehet 1.0 
Cadaveric or living donor 
cadaveric 149 (83) 47 (92) ref 9(100) 220(82) 83(93) ref 20(83) 
living 31 (17) 4(8) 1.0 (0.~3.9) 0(0) 49(18) 6(7) 0.7 (02-1.9) 4 (11) 
P-va/uehet 1.0 0." 
Number of transplantations 
1 146 (80) 36(71) ref 7(78) 236 (87) 78(88) ref 21 (88) 
2 or more 37(20) 15(29) 0.9 (0.4-2.3) 2(22) 35(13) 11 (12) 0.8 (0.~1.8) 3(13) 
P-va/uehet 0.9 0.6 
Primary diagnosis 
unknown 36(20) 6(12) ref 1 (11) 34(13) 9(10) ref 3(13) 
Glomerulonephritis 35(19) 15(29) 2.9 (0.8-10.9) 2(22) 82(30) 28(31) 0.7 (02-2.1 ) 8(33) 
Pyelonephritis 23(13) 9(18) 3.5 (0.8-15.3) 2(22) 41 (15) 12(13) 0.9 (0.~3.1) 1 (4) 
Cystic 33(18) 9 (18) 1.3 (0.~5.0) 4(44) 48(18) 16(18) 1.0 (0.~3.1) 8(33) 
Other 56(31) 12(24) 2.4 (0.6-9.1) 0(0) 66(24) 24(27) 1.1 (0.4-3.3) 4(17) 
P-valuehet O.l 0.9 
W~BT~ AND ~AN~EB tJ.1~TQRY 
Previous cancer 
no 166 (92) 47(94) 7(78) 250(94) 82(93) ref 24(100) 
yes 15(8) 3(6) 2(22) 15(6) 6(7) 1.1 (0.~3.6) 0(0) 
P-va/uehet 0.9 
Warts 
no 74(40) 7(14) ref 3(33) 76(28) 1 (1) 2(8) 
yes 109(60) 44(86) 2.8 (1.0-7.8) 6(67) 193(72) 85(99) 22(92) 
P-va/ue het. O.Ol 
Genital warts 
no 163(89) 48(94) 9(100) 249(95) n(92) ref 21 (95) 
yes 20 (11) 3(6) 0(0) 12(5) 7(8) 3.1 (0.9-10.0) 1 (5) 
P-valuehet 0.07 
Shingles 
no 119 (65) 29 (57) ref 5(56) 195(75) 53(61) ref 18(75) 
yes 63(35) 22(43) 1.1 (0.!>-2.5) 4(44) 65(25) 34(39) 1.3(0.7-2.5) 6(25) 
P-va/ue het. 0.8 0." 
Psoriasis 
no 171 (93) 49(96) 9(100) 253(95) 83(94) ref 23(100) 
yes 12 (7) 2 (4) 0(0) 14 (5) 5(6) 12(0.~4.1) 0(0) 
P-value het. 0.8 
Family history of other cancers 
no 79(46) 23(49) ref 6(67) 123(48) 50(58) ref 12 (50) 
yes 91 (54) 24(51) 0.9 (0.4-2.1) 3(33) 135(52) 36(42) 0.6 (0.~1.2) 12(50) 
P-valuehet 0.8 0.2 
WQMEN INFORMA TlON 
Abnormal smear 
no 50(70) 15(94) 2(100) 74(81) 24 (89) 5(83) 
yes 21 (30) 1 (6) 0(0) 17(19) 3(11) 1 (17) 
P-valuehet 
Stili menstruating 
no 38(21) 13(25) 2 (22) 52 (20) 21 (24) ref 2 (8) 
yes 34(19) 3(6) 0(0) 34 (13) 6(7) 1.0 (0.2-4.3) 4(17) 
P-value het 
1.0 
Hysterectomy 
no 60(33) 15(29) 2 (22) 69(27) 21 (24) ref 6(25) 
yes 11 (6) 1 (2) 0(0) 12 (5) 5(6) 1.0 (0.~3.8) 0(0) 
P-valuehet 
1.0 
Ever used oral contraceptive 2(8) 
no 24 (13) 10(20) ref 0(0) 33(13) 15(17) ref 
yes 48(26) 6(12) 1.3 (0.~6.1) 2 (22) 52(20) 12(14) 0.6(0.1-2.3) 
4(17) 
P-valuehet 0.8 
0.5 
Ever used hormone replacement therapy 5(21) 
no 53(29) 12(24) ref 1 (11) 65(25) 17(20) ref 
yes 18 (10) 4(8) 0.4 (0.1-2.5) 1 (11) 20(8) 9(10) 0.6 (02-1.9) 
1 (4) 
P-valuehet O.l 
0." 
* P-values were calculated using logistic regression and adjusted for sex, time since transplantation, age at recruitment and skin type. 
N: total number; Hel: Heterogeneity test; SCC: Squamous cell carcinoma; BCC: Basal cell carcinoma; CI: confidence interval; OR: Odds ratio 
When seropostivity if less than 5, no estimate was derived. 
Table 7.9: Potential risk factors from the questionnaire and their association with SCC and BCC 
only among Caucasian transplant patients, by centre (continued 1) 
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7- Human papi//omavirus in retation to cutaneous squamous and basal ceI/ carclfloma 
Controls SCC BCConly Controla SCC BCC only 
OXFORD LONDON 
risk f.ctor. number("") number("") OR'(95%C1) number("") number("") number("") number("") N=183 N=51 N=9 N=271 N=89 OR'(95%C1) N=24 
Eye color 
brownlhazel 59(33) 19(38) ref 6(67) 102 (42) 13(18) ref 6(29) 
green 28(16) 5(10) 0.6 (0.2-2.3) 1 (11) 32(13) 10(14) 3.7 (12-113) 2 (10) 
blue 93(52) 26 (52) 0.6(0.2-1.4) 2(22) 111 (45) 51 (69) 3.1 (1.4-6.9) 13(62) 
P-va/ua het. 0.5 0.01 
Hair color 
black/dark brown 90(49) 22 (43) ref 5(56) 147 (54) 37(42) ref 12(50) 
light brown 62 (34) 19(37) 0.9 (0.4-2.1) 1 (11) 87 (32) 27 (31) 0.9 (0.5-1.8) 11 (46) 
red or blonde 30(16) 10 (20) 1.4 (0.4-4.6) 3(33) 36(13) 24(27) 1.8 (0.8-4.2) 1 (4) 
P-va/ue hel. 0.8 0.2 
Birth country 
Other 4(2) 3(6) 0(0) 9(3) 3(3) 1 (4) 
UK/Europe/Ireland 179 (98) 48 (94) 9(100) 262 (97) 66(97) 23(96) 
P-va/ue het. 
Body mass Index 
<22.5 76(43) 27 (55) ref 4(44) 121 (45) 45(54) ref 13(54) 
22.5- 65(37) 18(37) 1.0 (0.4-2.4) 5(56) 99(37) 24(29) 0.6 (0.3-1.2) 6(25) 
25.0- 36(20) 4(8) 0.5(0.1-1.7) 0(0) 51 (19) 15(18) 0.9(0.4-1.9) 5(21) 
P-va/ue trend 0.3 0.5 
Job 
any 146 (80) 25(49) ref 5(56) 180(66) 51 (57) ref 16(75) 
unemployed 11 (6) 2 (4) 1.0 (0.2-5.5) 1(11) 54(20) 6 (7) 0.5 (0.2-1.5) 1 (4) 
retired 26(14) 24(47) 2.1 (0.7-6.1) 3(33) 37(14) 32(36) 1.3 (0.6-2.8) 5(21) 
P-va/ue het. 0.4 0.3 
Quallncatlon 
o level 26(16) 3 (6) ref 3(33) 86(32) 33(37) ref 7 (29) 
A leveVColI./uni 74(42) 11 (23) 1.2 (0.3-5.6) 2(22) 60(22) 16(18) 1.8 (0.8-4.4) 3(13) 
ClericaVcommercial 23(13) 16(33) 2.8 (0.6-13.3) 2 (22) 45(17) 10(11) 1.5 (0.6-3.9) 6(25) 
Other 51 (29) 18(38) 2.0 (0.5-8.9) 2 (22) 78(29) 30(34) 1.2 (0.6-2.3) 8(33) 
P-va/ue het. 0.4 0.6 
Exercise 
never/rarely/<1 72(40) 28(56) ref 2(22) 88(34) 32(36) ref 5(22) 
once or more 109(60) 22(44) 0.8 (0.3-1.7) 7(78) 171 (66) 56(64) 0.7 (0.4-1.4) 18(78) 
P-va/ue het. 0.5 0.4 
dL~QHQL AND TQBA~!<Q ~QN~!l.MPTlQ~ 
Tobacco use 
never 98(54) 31 (61) ref 3(33) 128 (47) 47(53) ref 9(38) 
past 25(14) 2 (4) 0.8(0.1-4.5) 1(11) 44(16) 12(13) 0.9 (0.4-2.3) 4 (17) 
current 60(33) 18(35) 0.9 (0.4-2.1) 5 (56) 99(37) 30(34) 0.5 (0.2-0.9) 11 (48) 
P-va/ue het. 1.0 0.08 
Alcohol consumption 
<1day 72(40) 14 (28) ref 4(44) 94(36) 30(34) ref 9(38) 
1+ 73(40) 23 (46) 0.9 (0.4-2.3) 5(56) 95 (37) 41 (47) 1.0 (0.5-2.1) 13(54) 
former 4(2) 0(0) 0(0) 21 (8) 10(11) 1.6 (0.5-4.7) 1 (4) 
Never 33(18) 13(26) 2.1 (0.7-6.2) 0(0) 48(19) 6(7) 0.4 (0.1-1.1) 1 (4) 
P-va/ue het. 0.2 0.2 
fRQXIMra 
Number In household 
1 34(19) 6 (12) ref 2 (22) 36(14) 8(9) ref 4(17) 
2 71 (39) 29 (57) 2.6 (0.8-8.4) 4(44) 105 (41) 52(60) 2.3 (0.9-6.0) 7 (29) 
3 34 (19) 12 (24) 3.9 (1.0-15.2) 2(22) 53(21) 17(20) 2.4 (0.B-7.5) 7(29) 
40r more 44(24) 4 (8) 1.3 (0.3-6.3) 1(11) 63(25) 10(11) 1.8 (0.5-5.9) 6(25) 
P-va/ue trend 0.5 0.5 
Number of sibling. 
0 15(8) 7(14) ref 1(11) 26(10) 9(10) ref 1 (4) 
1 60(33) 21 (41) 1.5 (0.4-5.7) 3(33) 78(29) 25(28) 1.4 (0.5-4.1) 4(17) 
2 49(27) 12(24) 1.0 (0.2-4.0) 4(44) 64(24) 20(22) 1.2 (0.4-3.8) 9(38) 
3 24(13) 6(12) 0.8(0.2-4.1) 1 (11) 40(15) 5 (6) 0.3(0.1-12) 6(25) 
40r more 35 (19) 5 (10) 0.4(0.1-1.9) 0(0) 63(23) 30(34) 1.6 (0.5-4.7) 4(17) 
P-va/ue trend 0.06 0.9 
Birth order 
1st 77 (42) 25 (50) ref 6(67) 102 (38) 41 (46) ref 6(25) 
2nd 61 (33) 19(38) 0.6 (0.3-1.5) 1(11) 81 (30) 21 (24) 0.7 (0.3-1.4) 10(42) 
3rd or more 45 (25) 6(12) 0.4 (0.1-1.2) 2 (22) 87(32) 27(30) 0.5 (0.3-1.1) 8(33) 
P-va/ua trend 0.08 0.07 
Sha .. a room as a child 
yes 119(66) 22 (43) ref 4(44) 167 (62) 61 (69) ref 19(79) 
no 62(34) 29 (57) 2.4 (1.1-5.3) 5(56) 101 (38) 28(31) 0.7 (0.4-1.3) 5(21) 
P-va/ua het. 0.03 0.3 
Sha .. a bed sa a child 
yes 35(19) 10(20) ref 2(22) 64(24) 40(45) ref 9(38) 
no 148 (81) 40(80) 2.6 (0.9-7.5) 7 (78) 205 (76) 49(55) 0.6 (0.3-1.1) 15(63) 
P-va/ua het. 0.07 0.08 
Number of children 
none 74(40) 11 (22) ref 2(22) 99(37) 15(17) ref 7(29) 
1 or 2 74(40) 29(57) 1.8(0.7-4.5) 6(67) 124(46) 57 (64) 1.9 (0.9-42) 14(58) 
3+ 35 (19) 11 (22) 0.9 (0.3-3.2) 1 (11) 48(18) 17(19) 1.3 (0.5-3.3) 3(13) 
P-valua trend 1.0 
0.6 
Partner 
no 60(33) 8(16) ref 2(22) 84(31) 16(18) ref 5(21) 
yes 123 (67) 43(84) 2.8 (1.1-7.6) 7(78) 187(69) 73(82) 1.9 (0.9-3.8) 19(79) 
P-va/ua ".t . 0.03 
0.07 
• P-values were calculated using logistic regression and adjusted for sex, tme since transplantation, age at recruitment and skin type. 
N: total number. Hel: Heterogeneity test; SCC: Squamous een carcinoma; BCC: Basal een carcinoma; CI: confidence intervat OR: Odds ratio 
When seropostivlty If le88 than 5. no estimate was derived. 
Table 7,10: Potential risk factors from the questionnaire and their association with SCC and BCC 
only among Caucasian transplant patients, by centre (continued 2) 
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7- Human papillomavirus in relation to cutaneous squamous and basaJ cell c:aronoma 
Controls SCC BCC only Controls SCC BCC only 
OXFORD LONDON 
risk factors number (%) number (%) OR*(95%CI) number ("to) number ("to) number ("to) number ("to) N=183 N=51 N=9 N=271 N=89 OR*(95"toCI) N=24 
!,!,L TRA VlQLET RADIA T/QN EXPOS!,!,R/i. 
Sunburn before 18 
never 41 (23) 11 (22) ref 2(22) 175(65) 43(48) ref 16(67) 
1102 77(42) 19(39) 1.5(0.5-4.4) 3(33) 55(20) 20(22) 2.0 (0.9-4.5) 4 (17) 
3ormore 64(35) 19(39) 3.1 (1.0-9.8) 4(44) 39(14) 26(29) 3.5 (1.6-7.6) 4 (17) 
P-value trend O.IU <0.001 
Ever used sun bed 
never 149(81) 45(88) ref 8(89) 219(81) 75(84) ref 18(75) 
ever 34 (19) 6(12) 1.2 (0.4-4.0) 1 (11) 51 (19) 14(16) 1.8 (0.8-4.1) 6(25) 
P-value het 0.7 0.2 
Sunbed use and sun bath 
none 46(25) 17(33) ref 0(0) 106(40) 35(40) ref 9(38) 
either 105(57) 28(55) 0.9 (0.3-2.2) 8 (89) 128 (48) 43(49) 0.8 (0.4-1.5) 12(50) 
both 32 (17) 6(12) 1.2 (0.3-4.5) 1 (11) 32(12) 10(11) 2.0 (0.7-5.8) 3(13) 
P-value trend 0.9 0.6 
Ever had outdoor hobbles 
no 45(25) 7 (14) ref 1 (11) 72(28) 20(23) ref 5(21) 
yes 137(75) 43(86) 2.1 (0.7-5.9) 8 (89) 188(72) 67 (77) 1.0 (0.5-2.0) 19(79) 
P-valuehet 0.2 0.9 
Ever had outdoor occupation 
no 126 (69) 28(55) ref 5(56) 174(64) 54 (61) ref 14(58) 
yes 57 (31) 23(45) 1.4 (0.6-3.3) 4(44) 96(36) 34(39) 1.0 (0.5-1.9) 10(42) 
P-valuehet. 0.4 0.9 
Ever lived abroad 
yes 45(25) 10(20) ref 2 (22) 41 (15) 14 (16) ref 9(38) 
no 138(75) 41 (80) 1.5 (0.6-3.7) 7 (78) 230(85) 75(84) 1.0 (0.4-2.3) 15(63) 
P-value het. 0.4 1.0 
llEFQRE rBAN§.PLANTA T/QN 
Sunburn 
never 25(14) 5(10) ref 1(11) 68(25) 16(18) ref 3(13) 
1 t02 63(34) 17(35) 1.6 (0.4-6.1) 3(33) 114(42) 35(39) 0.8 (0.3-1.7) 9(38) 
3 or more 95(52) 27(55) 2.0 (0.5-7.3) 5(56) 88(33) 38(43) 1.0 (0.5-2.3) 12 (50) 
P-value trend 0.3 0.8 
Sunbathing 
never 52 (29) 17(35) ref 0(0) 124 (47) 38(44) ref 13(54) 
1t02 28 (15) 7(14) 0.6 (0.2-2.3) 2 (22) 50(19) 12 (14) 0.7 (0.3-1.7) 0(0) 
3 or more 101 (56) 25(51) 1.3 (0.5-3.5) 7 (78) 88(34) 37 (43) 1.1 (0.6-2.1) 11 (46) 
P-value trend 0.6 0.5 (0.2-0.9) 
Sunbed 
never 150 (82) 44(88) ref 8(89) 218(81) 75(84) ref 18(75) 
ever 33(18) 6 (12) 1.4 (0.4-4.8) 1(11) 50(19) 14 (16) 1.8(0.8-4.1) 6 (25) 
P-valuehet. 0.6 0.2 
Sunny holidays 
never 44(24) 17(35) ref 3(33) 52(20) 20(22) ref 2(8) 
1 t02 29(16) 9(18) 1.1 (0.4-3.7) 1(11) 58(22) 22(25) 1.0 (0.4-2.3) 2(8) 
3t05 39 (21) 7 (14) 0.7 (0.2-2.4) 0(0) 41 (15) 14 (16) 1.0 (0.4-2.6) 5(21) 
6 or more 71 (39) 16(33) 1.4 (0.5-4.1) 5(56) 114(43) 33(37) 1.0 (0.5-2.2) 15(63) 
P-va/ue trend 0.7 1.0 
Outdoor hobbles 
yes 121 (66) 35(70) ref 8 (89) 176 (65) 62 (70) ref 17(71) 
no 61 (34) 15(30) 1.1 (0.4-2.5) 1 (11) 94 (35) 27(30) 1.1 (0.6-2.2) 7(29) 
P-valuehet. 0.9 0.7 
~Elfg.R TRANSPLANrAT1QN 
Sunburn 
never 145(79) 44 (88) ref 7 (78) 186(85) 63(84) ref 15(83) 
ever 38 (21) 6(12) 0.9 (0.3-2.7) 2 (22) 32 (15) 12(16) 0.5(0.2-1.2) 3(17) 
P-value het. 0.8 
0.1 
Sunbathing 
never 138 (75) 43(84) ref 7(78) 213(86) 78(91) ref 20(83) 
1 to 2 16 (9) 3(6) 1.4 (0.3-7.2) 0(0) 17(7) 1(1) 02 (0.0-1.4) 2 (8) 
3 or more 29 (16) 5(10) 0.7 (0.2-2.5) 2(22) 17(7) 7(8) 1.8 (0.6-5.5) 2(8) 
P-value trend 0.7 
0.8 
Sun bed 
never 180(99) 50(98) 9(100) 240 (100) 84(99) 23(100) 
ever 2 (1) 1 (2) 0(0) 1 (0) 1 (1) 0(0) 
P-va/uehet. 
Sunny holidays 
never 82 (45) 17(33) ref 3(33) 121 (50) 18(21) ref 
1 (4) 
1 t02 38 (21) 12 (24) 1.9 (0.7-5.5) 2 (22) 37(15) 17(20) 3.1 (1.2-7.8) 
4(17) 
3t05 29(16) 9(18) 1.5 (0.5-4.7) 1(11) 33(14) 13(15) 1.9(0.7-5.2) 
5(22) 
6 or more 34(19) 13(25) 1.4 (0.5-4.1 ) 3(33) 51 (21) 36(43) 2.4 (1.1-5.3) 
13(57) 
P-value trend 0.5 
0.06 
Outdoor hobbles 
ever 104(57) 35(70) ref 6(67) 131 (53) 47 (55) ref 
15(63) 
never 78(43) 15(30) 0.6(0.3-1.5) 3(33) 116(47) 39(45) 12 (0.6-2.1) 
9(38) 
0.3 0.6 P-va/uehet. 
• P-values were calculated using logistic regression and adjusted for sex, time since transplantation, age at recruitment and skin type. 
N: total number; Hel: Heterogeneity test; SCC: Squamous ceD carcinoma; BCC: Basal cel carcinoma; CI: confidence interval; OR: Odds ratio 
When seropostivlty if less than 5, no estimate was derived. 
Table 7.11: Potential risk factors from the questionnaire and their association with sec and Bee 
only among Caucasian transplant patients, by centre (continued 3) 
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Self-reported abnormal smear test 2 3 
Never Ever adjusted OR 1 
Risk factor centre (No. never/ever) No. POS (%) No. POS (%) (95%CI) P-value 
HPV16 Both (215/56) 32 (15) 28 (50) 5.1 (2.6-10.2) <0.001 
Oxford (83/27) 9 (11) 13 (48) 8.6 (2.5-29.4) <0.001 
London (132/29) 23 (17) 15 (52) 4.3 (1.8-10.5) 0.001 
Self-reported history of genital warts 3 
Never Ever adjusted OR 1 
Risk factor centre (No. never/ever) No. POS (%) No. POS (%) (95%CI) P-value 
HPV6 Both (688/53) 172 (25) 31 (58) 4.0 (2.2-7.2) <0.001 
Oxford (270/26) 51 (19) 15 (58) 4.6 (1.9-11.2) <0.001 
London (418/27) 121 (29) 16 (59) 3.4 (1.5-7.6) 0.003 
HPV: human papillomavirus 
OR: Odds ratio; CI: Confidence interval; No. pas: Number of seropositive samples; No: number 
1 Analyses are stratified by centres (where appropriate) and adjusted for age at recruitment, time since transplantation, 
and sex. 
2 Restricted to women only. 3 No restriction for ethnicity. 
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• When the number of seropositive patient was less than 5, P-value was derived using Fisher's exact test 
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:::J CD en 8 58 (24) 26 (29) 1.7 (0.8 to 3.2) 0.14 19 (28) 1.4 (0.6 to 2.9) 0.4 7 (35) 8 (36) 5 (28) 3 
=:- ...... 0 20 39 (16) 11 (12) 0.9 (0.4 to 2.2) 0.9 7 (10) 0.6 (0.2 to 1.7) 0.4 4 (20) 4 (18) 2 (11) 2 0.> '< CD 1 
:::J -0 - 24 26 (11) 12 (13) 2.4 (1.0 to 5.9) 0.05 7 (10) 1.7 (0.6 to 4.9) 0.4 5 (25) 3 (14) 1 (6) 2 
en CD 0 36 36(15) 6 (7) 0.4 (0.1 to 1.0) 0.04 4 (6) 0.06 2 (10) 4 (18) 2 (11) 2 
-0 0 0.> 
0.> 0 n 93 11 (5) 7 (8) 1.6 (0.5 to 5.1) 0.4 5 (7) 1.5 (0.4 to 5.6) 0.5 2 (10) 0(0) 0(0) 0 
~ 3 S· 9 45 (19) 13 (15) 0.9 (0.4 to 1.9) 0.7 9 (13) 0.6 (0.3 to 1.6) 0.4 4 (20) 3 (14) 2 (11) 
'" ...... 
-0-00 ~ 0'> 15 64 (26) 20 (22) 1.0 (0.5 to 2.1) 0.9 16 (23) 1.0 (0.5 to 2.2) 0.9 4 (20) 8 (36) 6 (33) 2 CO ~~3 !!I 3 
.! 2 17 61 (25) 29 (33) 1.8 (0.9 to 3.4) 0.09 23 (33) 1.9 (0.9 to 3.9) 0.09 6 (30) 5 (23) 3 (17) 2 '" _. CD 0.> OJ ~ 0. 0.> 23 29 (12) 9 (10) 1.0 (0.4 to 2.6) 0.9 5 (7) 0.7 (0.2 to 2.1) 0.5 4 (20) 3 (14) 3 (17) 0 1:> 
'" --:::J 1;> 
en0o. 38 56 (23) 20 (22) 1.1 (0.5 to 2.2) 0.8 16 (23) 1.1 (0.5 to 2.4) 0.8 4 (20) 8 (36) 6 (33) 2 '" 0 S· go- 49 46 (19) 22 (25) 2.1 (1.0 to 4.2) 0.05 17 (25) 2.0 (0.9 to 4.5) 0.09 5 (25) 4 (18) 2 (11) 2 3 
'" rOo.> 3 75 33 (14) 15 (17) 1.7 (0.8 to 3.8) 0.2 10 (14) 1.3 (0.5 to 3.2) 0.6 5 (25) 5 (23) 3 (17) 2 ~ o en en 
'" :::J CD 0.> 76 29 (12) 11 (12) 1.2 (0.5 to 3.0) 0.7 9 (13) 1.2 (0.5 to 3.2) 0.7 2 (10) 4 (18) 2 (11) 2 :; 
o.:Eo 4 I 92 37 (15) 16 (18) 1.0 (0.5 to 2.2) 1.0 10 (14) 0.6 (0.2 to 1.5) 0.3 6 (30) 5 (23) 3 (17) 2 <i! o :::r CD 6; 
:::J 0 = 5 96 36 (15) 15 (17) 1.5 (0.7 to 3.4) 0.3 10(14) 1.1 (0.4 to 2.7) 0.8 5 (25) 3 (14) 1 (6) 2 is OJ 
0.> 0 4 66 (27) 32 (36) 1.9 (1.0 to 3.6) 0.05 23(33) 1.7 (0.8 to 3.5) 0.2 9 (45) 11 (50) 9 (50) 2 0 
-. 0.> 8 CD -. 1 65 74 (30) 24 (27) 1.1 (0.6 to 2.2) 0.7 15 (22) 0.8 (0.4 to 1.8) 0.7 9 (45) 10 (45) 8 (44) 2 0 Qj en _. i 95 54 (22) 16 (18) 0.9 (0.4 to 1.9) 0.8 11 (16) 0.7 (0.3 to 1.7) 0.4 5 (25) 4 (18) 2 (11) 2 ~ CD :::J 
-. 0 2 48 39 (16) 21 (24) 2.1 (1.0 to 4.4) 0.05 16 (23) 2.3 (1.0 to 5.3) 0.05 5 (25) 5 (23) 3 (17) 2 ~ o 3 I!, 
:::J 0.> 3 50 19 (8) 12 (13) 2.2 (0.8 to 5.8) 0.1 10 (14) 2.4 (0.8 to 7.0) 0.1 2 (10) 1 (5) 1 (6) 0 II CD ai 
co :::J 4 60 12 (5) 12(13) 3.6(1.2t010.3) 0.02 7 (10) 2.1 (0.6 to 7.1) 0.2 5 (25) 2 (9) 2 (11) 0 g ~-o ~ 1 41 32 (13) 14 (16) 1.5 (0.7 to 3.4) 0.3 11 (16) 1.7 (0.7 to 4.4) 0.3 3 (15) 5 (23) 4 (22) 1 <' ~ 
'" CD -. ~ I 1 1 81 (33) 25 (28) 0.8 (0.4 to 1.5) 0.5 20 (29) 0.9 (0.4 to 1.7) 0.7 5 (25) 8 (36) 6 (33) 2 R _CD ~ 2 63 67 (28) 22 (25) 0.9 (0.5 to 1.7) 0.7 17 (25) 0.8 (0.4 to 1.7) 0.6 5 (25) 9 (41) 6 (33) 3 ~ o :::J -_ en 101 25 (10) 14 (16) 1.6 (0.7 to 3.7) 0.3 11 (16) 1.6 (0.6 to 4.2) 0.3 3 (15) 5 (23) 2 (11) 3 ~:E 0 ~ z 103 18 (7) 6 (7) 0.8 (0.2 to 2.4) 0.6 3 (4) 0.6 3 (15) 1 (5) 1 (6) 0 
en :::r § 0.> 0 
3 ~ OR odds ratio, N total number, n number; see squamous cell carcinoma; Bee basal cell carcinoma ND not defined; Incident see are from london only, a 
CD CD • P-values and odds ratIOs were calculated using condrtional (on centre) logistiC regression and adjusted for sex, age at recruitment, time since transplantation and skin type ~ 
• When the number of seropositive patient was less than 5, P-value was derived uSing Fisher's exact test 
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1 I 65 
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3 
4 
" E 1 
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o 
z 
50 
60 
41 
1 
63 
101 
103 
controls 
!:!=.ill 
No.(%) No.(%) 
15 (8) 1 (2) 
20(11) 4(8) 
22 (12) 5 (10) 
13 (7) 2 (4) 
27 (15) 6 (12) 
47 (26) 10 (20) 
10 (5) 1 (2) 
12 (7) 7 (14) 
33 (18) 8 (16) 
22 (12) 8 (16) 
21 (12) 5 (10) 
14 (8) 4 (8) 
1 (1) 1 (2) 
20 (11) 10 (20) 
52 (29) 18 (36) 
39 (21) 14 (28) 
12 (7) 4 (8) 
39 (21) 12 (24) 
38 (21) 15 (30) 
17(9) 7(14) 
13 (7) 7 (14) 
15 (8) 4 (8) 
26 (14) 6 (12) 
42 (23) 15 (30) 
45 (25) 14 (28) 
37 (20) 12 (24) 
27 (15) 4 (8) 
13 (7) 4 (8) 
7 (4) 0 (0) 
14 (8) 5 (10) 
43 (24) 14 (28) 
31 (17) 9 (18) 
5 (3) 5 (10) 
8 (4) 2 (4) 
SQUAMOUS CEll CARCINOMA 
all 
N=50 
OR (95%CI) 
0.8 (0.2-3.1) 
1.0 (0.3-3.5) 
1.5 (0.6-4.0) 
4.8 (1.3-17.3) 
1.0 (0.4-2.9) 
0.9 (0.3-2.6) 
0.9 (0.3-3.0) 
2.3 (0.8-7.0) 
1.1 (0.5-2.5) 
1.6 (0.7-4.0) 
0.8 (0.3-2.0) 
1.0 (0.4-2.4) 
1.3 (0.4-4.1) 
1.3 (0.4-4.2) 
0.7 (0.2-2.1) 
1.0 (0.4-2.3) 
1.3 (0.5-3.1) 
0.7 (0.3-1.9) 
1.4 (0.4-5.2) 
0.9 (0.4-2.3) 
14 (0.5-3.8) 
2.8 (0.6-13.8) 
prevalent 
N=50 
incident 
N=O 
p-
P-value* No. (%) OR (95% Cll value No. (%) 
0.2 
0.8 
0.8 
0.5 
1.0 
0.4 
0.5 
0.02 
1.0 
0.8 
0.8 
1.0 
0.4 
0.1 
0.8 
0.3 
0.8 
0.7 
1.0 
0.7 
0.7 
1.0 
0.5 
0.9 
0.6 
0.5 
0.2 
0.8 
0.4 
0.6 
0.9 
0.5 
0.2 
1.0 
BASAL CEll CARCINOMA 
(only) 
all prevalent incident 
N=9 N=8 N=1 
No. (%) No. (%) 
1 
1 
1 
1 
o 
1 
1 
3 
2 
1 
1 
2 
1 
2 
2 
1 
o 
2 
2 
1 
o 
1 
1 
3 
2 
3 
o 
o 
o 
2 
4 
4 
1 
1 
1 
1 
1 
1 
o 
1 
1 
3 
2 
1 
1 
2 
1 
2 
2 
1 
o 
2 
2 
1 
o 
1 
3 
2 
3 
o 
o 
o 
2 
4 
4 
1 
1 
No. 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
o 
()I, o(j,1', r iitlQ rJ total number; n: number; SCC: squamous cell carcinoma; BCC: basal cell carcinoma: NO: nof defined; Incident SCC are from 
London only. 
• P-values and odds ratios were calculated using conditional (on centre) logistic regression and adjusted for sex, age at recruitment, time since 
transplantation and skin type . 
• When the number of seropositive patient was less than 5, P-value was derived using Fisher's exact test 
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7- Human papil/omavirus in relation to cutaneous squamous and basal cell carOrlO"'a 
CONTROLS SQUAMOUS CELL CARCINOMA BASAL CELL CARCINOMA 
N=425 
All Prevalent Incident All Prevalent Inddent 
N=139 N=119 N=20 N=31 N=26 N=5 
II!nus No.(%) No. (%) OR' !95%CII No.(%) OR' !95%CII No.(%) No. (%) OR' !95%CII No. (%) OR' !95%CI) No. 
alpha-mucosal 
negative 250(59) 77(55) ref 67(56) ref 10(50) 20(65) ref 17(65) ref 3 
1 127 (30) 46(33) 1.5 (0.9-2.6) 37(31) 1.7 (1.D-3.0) 9(45) 10(32) 1.0 (0.5-2.4) 8(31) 1.0 (0.4-2.6) 2 
2 or more 48(11) 16(12) 2.2 (1.D-4.9) 15(13) 2.8 (1.2-6.6) 1 (5) 1 (3) 0.4 (0.D-3.1 ) 1 (4) 0.4 (0.1-3.5) 0 
P-trend 0.02 0.007 0.4 0.4 
alpha-cutaneous 
negative 285(67) 102 (73) ref 90(76) ref 12(60) 21 (68) ref 18(69) ref 3 
1 92 (22) 16 (12) 0.5 (0.3-1.1) 12 (10) 0.4 (0.2-0.9) 4 (20) 5(16) 0.7 (0.3-2.0) 4 (15) 0.7 (02-2.1) 
2 or more 48 (11) 21 (15) 1.6 (0.8-3.3) 17 (14) 1.6 (0.7-3.4) 4 (20) 5(16) 1.6 (0.5-4.8) 4 (15) 1.5 (0.5-4.9) 
P-trend 0.6 0.6 0.7 0.8 
beta 
negative 188 (44) 59(42) ref 51 (43) ref 8 (40) 11 (35) ref 10 (38) ref 1 
1 76(18) 21 (15) 0.9 (0.5-1.7) 18(15) 0.9 (0.4-1.9) 3(15) 5(16) 1.0 (0.3-3.0) 5(19) 1.1 (0.3-3.4) 0 
2 or more 161 (38) 59(42) 1.3 (0.8-2.2) 50(42) 1.2 (0.7-2.1) 9(45) 15(48) 1.6 (0.7-3.7) 11 (42) 1.3 (0.5-3.3) 4 
P-trend 0.3 0.5 0.3 0.6 
beta1 
negative 292 (69) 91 (65) ref 80(67) ref 11 (55) 18(58) ref 17(65) ref 1 
1 58(14) 20(14) 1.2 (0.6-2.5) 18(15) 1.2 (0.6-2.5) 2 (10) 6(19) 1.9 (0.7-5.3) 5(19) 1.7 (0.6-5.0) 1 
2 or more 75(18) 28(20) 1.4 (0.8-2.6) 21 (18) 1.1 (0.6-2.1) 7(35) 7 (23) 1.3(0.5-3.4) 4 (15) 0.8 (0.3-2.6) 3 
P-trend 0.2 0.7 0.4 1.0 
beta2 
negative 248(58) 76(55) ref 64(54) ref 12 (60) 16(52) ref 14 (54) ref 2 
1 73(17) 24(17) 1.1 (0.6-2.0) 21 (18) 1.1 (0.6-2.3) 3(15) 6(19) 1.1(0.4-32) 5(19) 1.1 (0.4-3.3) 1 
2 or more 104 (24) 39(28) 1.3 (0.8-2.2) 34(29) 1.3(0.7-2.3) 5(25) 9 (29) 1.4 (0.6-3.4) 7(27) 1.3 (0.5-3.4) 2 
P-trend 0.4 0.4 0.5 0.7 
beta3 
negative 328(77) 99(71) ref 85(71) ref 14 (70) 24 (77) ref 21 (81) ref 3 
1 48 (11) 15(11) 1.0 (0.5-2.1) 14 (12) 1.1 (0.5-2.3) 1 (5) 2 (6) 0.6 (0.1-2.6) 2 (8) 0.7 (0.1-3.0) 0 
2 or more 49(12) 25(18) 1.6(0.9-3.1) 20(17) 1.3 (0.6-2.6) 5(25) 5(16) 1.2 (0.4-3.4) 3(12) 0.8 (0.2-3.0) 2 
P-trend 0.2 0.5 1.0 0.7 
gamma 
negative 225 (53) 61 (44) ref 57(48) ref 4 (20) 10(32) ref 8(31) ref 2 
1 92 (22) 34 (24) 1.3 (0.7-2.3) 29(24) 1.2 (0.6-2.2) 5(25) 11 (35) 2.9 (1.1-7.4) 10(38) 3.2 (1.2-8.8) 1 
2 or more 108(25) 44 (32) 1.7 (1.0-3.0) 33(28) 1.3 (0.7-2.4) 11 (55) 10(32) 2.1 (0.8-5.4) 8(31) 2.1 (0.7-6.1) 2 
P-trend 0.05 0.3 0.09 0.1 
gamma1 
negative 247 (58) 72(52) ref 65(55) ref 7 (35) 10(32) ref 8(31) ref 2 
1 86 (20) 34(24) 1.2 (0.7-2.1) 30(25) 1.2 (0.7-2.2) 4 (20) 12 (39) 3.5 (1.4-8.8) 11 (42) 4.0(1.5-10.9) 1 
2 or more 92 (22) 33(24) 1.4 (0.8-2.4) 24(20) 1.0 (0.5-1.9) 9 (45) 9(29) 2.3(0.9-6.1) 7(27) 2.3 (0.8-6.7) 2 
P-trend 0.3 0.9 0.06 0.08 
nu 
negative 379 (89) 120(86) ref 103(87) ref 17(85) 24(77) ref 20 (77) ref 4 
positive 46 (11) 19(14) 1.5 (0.7-2.9) 16(13) 1.5 (0.7-3.2) 3(15) 7 (23) 2.3 (0.9-5.8) 6(23) 2.3 (0.9-6.4) 1 
P-het. 0.3 0.3 0.1 0.1 
mu 
negative 264 (62) 88(63) ref 74(62) ref 14 (70) 16(52) ref 14 (54) ref 2 
1 100(24) 32 (23) 1 (0.6-1.7) 30(25) 1.1 (0.6-2.0) 2 (10) 5(16) 1.0 (0.3-2.8) 4 (15) 0.9 (0.3-2.8) 1 
2 or more 61 (14) 19(14) 0.9 (0.5-1.8) 15(13) 0.8 (0.4-1.8) 4(20) 10(32) 2.3 (0.9-5.7) 8(31) 2.1 (0.8-5.7) 2 
P-trend 0.8 O.S 0.1 0.2 
NO 
negative 378 (89) 118(85) ref 102(86) ref 16(80) 25(81) ref 23(88) ref 1 
1 38(9) 15 (11) 1.2 (0.6-2.6) 13(11) 1.2 (0.5-2.7) 2 (10) 4 (13) 1.3(0.4-4.1) 1 (4) 0.3 (0.D-2.7) 2 
2 or more 9(2) 6 (4) 1.4 (0.4-5.1) 4(3) 1.1 (0.3-4.8) 2(10) 2 (6) 1.9 (0.3-10.9) 2 (8) 2.4 (0.4-13) 2 
P-trend 0.5 0.7 0.4 
0.9 
Any types 
negative 59 (14) 12 (9) ref 12 (10) ref 1 (5) 1 (3) I ref 0(0) I ref 1 
1 or 2 136(32) 47(33) 2.0 (0.9-4.5) 39(33) 2.0 (0.8-4.7) 7(35) 9(29) 9(35) 0 
3t06 123(29) 37(27) 1.5 (0.6-3.5) 33(28) 1.7 (0.7-4.0) 4 (20) 10(32) 1.4 (0.5-3.6) 9(35) 1.4 (0.5-3.9) 
1 
7 or more 107 (25) 43(31) 2.7 (1.2-6.3) 35(29) 2.4 (1.D-5.8) 8(40) 11 (35) 2.1 (0.8-5.5) 8(31) 1.8 (0.6-4.9) 
3 
P-trend 0.06 0.1 
0.1 0.3 
OR: Odds ratio, CI: Confidence interval, SCC: Squamous cell carcinoma, BCC: Basal cell carcinoma, HPV: Human papillomavirus. no:number: 
N: total number; Het :heterogenelty: ND: Not defined 
'Adjusted for age at recruitment, sex, time since transplantation, skin type and stratified by centres. 
": Beta 1 , 2 or 3: Positive to HPV types from species 1, 2 or 3 respectively of genus beta. Gamma1: Positive to HPV types from species 1 of genus gamma. 
Table 7.16: Association between multiple HPV seropositivity, squamous cell carcinoma and basal 
cell carcinoma only, among Caucasian transplant patients (using conditional logistic 
regression) 
170 
7- Human papil/omavirus in reiabon to cutaneous squamous and basal rell carDnoma 
OXFORD LONDON 
controls Prevalent SCC controls Prevalent SCC Incident SCC 
N=182 N=50 N=243 N=69 N=20 
genus No. (%) No. (%) OR1 (95%CI) No. (%) No.(%) OR1 (95%CI) No. (%) 
alpha-mucosal 
negative 119(65) 36 (72) ref 131 (54) 31 (45) ref 10 
1 48 (26) 11 (22) 1.1 (0.4-2.7) 79 (33) 26 (38) 2.3 (1.1-4.9) 9 
2 or more 15 (8) 3 (6) 2.9 (0.5-16.5) 33 (14) 12 (17) 3.9 (1.4-11.0) 
P-trend 0.4 P< O. 001 
alpha-cutaneous 
negative 127 (70) 43 (86) ref 158 (65) 47 (68) ref 12 
1 42 (23) 2 (4) 0.1 (0.0-0.6) 50 (21) 10 (14) 0.7 (0.3-1.7) 4 
2 or more 13 (7) 5 (10) 1.6 (0.4-7.0) 35 (14) 12 (17) 1.7 (0.7-4.4) 4 
P-trend 0.4 0.5 
beta 
negative 85 (47) 22 (44) ref 103 (42) 29 (42) ref 8 
1 31 (17) 10 (20) 1.5 (0.5-4.4) 45 (19) 8 (12) 0.6 (0.2-1.8) 3 
2 or more 66 (36) 18 (36) 0.9 (0.4-2.2) 95 (39) 32 (46) 1.6 (0.8-3.4) 9 
P-trend 0.9 0.2 
beta1 
negative 131 (72) 32 (64) ref 161 (66) 48 (70) ref 11 
1 24 (13) 11 (22) 1.5 (0.5-4.3) 34 (14) 7 (10) 1.0 (0.3-2.9) 2 
2 or more 27 (15) 7 (14) 1.3 (0.4-4.0) 48 (20) 14 (20) 1.1 (0.5-2.4) 7 
P-trend 0.5 0.9 
beta2 
negative 108 (59) 29 (58) ref 140 (58) 35 (51) ref 12 
1 29 (16) 6 (12) 1.1 (0.3-3.5) 44 (18) 15 (22) 1.3 (0.6-3.1) 3 
2 or more 45 (25) 15 (30) 1.1 (0.4-2.6) 59 (24) 19 (28) 1.8 (0.8-4.0) 5 
P-trend 0.9 0.2 
beta3 
negative 141 (77) 35 (70) ref 187 (77) 50 (72) ref 14 
1 23 (13) 6 (12) 0.6 (0.2-2.0) 25 (10) 8 (12) 1.5 (0.5-4.4) 1 
2 or more 18 (10) 9 (18) 1.2 (0.4-3.7) 31 (13) 11 (16) 1.7 (0.6-4.3) 5 
P-trend 1.0 0.2 
gamma 
negative 105 (58) 27 (54) ref 120 (49) 31 (45) ref 4 
1 33 (18) 9 (18) 0.6 (0.2-1.8) 59 (24) 19 (28) 1.9 (0.8-4.3) 5 
2 or more 44 (24) 14 (28) 1.0 (0.4-2.4) 64 (26) 19 (28) 1.7 (0.8-3.9) 11 
P-trend 0.8 0.1 
gamma1 
negative 114 (63) 28 (56) ref 133 (55) 37 (54) ref 7 
1 31 (17) 9 (18) 0.8 (0.3-2.3) 55 (23) 21 (30) 1.7 (0.8-3.7) 4 
2 or more 37 (20) 13 (26) 1.0 (0.4-2.7) 55 (23) 11 (16) 0.9 (0.4-2.3) 9 
P-trend 1.0 0.8 
nu 
negative 168 (92) 45 (90) ref 211 (87) 58 (84) ref 17 
positive 14 (8) 5 (10) 1.4 (0.4-5.2) 32 (13) 11 (16) 1.7 (0.7-4.4) 3 
P-het. 0.6 0.3 
mu 
negative 125 (69) 32 (64) ref 139 (57) 42 (61) ref 14 
1 40 (22) 13 (26) 1.2 (0.5-2.9) 60 (25) 17 (25) 1.1 (0.5-2.5) 2 
2 or more 17 (9) 5 (10) 1.1 (0.3-4.1) 44 (18) 10 (14) 0.7 (0.3-1.8) 4 
P-trend 0.8 0.6 
ND 
negative 169 (93) 44 (88) ref 209 (86) 58 (84) ref 16 
1 13 (7) 5 (10) 1.2 (0.3-4.7) 25 (10) 8 (12) 1.2 (0.4-3.5) 2 
2 or more 0(0) 1 (2) 9 (4) 3 (4) 0.8 (0.2-4.1) 2 
P-trend 0.3 1.0 
Any types 
negative 35 (19) 6 (12) ref 24 (10) 6 (9) ref 1 
1 or 2 63 (35) 21 (42) 1.9 (0.6-6.4) 73 (30) 18 (26) 1.7 (0.5-6.1) 7 
3 to 6 41 (23) 9 (18) 1.2 (0.3-4.5) 82 (34) 24 (35) 2.0 (0.6-7.0) 4 
7 or more 43 (24) 14 (28) 1.7 (0.5-6.0) 64 (26) 21 (30) 3.3 (0.9-12.1) 8 
P-trend 0.7 0.1 
OR: Odds ratio, CI: Confidence interval, SCC: Squamous cell carcinoma, BCC: Basal cell carcinoma, 
HPV: Human papillomavirus, No.:number 
N: total number; Het. : heterogeneity; NO: Not defined 
•• Beta 1, 2 or 3: Positive-HPV types from species 1, 2 or 3 respectively of genus beta. Gamma 1: Posltive-
HPV types from species 1 of genus gamma. 
Table 7.17: Association between multiple HPV seropositivity, squamous cell carcinoma among 
Caucasian transplant patients, by centre (using logistic regression) 
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BOTH CENTRES 
HPV 
alpha - mucosal 
alpha - cutaneous 
beta 
gamma 
nu, mu and NO 
LONDON 
HPV 
alpha - mucosal 
alpha - cutaneous 
beta 
gamma 
nu. mu and NO 
OXFORD 
CONTROL 
N=425 
%neg I "I.pos 
to 2 or more 
59/11 
67/11 
44/38 
53/25 
55/20 
N= 243 
%neg I "I.pos 
to 2 or more 
54/14 
65/14 
42/39 
49/26 
49/25 
"loOeg I %pos 
to 2 or more 
55/12 
73/15 
42/42 
44/32 
50/22 
%neg I '/.pos 
to 2 or more 
46/15 
66/18 
42/46 
38/34 
47/24 
SQUAMOUS CELL CARCINOMA 
all 
N=139 
CR' (95% CII P-value 
1.4 (1.0-1.9) 0.04 
1.1 (0.8-1.6) 0,5 
1.2 (0.8-1.7) 0.4 
1.3 (0.9-1.8) 0,1 
1.1 (0.8-1.5) 0.5 
all 
N=89 
'/oOeg I "I.pos 
to 2 or more 
56/13 
76/14 
43/42 
48/28 
50/21 
%neg I '/.pos 
CR' (95% CII P-value to 2 or more 
1.4 (1.0-2.1) 0.04 45/17 
1.3 (0.8-2.0) 0.2 68/17 
1.2 (0.8-1.9) 0.3 42/46 
1.5 (1.0-2.2) 0.03 43/28 
1.0 (0.7-1.5) 0.9 46/22 
prevalent 
N=119 
"loOeg I %pos 
CR' (95% CII P-value to 2 or more 
1.4 (1.0-2.0) 0.04 50/5 
1.0 (0.7-1.5) 0,9 60/20 
1.0 (0.7-1.5) 0.9 40/45 
1.2 (0.8-1.6) 0.4 20/55 
1.1 (0.8-1.5) 0.7 50/30 
prevalent 
N=69 
CR' (95% CII P-value 
1.6 (1.1-2.4) 0.02 
1.2 (0.7-1.9) O.S 
1.0 (0.6-1.7) 0.9 
1.4 (0.9-2.1) 0.2 
1.0 (0.7-1.5) 0.9 
"loOeg I '/.pos 
to 2 or more 
50/5 
60/20 
40/45 
20/55 
50/30 
Incident 
N=20 
CR' (95% CII P-value 
1.2 (0.7-2.3) O.S 
1.6 (0.9-2.9) 0.2 
1.7 (0.8-3.5) 0.2 
2.0 (1.1-3.6) 0.03 
1.3 (0.7-2.3) O.S 
Incident 
N=20 
CR' (95'/, CII P-value 
1.0 (0.5-1.9) 0.9 
1.4 (0.7-2.7) 0.3 
1.6 (0.8-3.5) 0.2 
2.0 (1.1-3.6) 0.02 
1.0 (0.6-1.9) 0.9 
all prevalent Incident 
N=182 N=50 N=50 N=O 
'/oOeg I "/.pos "I.neg I "Iopos "IoOeg I '/opos '/oOeg I '/.pos 
HPV to 2 or more to 2 or more CR' (95% CII P-value to 2 or more CR' (95% CII P-value to 2 or more CR' (95% CII P-value 
alpha - mucosal 65/8 7216 1.2 (0.7-2.3) 0.5 
alpha - cutaneous 7017 86/10 0.8 (0.4-1.7) 0.6 
beta 47/36 44/36 1.2 (0.7-2.2) 0.5 
gamma 58/24 54/28 1.0 (0.6-1.8) 1.0 
nu, mu and NO 62/14 56/20 1.3 (0.8-2.2) 0.3 
--~~--~--~--~--------------~-------------------HPV: Human papillomavirus; SCC: squamous cell carcinoma, BCC: Basal cell carcinoma; N: number; CR: Count ratio; CI: confidence interval. 
Neg: seronegative Pos: seropositive 
, Using negative binomial regression adjusted for sex, age at recruitment, time since transplantation, skin type and centre (where appropriate). 
%neg I "lopos 
to 2 or more 
65/3 
68/16 
35/48 
32/32 
39/39 
%neg I %POS 
to 2 or more 
59/5 
68/18 
27/55 
27/36 
36/32 
"Ioneg I "I,POS 
to 2 or more 
78/0 
67/11 
56/33 
44/22 
44156 
BASAL CELL CARCINOMA 
All 
N=31 
CR' (95'/, CII 
0.9 (0.5-1.6) 
1.3 (0.7-2.2) 
1.2 (0.7-2.2) 
1.4 (0.8-2.4) 
1.7 (1.1-2.7) 
All 
N=31 
CR' (95%CII 
0.9 (0.5-1.7) 
1.2 (0.6-2.3) 
1.2 (0.6-2.5) 
1.6 (0.9-2.8) 
1.4 (0.8-2.3) 
All 
N=9 
CR' (95'/, CII 
0.8 (0.2-3.4) 
1.5 (0.5-4.4) 
0.8 (0.3-2.4) 
0.9 (0.3-2.7) 
2.5 (1.1-5.5) 
P-value 
0.7 
0.4 
0.5 
0.2 
0.03 
P-value 
0.7 
0.7 
0.6 
0.1 
0.3 
P-value 
0.8 
0.5 
0.7 
0.9 
0.03 
"loOeg I "lopos 
to 2 or more 
65/4 
69/15 
38/42 
31/31 
42/38 
"loOeg I '/opos 
to 2 or more 
61/6 
72117 
33/44 
28/33 
44/28 
"/oOeg I 'IopOS 
to 2 or more 
75/0 
63/13 
50/38 
38/25 
38/63 
Prevatent 
N=26 
CR' (95%CII 
0.9 (0.5-1.7) 
1.2 (0.6-2.2) 
1.0 (0.5-1.9) 
1.3 (0.7-2.3) 
1.5 (0.9-2.5) 
Prevalent 
N=26 
CR' (95%CII 
0.8 (0.4-1.7) 
1.0 (0.5-2.1) 
0.8 (0.4-1.8) 
1.4 (0.7-2.7) 
1.1 (0.6-2.0) 
Prevalent 
N=8 
CR' (95'10 CII 
0.9 (0.2-4.01 
1.7 (0.6-4.9) 
0.9 (0.3-2.8) 
1.0 (0.3-3.1) 
2.8 (1.3-6.3) 
P-value 
0.7 
0.6 
0.9 
0.3 
0.09 
P-value 
0.6 
1.0 
0.6 
0.3 
0.7 
P-valu8 
0.9 
0.4 
0.9 
1.0 
0.02 
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Main analyses 
CIS excluded 
BOTH CENTRES 
<II <II 
j .!! 
c: () 
<II <II 
CI Q. 
<II 
<II controls 
~ No. pos (%) 
N=425 
prevalent 
SCC P-
No. pos OR' (95% el) I * 
(%) va ue 
2 3 
41 2 ~I 27 
Q. 8 7 
iU 
s 
9 16 
10 1163 
5 
8 
20 
24 
36 
93 
9 
1: 2 
15 
17 
23 
38 
49 
75 3 
76 
4 192 
5 96 
., 1'16~ E 95 
~ 2 48 
CI 3 50 
. 4 60 
E 1 41 
j \1 
c: 2 
o 
z 
63 
101 
103 
N=119 
36 (8) 10 (8) 
61 (14) 18(15) 
73 (17) 19 (16) 
1.2 (0.5-2.9) 
1.3 (0.7-2.7) 
1.2 (0.6-2.4) 
0.7 
0.4 
0.6 
36 (8) 4 (3) 0.07 
67 (16) 22 (18) 1.8 (0.9-3.6) 0.09 
128 (30) 38 (32) 2.0 (1.1-3.5) 0.02 
42 (10) 14 (12) 2.2 (1.0-5.1) 0.06 
39 (9) 18 (15) 1.9 (0.9-4.0) 0.09 
91 (21) 27 (23) 1.2 (0.6-2.1) 0.6 
61 (14) 15(13) 0.7(0.4-1.5) 0.4 
47(11) 12(10) 1.1(0.5-2.5) 0.7 
50 (12) 8 (7) 0.4 (0.2-1.1) 0.06 
12 (3) 6 (5) 2.0 (0.6-6.6) 0.3 
65 (15) 19 (16) 1.0 (0.5-2.0) 0.7 
116(27) 34(29) 1.0(0.6-1.7) 0.9 
100 (24) 37 (31) 1.7 (1.0-2.9) 0.07 
41 (10) 9 (8) 0.9 (0.4-2.1) 0.7 
95 (22) 28 (24) 0.9 (0.5-1.6) 0.7 
84 (20) 32 (27) 1.4 (0.8-2.5) 0.3 
50 (12) 17 (14) 1.1 (0.5-2.2) 0.8 
42 (10) 16 (13) 1.1 (0.5-2.4) 0.7 
52(12) 14(12) 0.7(0.3-1.4) 0.3 
62(15) 16(13) 0.9(0.4-1.7) 0.7 
108 (25) 38 (32) 1.3 (0.8-2.2) 0.3 
119(28) 29(24) 1.0(0.6-1.7) 1.0 
91 (21) 24 (20) 0.8 (0.4-1.4) 0.4 
66 (16) 20 (17) 1.3 (0.7-2.6) 0.4 
32 (8) 14 (12) 2.1 (0.9-4.8) 0.1 
19 (4) 7 (6) 1.2 (0.4-3.6) 0.7 
46(11) 16(13) 1.5(0.7-3.2) 0.3 
124 (29) 34 (29) 0.9 (0.5-1.6) 0.8 
98 (23) 26 (22) 1.0 (0.5-1.8) 0.9 
30 (7) 16 (13) 1.8 (0.8-3.9) 0.2 
26 (6) 5 (4) 0.6 (0.2-1.7) 0.3 
CIS included in case group 
BOTH CENTRES 
Prevalent 
SCC 
No. pos (%) OR' (95% CI) 
N=141 
10 (7) 
18 (13) 
21 (15) 
5 (4) 
23 (16) 
42 (30) 
16 (11) 
20 (14) 
29 (21) 
16 (11) 
13 (9) 
8 (6) 
6 (4) 
21 (15) 
37 (26) 
37 (26) 
10 (7) 
30 (21) 
33 (23) 
18 (13) 
16 (11) 
14 (10) 
19 (13) 
41 (29) 
32 (23) 
29 (21) 
20 (14) 
14 (10) 
7 (5) 
17 (12) 
39 (28) 
28 (20) 
17 (12) 
5 (4) 
1.0 (0.4-2.3) 
1.1 (0.5-2.1) 
1.1 (0.6-2.0) 
0.4 (0.1-1.2) 
1.4 (0.7-2.7) 
1.6 (1.0-2.7) 
1.9 (0.9-4.2) 
1.8 (0.9-3.5) 
1.0 (0.6-1.8) 
0.6 (0.3-1.3) 
0.9 (0.4-2.0) 
0.4 (0.2-0.9) 
1.5 (0.5-4.9) 
1.0 (0.5-1.9) 
0.9 (0.5-1.4) 
1.2 (0.7-2.1) 
0.8 (0.3-1.8) 
0.8 (0.4-1.3) 
1.1 (0.7-2.0) 
0.9 (0.5-1.8) 
0.9 (0.4-1.9) 
0.5 (0.3-1.1) 
0.9 (0.5-1.7) 
1.1 (0.7-1.9) 
0.9 (0.5-1.5) 
0.8 (0.4-1.4) 
1.1 (0.6-2.0) 
1.6 (0.7-3.6) 
1.0 (0.4-2.8) 
1.3 (0.6-2.6) 
1.0 (0.6-1.6) 
0.9 (0.5-1.5) 
1.5 (0.7-3.3) 
0.5 (0.2-1.5) 
P-
value* 
1.0 
0.9 
0.9 
0.09 
0.3 
0.07 
0.1 
0.1 
0.9 
0.2 
0.8 
0.02 
0.5 
0.9 
0.5 
0.5 
0.5 
0.3 
0.6 
0.9 
0.8 
0.09 
0.7 
0.6 
0.7 
0.4 
0.9 
0.3 
1.0 
0.5 
0.9 
0.6 
0.3 
0.2 
sec only (with or without CIS) 
BOTH CENTRES 
Prevalent 
SCC 
No.pos 
(%) 
N=55 
4 (7) 
7 (13) 
8 (15) 
3 (5) 
15 (27) 
26 (47) 
7 (13) 
12 (22) 
14 (25) 
9 (16) 
6 (11) 
4 (7) 
3 (5) 
9 (16) 
16 (29) 
17 (31) 
6 (11) 
15 (27) 
18 (33) 
7 (13) 
5 (9) 
6 (11) 
6 (11) 
23 (42) 
14 (25) 
15 (27) 
12 (22) 
7 (13) 
5 (9) 
10 (18) 
16 (29) 
13 (24) 
7 (13) 
4 (7) 
OR' (95% CI) P-value* 
1.0 
1.0 (0.4-2.5) 1.0 
1.0 (0.4-2.3) 0.9 
0.6 
2.4 (1.2-5.2) 0.02 
3.2 (1.6-6.2) <0.001 
2.0 (0.7-5.3) 0.2 
2.3 (1.1-5.8) 0.03 
1.3 (0.6-2.6) 0.5 
0.9 (0.4-2.1) 0.8 
1.0 (0.4-2.8) 0.9 
0.5 
0.4 
1.0 (0.5-2.4) 0.9 
1.0 (0.5-2.0) 1.0 
1.5 (0.8-3.1) 0.2 
1.1 (0.4-2.9) 0.9 
1.1 (0.5-2.2) 0.8 
1.7 (0.8-3.3) 0.1 
0.9 (0.7-2.3) 0.8 
0.7 (0.3-2.1) 0.5 
0.6 (0.2-1.5) 0.2 
0.6 (0.2-1.7) 0.3 
1.9 (1.0-3.7) 0.05 
1.0 (0.5-1.9) 0.9 
1.1 (0.5-2.2) 0.9 
1.7 (0.8-3.7) 0.2 
2.1 (0.8-5.8) 0.2 
1.8 (0.6-5.6) 0.9 
1.9 (0.8-4.4) 0.2 
0.9 (0.5-1.8) 0.8 
1.0 (0.5-2.0) 0.1 
1.6 (0.6-4.3) 0.4 
0.8 
SCC only (withlwithout CIS and 
withlwithout BeC) 
BOTH CENTRES 
Prevalent 
SCC 
No.pos 
(%) 
N=110 
9 (8) 
16 (15) 
16 (15) 
4 (4) 
20 (18) 
35 (32) 
12 (11) 
16 (15) 
23 (21) 
14 (13) 
9 (8) 
7 (6) 
5 (5) 
18 (16) 
30 (27) 
34 (31) 
9 (18) 
26 (24) 
30 (27) 
15 (14) 
14 (13) 
12 (11) 
14 (13) 
36 (33) 
27 (25) 
21 (19) 
17 (15) 
13 (12) 
7 (6) 
16 (15) 
31 (28) 
22 (20) 
13 (12) 
5 (5) 
OR' (95% Cil P-value* 
1.1 (0.5-2.8) 0.8 
1.2 (0.6-2.6) 0.6 
1.1 (0.5-2.2) 0.8 
0.1 
1.7 (0.9-3.5) 0.1 
2.0 (1.1-3.5) 0.02 
1.9 (0.8-4.6) 0.1 
1.8 (0.8-3.8) 0.1 
1.1 (0.6-2.0) 0.9 
0.7(0.3-1.5) 0.4 
0.8 (0.4-2.0) 0.7 
0.4 (0.2-1.1) 0.05 
1.7 (0.5-6.2) 0.4 
1.0 (0.5-2.0) 1.0 
0.9 (0.5-1.6) 0.7 
1.6 (0.9-2.8) 0.1 
1.0 (0.4-2.3) 0.9 
0.9 (0.5-1.6) 0.7 
1.4 (0.8-2.5) 0.3 
1.0 (0.5-2.1) 1.0 
1.0 (0.5-2.2) 1.0 
0.6 (0.3-1.3) 0.2 
0.8(0.4-1.6) 0.5 
1.3 (0.8-2.3) 0.3 
1.0 (0.5-1.7) 0.9 
0.7(0.4-1.3) 0.2 
1.2 (0.6-2.3) 0.7 
2.1 (0.9-5.1) 0.09 
1.4 (0.5-4.0) 0.5 
1.7(0.8-3.6) 0.2 
0.9 (0.5-1.5) 0.6 
0.8 (0.5-1.6) 0.6 
1.5 (0.7-3.5) 0.3 
0.6 (0.2-1.9) 0.4 
HPV: Human papillomavirus; OR: odds ratiO, CI: confidence interval; N: total number; SCC: squamous cell carciNo.ma; No. POS: number of seropositive samples; NO: Not defined. 
CIS: Carcinoma in Situ, BCC: basal cell carcinoma 
• Analyses are stratified by centres and adjusted for age at recruitment, time since trasnplantation, sex and skin type. 
• When the number of seropositive patient was less than 5, P-value was derived using Fisher's exact test 
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I\) MAIN ANALYSES analysis years transplantation greater than 5 years. 
0 controls Prevalent Prevalent controls Prevalent 
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1/1 
Q'(,,)Ol(J)::ECJ) 1/1 j! CD see p. Fully adjusted p. 
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CHAPTER 8 
Summary and conclusions 
8.1 Introduction 
Established risk factors for basal cell carcinoma (Bee) and squamous cell carcinoma 
(See) include exposure to solar ultra-violet radiation and, for see in particular, immuno-
suppression, such as that experienced by organ transplant recipients (OTR). In addition, 
there is a suggestion of an association between certain human papillomaviruses (such as 
betaHPV types 5 and 8) and the development of cutaneous squamous (but not basal) cell 
carcinoma. To date, more than 118 papillomaviruses have been completely described, 
of which about a hundred infect humans. The alpha types, particularly HPV-16, 18, 33 
and 45 are well established causes of cancer of the uterine cervix; the viral E6 and E7 
proteins are associated with the degradation of tumour suppressor proteins p53 and pRb 
respectively. A role for HPV in the aetiology of skin cancers is uncertain. 
Most studies of HPV and cutaneous squamous cell carcinoma have used HPV-DNA de-
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tection methods to examine the association. Due to the high sensitivity of peR methods 
and the ubiquity of HPV, previously unknown types are often identified. The ability to de-
tect HPV-DNA varies widely between samples from the same patient, in part depending 
on the type of sample (hair follicle or skin biopsy), the section of the sample examined (the 
surface or deeper within the specimen) or the location on the body from where the sample 
originated (sun exposed or not). More recently, studies have used new serological assays 
that detect antibodies against HPV; all recruited immunocompetent individuals and have 
used case-control designs in which sera were obtained after the cancer was diagnosed. 
The main aim of this thesis was to examine the association between squamous and 
basal cell carcinoma and antibodies against the L 1 antigen of 38 HPV types. The main 
hypothesis was therefore: is human papillomavirus a cause of squamous cell carcinoma? 
Data came from a small prospective pilot study from the Oxford component the European 
Prospective Investigation into Cancer and Nutrition and new data from case-control stud-
ies nested among high-risk cohorts of OTR from London and from Oxford. Plasma and 
sera were tested using Luminex technology. 
Few data are available on the seroprevalence and risk factors associated with HPV types 
other than those associated with cancer of uterine cervix. A secondary aim of this thesis 
was to examine the seroepidemiology of HPV among OTR and to investigate seropreva-
lence and epidemiology of HPV among different ethnic groups and among people with 
different immunological status. 
8.2 Summary of the findings in this thesis 
Risk factors from the questionnaire associated with post-transplant sec and Bee 
among Caucasian OTR (Chapter 7) 
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Using questionnaire data, risk factors for SCC and BCC only were examined among Cau-
casian OTR. Both SCC and BCC were more common in people with susceptibility to burn 
easily. For both types of lesions, the risk increased with increasing time since transplan-
tation and age. SCC was more common in men than women and in transplant patients 
with higher self-reported number of sunburns as a child and with the presence of kera-
totic lesions (viral warts or AK). In contrast, BCC was associated with a higher number 
of sunny holidays after transplantation. SCC was more common in patients who were 
married or living with a partner probably reflecting a screening effect, and the presence 
of SCC was also inversely related to birth order. This last finding might suggest an early 
exposure to infectious agents, but its significance in this context remains highly specula-
tive. A larger proportion of SCC was found on sun-exposed areas compared with BCC, 
which occurred on the back as well as the head. In contrast to SCC, very few BCC were 
diagnosed on the hand, suggesting a difference in the mechanisms involved in SCC and 
BCC pathogenesis. 
HPV seroprevalence by ethnicity, centre and immune-status in individuals without 
skin cancer (Chapter 6) 
A large body of research has been undertaken on mucosal HPV types but the natural 
history of cutaneous HPV is not known. This is the first report describing antibody re-
sponses in high-risk transplant populations and comparing HPV seroprevalence across 
groups with different immune-status and with different ethnic origins. Among organ trans-
plant recipients, HPV 5, 93 and 101 were detected more frequently in non-Caucasians 
than Caucasians and HPV 1 more frequently among Caucasians. For all ethnic groups, 
HPV4 seroprevalence was lower among OTR than IC or dialysis patients. Overall, be-
tween 81 % and 94% of individuals were seropositive to at least one HPV type and no 
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statistically significant difference was observed between the three groups with different 
immune-status (transplantation, dialysis or immunocompetent patients). The seropreva-
lence of 8 HPV types differed significantly between the two geographically close cen-
tres (London and Oxford). Those individuals seropositive to multiple types of one genus 
were more likely to be seroreactive to multiple types of another genus independently of 
immune-status or ethnicity. 
Risk factors associated with HPV seropositivity among Caucasian OTR without 
skin cancer (Chapter 6) 
Since NMSC occur mainly in Caucasians, further analyses were restricted to these pa-
tients. Among Caucasian control OTR, associations between risk factors from question-
naire and HPV seroprevalence were examined. Around 86% were seropositive to at least 
one HPV: 57% to alpha types, 56% to beta, 47% to gamma types and 45% to other types. 
As expected, antibodies against HPV 16 were associated with a self-reported history of 
an abnormal cervical smear and antibodies against HPV 6 were associated with a self-
reported history of genital warts. These findings validated the methodology. As expected, 
antibodies against mucosal alphaHPV types were more frequent in younger patients and 
among women. Skin type and self reported markers of exposure to ultraviolet radiation 
were not consistently associated with any HPV types. No other distinguishing epidemi-
ological features of transplant recipients with antibodies against single or multiple HPV 
types were identified. 
Association between HPV seroprevalence and SCC and BCC among Caucasian 
OTR (Chapter 7) 
In contrast with the results on the association between a self-reported history of abnormal 
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smears or genital warts and mucosal types 16 and 6 respectively, there were no consis-
tent associations between any of the HPV types examined (including cutaneous betaH-
PVs) and prevalent or incident SCC in the prospective study or in the case-control study_ 
Nor was seropositivity to multiple types associated with sce or BeC. Numbers were too 
small to examine thoroughly the association between Bee and antibodies against HPV. 
8.3 Conclusions and suggestions for future work 
There was no consistent association between any of the 38 HPV types and see. Con-
sequently, our serological data do not support a role for any of the HPV types examined 
in the aetiology of SCC. 
Table 8.1 summarises all HPV-DNA case-control studies that have, to date, examined the 
association between HPV genotyping and SCC with more than 50 cases. Due to the high 
sensitivity of PCR methods and the ubiquity of HPV, previously unknown types are often 
identified. The ability to detect HPV-DNA varies widely between samples from the same 
patient, in part depending on the type of sample (hair follicle or skin biopsy), the section 
of the sample examined (the surface or deeper within the specimen), the location on the 
body from where the sample originated (sun exposed or not) or the choice of the primer. 
Consequently, studies have not shown consistent associations between the presence of 
HPV DNA and SCC. 
Given the low copy numbers of HPV DNA in skin cancers, the association between HPV 
and SCC and, the question of high risk might be better adressed using serological meth-
ods. Studies detecting antibodies against HPV have all recruited immunocompetent indi-
viduals and have used case-control designs in which sera were obtained after the cancer 
was diagnosed. Table 8.2 summarises the serological data on the association between 
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HPV and skin cancer available to date together with the results of the thesis. Although 
possible molecular mechanisms with E6 and E7 betaHPV proteins probably working as a 
co-factor with ultraviolet radiation early in the development of sec has been suggested, 
there is as yet no convincing epidemiological evidence to support such a role. There is 
also no indication of a hierarchy of high-risk beta-HPV types. It is also possible that the in-
creased risk of SCC observed in OTR is simply a result of immunosuppression impairing 
the normal capacity to repair UV-damaged DNA. 
Difficulties with establishing a role 'epidemiologically', if any, include the ubiquity of HPV, 
the sensitivity of PCR detection methods and the lack of viral load data. Equally, few sero-
epidemiological studies have used the recently developed multiplexed and high through-
put technologies such as Luminex and new HPV types or combination of types might 
still be found to be associated with SCC development in the future. Luminex assay is 
a powerful tool for sero-epidemiological studies to detect antibodies against up to 100 
HPV types simultaneously. It is currently the 'gold standard' method but more research is 
needed on validation (sensitivity and specificity) of the assay for each HPV type. 
In February 2009, following the results of this thesis and work of other groups, the Inter-
national Agency for Research on Cancer (IARC) published an update on the association 
between HPV and squamous cell carcinoma. The conclusion was that there is "a need 
for further research of cutaneous HPV types of the beta and gamma genera. These 
widespread HPV types were classified in Group 3 on the basis of inconclusive evidence 
of causing skin cancer in humans and limited mechanistic data. Exceptions were the 
beta HPV5 and HPV8, which are 'possibly carcinogenic' in patients with epidermodyspla-
sia verruciformis" [343]. 
Further research is needed to clarify the natural history of cutaneous type using detailed 
questionnaire, in particular given the growing research interest in the possible role of HPV 
180 
8- SUmrTlClty and concIlJSIOfIS 
in the pathogenesis of cutaneous SCC. Large prospective study with repeated serolog-
ical measurements and with HPV-DNA and viral load data are needed to elucidate any 
genuine association between HPV infection and SCC. 
Number sample 
Author, year SCC/controls group location Results 
Struijk, 2003 155/371 IC Plucked eyebrows All beta HPV and 
Termorshuizen, 2004 156/320 IC 
types 5, 15 and 20 
Plucked eyebrows All beta HPV and 
types 5, 15 and 20 
Struijk, 2006 64/58 IC Plucked eyebrows No association 
Forslund, 2007 82/92 IC Skin biopsies Beta species 2 
Patel, 2008 101/101 IC Skin biopsies Beta species 1 
IC: immunocompetent 
Table 8.1: Case-control studies on cutaneous cell carcinoma in relation to the detection of HPV-
DNA (~ 50 cases; Appendix A) 
Number incident! 
Author, year SCC/controls group assay prevalent Results 
Feltkamp, 2003 160/333 IC ELISA prevalent HPV8 (beta-1) 
Masini, 2003 46/84 IC ELISA prevalent HPV8 (beta-1 ) 
Struijk, 2003 64/58 IC ELISA prevalent HPV8 (beta-1 ) 
Karagas, 2006 252/461 IC Luminex prevalent HPV5 (beta-1) 
Casabonne,2007 39/80 IC Luminex incident No association 
Andersson, 2008 72/121 IC Luminex prevalent No association 
Waterboer, 2008 43/77 IC Luminex prevalent beta-2 species 
combined and gamma 
species combined 
Casabonne,2009 119/425 OTR Luminex prevalent No association 
(inconsistent results 
across 2 centres) 
*Incident or prevalent: blood taken prior or after diagnosis of SCC respectively; IC: immunocom-
petent; OTR: organ transplant recipients. 
Table 8.2: Case-control studies on cutaneous squamous cell carcinoma in relation to the detec-
tion of antibodies against some beta, gamma, nu and mu HPV types (Figure 4.4). 
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APPENDIX A 
Case-control studies that used HPV-DNA methods 
183 
...... 
CX> 
~ 
~ 
,~-~-.~ .. ~~'-~~~~-,.~ ~ 
n c.es (B8C'" SCC 18 
BoJ-I'I'Wt".l. boll 7) IC 
1m The "...,.. ... 
-
19<OOeS 
12 ""*'* 
ISRTR 
OeJoot-Toobenll 5SCC 01. 2000 The_ 
' cinaII nomlIIi skin ., pants RTR 
wttKMsbnc:anter1 
_lIat, NIoISC 51 BeCS ~SCC 2000_ IC 89ccn .... 
O·c:cnncr ".1 12SCC 2OO1h_ IC 20C ... ", 
SOuojt 11.1.2003 155 SCC The __
371_ IC 
""" 2003 ... 1, 72SCC USA (C-....) lot_ IC 
TtrmCf""IhuCltft ., 
.t 2~' 1M: 156 SCC N_ m_ IC 
10N ..... ,c(II.....,..} 
It_Cli_Ie.) IC 
............. ~ 
200t ... 1Jl< 
II NIoISC (51_) IS 
1'-(10_} RTR 
--- .. 
~_" _ L _. ~ _ .. ~ ~ ..... . 
__ ,._ .. 1' 
......... '-'offtIJ):.fIc:;wtC« 
-
_. 
. . 
pb;\edh __ 
eyebrow. ~. orm. 
leg. 
(1.1 eoM) 
skln bIOpSies 
(1.1 eoM) 
pkJcked h_lrom 
.yeb ..... ~. orm. 
leg. 
(1.1 g.ne) 
sian bIOpSies 
(L1 eone) 
plucked eyebrow han 
('£1 gen.) 
I bnblO9llel 
(Elg"") 
pkJcked eyebrown han 
('£1 gM.) 
,""bGptIlH 
(1.1 eone) 
_. _- -
- '---- ..... 
~~£~ .~. I~r~ . 
.aiifu ~. (}l'l'. .... J 
1.1 (U·3.0) 
5 16%115% 
04(0.1·2.3) 
37%158% 
b ... 20%10% 
"'U-Hf'VDNA 
& NMSC 
0.8(0 .~1.8) 
63%167% 
& BeC: 
b ... 0.6 (0.2·1.5) 
61%171% 
& SSC: 
2.0 (0.5-.1.0) 
68%156% 
.. 
umpkl 28.3 (3.2 10 338.2) 
.... ". .. -IlPV· 2.1 (1 .4-3.2) 1.7(11·2.7} 
75%158% 
~2.0(U·31) ~1.7(1.1-2.6) 
bela 5.8. HPV5 2.8 (16., 5.0) HP1/5 2.8 (16 "5.D) 
1520.2438 23%113% HPVI 26 (1410 49) HPV8 1& (0910 3.4) 
17%110% ~ha""cosa[ HPV15 3.2 (16 10 62) HPV15 2.5(1 Ho4&) 16 17%/8% 
01her2 HPV20 2.1(1.3103.5) HPV20 1.7 (1.0 10 2.9) 33%124% 
HPV24 2.6 (1.5 10 4.5) HPV24 1.4 (O.BID 2.6) 
25%115% 
HPVlI 20 (1.2 10 3.3) HPVlII5(09 .. 26) 
32%125% 
~ha""cosa[ 
.... HPV' 30 0 (lD.9 to 830) 16313335 60%/5% 32.0 (10 0 10 100 0) 
end 51 
bOIl 
5.81217.19)2 In POItlmpMl b .... 9%120% 
. and 3& cutaneous- 21%/20% 
AI bot.-IlPV 2.1(1.3,.3.2) 
71%154% 
HM 2.2 (1.3 10 38) HM 20 (1'=0 02) 2<%/12% 
5 HPVI 18(10 .. 33) 
8 17%110% 
15 HPV15 U (11 III tI) 
20 17%18% HPVI5 2 1 (1'--003) 
24 HPV20 1 6 (10 .. 2.6) 
38 33%123% HPV20 1 6 (p.0 Oi) 
HPV2< 18(11.,30) 
25%/15% 
HPVlI It (0.9 .. U) 
32%125% 
~ 1 i!m2I!1 
MjHPV 
73( 1.2 .. 530) 1 1.5 (0 <., 53) ......... m .. '«181022.9}P=OOO4 
70%124% 42%133% 
... "".oy"" U(13 .. 36 I) f'oO 02 
tnpod:rw ... mp ... ~. 63% 125% rr&lcoslil: 0% I 
.. 0% "' ......... 63% 175% ....... NSf."'" 73(15"J54}f'oOOI 
Potion" 1 ~ 
MjHPV ....... SE.Ion 49(20102S.I)f'oOot 
109 (0 9 .. 1532) 1 69 (10 "(20) 
94%151% 91%160% Po ....... NS __ torffnyHPV ondNlASC 
tnposltw. tlq>'" ...... 94%/37% __ 2%1 Neg .... HS..ocaon Jew CUlill"lcaII t-I'V .-td N"-SC 0% __ "_ 
- ~ ~ _. ~ .. 
.- ...... -.~ 
_ .
.. ............ . -_. 
- 1... .... ____ ....... _~_I.-a uo::.lC: ............. 
~iP' r .... _". .~.,,;,~ •. ~, 
11~forege..sunscrefll 31 RTR. (Dutth pabenb) 
_n 5181C. (Au ...... 1he N_ourl 
H,her ~ce m sun-exposed IRS but onty In patJtnts 
with ,bl cel'lCen 
HPV5 8.9.12,15.24)(1 
Mu",1e ,,'op.'1IMIy ~ pabonts will SCC (60% '" 45%, 
11 matched tor age sunscnen P<0.05) Wittun the cohort of resident 01 Nembour. 
aiIoeobon Problem 0' detectIOn 
Mamty bel&-HPV types 
HPV38(,3). 36 (xl). XI (X2). 15 (,2). 20 
HPV 16 .1 caes 'ftf't negetrve 
HPV2 Orlt indMduel was posarve 
MulUpte infecbon m(lIe common In pabtlnts WIth sec 
AdJUsted fOf age and '0. (OR 19. 95%C11.210 31) 
Anatysis restncted 10 HPV-ONA+ non, of HPV types ,toodd 
out 
No edjustement fO( .un eKpOStI't, slun type, smomg •• ttun 
ere "04 HSOCl8led WYth the presence of HPV DNA n etHrow 
han 
·~~Ie Infecoon more common In plbtnts WIth see 
.ceWomil (morl c .... , Germany mtll:ed (moll conton, 
-OetectlOn problem (not .. typH) Ad~sted lor age .u end ,un 
expOll.I"e (Iocabon) ~oblem ""'''g YIWe. 
..s.!T'fl.sU:. 
New Mlborwtory mtthod r8Yef'Sfl h)ttJdlllbOn method 
AdJUs1ed lor lOt. III .Ion type 
lun exposLJ"' Ind pelnN! 
sunbllTl' 
UnrMl£:hed 
S~. ( .... e<poMd ond ... ,'pootd) 
a.....". "",",pr .. _,~ RTfI ..... 1C (OR-" p. O 001) 
AdJUs*-d ~ nn".,.,,1 stalin 
H:t ItId etft« toIMt. of ,*",It 
(ttln npOMd 01 nOll) 01 nutrbtr 
oI""l'lt.pet-'. ~.I''''' et:pOMd Md not "poaedJ 
80 .. .."... ..... "'-., .. RTR"", IC (OR" . I P'O 00 1 
-...I c::c ......... ..-- 1.I . t.I~._""'_I .. 'IIiL'--I 
~ 
~ 
CI> § 
~ 
~ 
!R 
~ 
~ 
J: 
11 
$ 
)i; 
t 
co 
01 
.~ 
.. 
s..,' 010( 2006 
--
Fonb>d ... i. 
7OO7._n 
loRn ... 1. 7001 . 
FnwIee 
,t,tubjft.l 
2006 e_ 
As9Ir1" .1. 7008 
USA 
Al'ldttUOf\ lIt.t 
7008 S_n 
If ....... on twt ... 
Fonb>d ... 1 
7001_) 
"-I ... t, 7008 
USA 
",I''' .. _ _ 
- .. -. 
HPV """WI' 
~, !! Z1!itl'J 
usce 58 ...... _~ .. 
82SCC 
I2liBCe 
92 benognle.oons 
mOII:l\e<I.9. healhy .!on 
S4 plbrnts dl 
4Gsce 
21BCe 
H ... hy.kIn 
8SCe 
47 heelhy ",",,01 
85 sce (3G ... 1M'" SCe) 
i_eon", 72 p ....... 
95 oge-mo4C/Ied .demo! eonrob ( ...... .....,..on_.un-
1q»Hd lind one tom not.,un 
flII_.~n} 
72SCe 
121 Bonogn 
101 sce 
101 ace 
......... .. _--'-_ .. - - ...... 
• NtoISC non-melenorr. SOl uncer 
IEl ~ ~ ~ .. ~ .. 
pklc: ... eyebrowllan 5. 8 IS. 16. 20 IC (E7l1"nt) 24.nd 38 
smbtOpsle5 
ie (ll gene) .. 
sec: Any HPV (22%/50%) 3.5 (06-37.7) 
d sm btopsl6 a.te HPV (22% 1 48%} 3.2(0.>~1) 
b" (ll gene) 
.. 
euteneou. HPV(II%/8%} 0.6 (00)18.3) 
H Bee· AnyHPV(2:2%1 IS%) 0.6 (0.07~.2) ><~ a.te HPV (22% 1 15%) 0.6 (0 .07~1) 
eUlan ..... HPV (11% 1 4%) 01 (01).31) 
ie swab SlIT1J~' be .. s ec 7 (88%}141 (87%) 1.0 (O.1-5J8) (ll gen.) 
tim bIOpSIeS 
Ie (ll gen.) .. 
lUI biOpslH ie (ll gen.) ""hI end be .. 
skrlblOpSieS ie (Elgone) bete 
.. _- . -'- - ' - -'. ~ ,,,. ... . L _ _ . . .............. 
-
.. <L ._-_ ........... _- .. -- '--._-
~ '1'1 
,~ ' ::rli:i~"IlI ~!'rtI ~ 
HPV5: 19% 1 13% 0.6 (01-21) 
HPV8: 3%/3% 0.4 (0.1-4.1) 
HPV15: 2%/2% 0.6 (0.04-11.0) AdJUsted for age end so Basdine pabents who were setlllleganw to any bete types HPYlO: 10%/17% 0.9 (01-3.7) 
HPYl4: 12%/ 14% 0.8(0.2-3.1) 
HPVlI: 26%1 13% 0.3(01-lj} 
see: belupoci .. , : 1.6 (0.1-3.4) "Stwed',lI1oce Hlghef HPV-ONA detectIOn In UV~xpo:sed sm bel •• pec ie. 2: U (1.9-10.1) AdfJsted kf ege. St!~ sm type. 3dJf!orentlol> ........... 31%(219";98),_Ie,pos_"'eny 
sunbllnS, eye cob', Ioc8bon of HPV 'YPe,. oi whom 17% (120,.;98) ...... po,iMI 10 lIIon"'o! Bee: be' •• peci .. , : 11 (0.6-2.5) ~SIOfl (sun exposed or no_) HPV!ypo (delec1>on ~ 0I1eo,1 2101> ... _.) bell .poei .. 2. 1.7 (0.1-4.0) 42 dllloroni 'YPes ., ... found (37 bela. 3 01""" 2 ",hI) 
Most prelllieni HI'VlO. HPV2I . HPVJ3 
Age between .. end 35 ye., okI. 
AlblOPsles from su~ed 1m. 
Mo"prelllient HPV24 (2 I%) .,d HPV 19 (2 I%) 
Problem. mul"hI slfl1lies from seme patte'll (LI HPV241n 3 
sec Itom ..... p ... nO 
AI new PUtative HPV ~tS 'or sec 
L .. 1on venus pe rt •• Jon I combNd cu . ... Frequerq matched on age and 
controfs 
./pho-lypos 0.1 (01-2.4) 1 28 (08-9 8) sex AdJusted for propensty of belo-lypH 1.3 (06-2.1) 1 0 1 (0 8-3.5) 
SUr(lt.ll\ g.mmo-lypH- 1.5 (0 4-5.3) 11.3 (0 >4 0) 
Adjusted lor leX, 'Of!, tocallOn ~ 39% end 39% of patlenl1 with sec, Bee end benign 
see· Any HPV 2.111 0-41) tumour, prtwlUS .unbUll and lesIOns were pOlIlrVe In elleest one of the ltv-tt leborllOOl' Bee AnyHPV O%(057-162} lmo~ng Pored dilla (lesIOnS .,d b.n~n ... "",Ie tom ume pebetlQ 
sec ., tflUS Bee 
Anybelll-lypH 15(01035) Ad~,ted for lOt sex C.s.-<;as. eft'ign HPV5. 8. IS. 20. 24 36. WldAlr 38 26 (14-5 I) educallon, smoking, IkrI New 1IIb00000ory method tewne hybl1chlitlOn metnod Betespecae:s 1 20 (11).36) stns!tMty to sun~ht and HI'Vl4 (9'h",,,, 15,.) Be .. spede. 2 14 (07·25] iltetrnesunbl.fnl 
a.te .. ,,\e. 3 41)( 5 1.00.>20i 
, _ _ '- a u _ • .• • _ _ ~ ____ ~ .., __ • •.• 
. . ..... __ •• •• • _ ___ ... .. ." ••• • ____ ..I ., " U .... _>-_"-a_._C ... .... _. 
::-
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~ 
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APPENDIX B 
HPV-DNA prevalence in patients with see or Bee 
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SCCorBCC 
Cf!f.f' .. 
I:l~:l - .~~ W r,::!';II 
o.Jo~r ... ."tI c.cplbents I." I." ". .Ion 01.1995 sec 51 specs b""' .... b<ta 
The Nethenonds 80'41-
_PeR 0.,-.7' Bee 8 spe", 50'1001- ~"'1l1go ... 
IC 
Shlnwrun tlaL sec 19 po1le nts (26 speamons) 
.!un ~h. (low<o "'" 0 
--1996_ 
BeC 9 pOC>enl> (11 .peclmens) bops.es 
PeROOV ...... 
'*"<, 
UK.Gormony IS 
mucosal) 31%1- 65%1- 36%1- 60%1- ·16d eretllfll'Jr"'ltl' 20% ... _"". "-Tr~ 
sec II pobonl> (20 specimens) be .. ~-
BCC 4 pOC>enls is soecrnen.j-· (llgonl) ....cos.tIIIISlSoIS66IU aoWleO\oIS,41601 
Box""", e/ 01 . 1997. 25 pOC>enl> (68 spec .... n.) 
.kin 
bK>pslel 
--Th. N.1hetJonds 9 polienl> (22 seC) 
beta. evtaneous 91%1 - PeR 009"""" UoII_ (l11l'J'01 12757 38 23 Ct."! Dt.2fl.20 
f()""""" 
f() """"" PeR 009"'''' 
De VIler, ,t at. sec 9 pobonts (22 Spoc"",ns) 50'1001-
1997.1h. UK.nd 
.kin AM 0%1- ( ... "'"1 7. 
-Germany BCC 2 •• ",,1e. 
bIOpSIeS beta, cWlneotn pnmer AM""""" HPVlO (21 OUl711""-
81%1- 0%1- f()pm1Ir(Sha".,..., 1994) Ol40115%1 HPV2l(N HPVJI 
teal AM pm1<f (8fnJ\OIA 1995) (W) ~7 ond '*"<11'''' 
91%~ (L1 gone) 
.kin 
Harwood ,I aL 16 SCC blOpsteS beta. tvt!neous PeROOV"' .... 
1999. th.UK 6 BCC P~:I ~ha 79% 1- 17%1- Ino.1od} 
Norype(Oll't ,,-
1L1l1"oe) HP1i5 20 21232438 
Boxman tiel .. 2000. 51 BCC plocked 
In ty<!>row ""n 01 p ...... Will 
AustnWa 25 sec • her be .. -168% -161% 
PCRdtgttl ... ..... <a'ICW1 
(l1l1"ne) I4'V38 (>.2'1 XI(J.ll).17fJa~0:5~;:1111.815121 
Boxm"" "aL. 2000. 14BCe skin 
In~~, 
AIIxballa b"",.1es be .. -1'3% 
PeRd'1l"' .... I4'V38 fJal ' l 
(lII1"M) XI(illll71.10) II XI 11.8) 5 121 
, 151RI 
W~land 0101. 2000. 61 BCC 169.peclmen.) .kin 
4-4%1-
Ger_y(n'31) bJOpsles beta, cutaneous. 
Ho.ted PeR 
"'-"Y HPV 8 ond 20 IGormonyI 
Germany & Poland ~hal""c .. aI) 0'11""""" (6 cW! pmiIn) Poland (n'38) tMll.,beta HPVJa' HPV T09ft In Poland 
'1%1- (llll""') 
Harwood el.L, the IC 51 patients (22SCC. 3OBCC) ,Ion BeLl. cutaneous, 
New_ 
UK. 2000 IS 32 p.lienlS 144SCC. 24BCC) b"",.1es ~h·lmuc .. ·O 27%127% 84%18'% 
37%1l7\\ 75%175% DegeMtate PeR !Ued .'ecaon ~ 57\\ .~Ioo 1L1l1"nel Prodom...,t belli 183%) 
cu"''''''-;6Ni-__ "" [15") 
Meyer .! at. 2000 IC 10 p.llenls III specme",) .~n bela 
PeR Oo9.n .... & ",eciIc FOUnd 
Germany RTR 14 pobents (21 specimens) bIOpSIeS ~ha(...c .. oI) 36%130\\ 57\\150% 
MY09fl1 MYN9/JO.,d 568 1114 IS 1622 26 25 36 70 CP6S170 CP6&'69 
(lIl1"nel 
78%1- 36\\1-
beta-A. bef&.A bef&.A 
BerkhoU1 ttel.. 21 p.bonls (351 spoelmons) skin 40% 0\\ 
S/8J1VI4119f20JlIn5I36J47 
2000 81 SCC . 14 BCC bIOpsies beta. cutaneous be..a be<&-8 PCR deoennte 
be..a 
The Netheriands 51\\ 21% III gone) 
911S117n1n3l37f33J'9 
b.ta-C b.ta-C beta-C 
28\\ 29% 24 
AlI4 2211 161M"l)'p~ 
B~rl'" ., .. 2000 95pllllents .l<Jn 
Greece 3 SCC In 23 p.llenls bOpsles q,h' lmucosaO -113\\ -131% 
PeR d'1len_. & speck NMSC 01 HPV-DNA po._ .''''9 
22 Bce " 72 p.lients 11III"nei PeR 19eciftc 
De Jong Tleben at 41 plltJents 
" .. 2000 45SCC .Ion b ... 
PCRdeoenne 
The Nelhet'Wlds 6BCC bIOpsieS 
73%1 - 33\\/- lne.tad) IS n,""lYPH 
(ll g.ne) 
O'c:onnOfetllL. 12 p.llenlS)1 2 SCC) ,Ion b ... PCRdegenerwte 
2001. '.land 6 p.llenlS 19 SCC) blOpsles .,h·l...conO 83%/8l% 88%183".4 Ntwtypes III g.ne) 
JC 13p.tients Some .tudy IS 2003 
Meyer " ai" 2001 , .kin beI8,cutane04Js, 
PeR In pte and mallgnanl bela-ffle!e<l 
Germany IS 15 p.llenls IRTR p,,," .. is. biopsies elpha(nmucosal) 54\\1- 73%/· 50%1 - SO\\I- Degenento (A9~IO) 
HIV. other treatmen~ (ll gene) Higher prevMence tor sec Ifl IN· peOentsn W+ 
Boxman tlol. 2001 SCC only IS plocked 
PCRdegentnte Peq>1e """ AY. moro ike/y ID have 
• .., cancen 
Th. No1hetlands BCC only 69 han b.ta 75\\1- 59%/- I"'''d) (lll1""') 
AU beb-HPV: 
75% 
pkicked HM 23\\ be .. 5.8. HPVI6: 0% 
5oul)l< elol . 2003. eyebt'l)wn 15.2024.38 HPW 17\\ PCR deoenerate 
The Netherlands 64 SCC han Genllll16 HPV2. 0% 
(EI g."e) 
01h 2 HPV15 17% 
HPYlO 33\\ 
HPVl' 25% 
HPVl8 32\\ 
~ha (""cO$aI) 
72SCC 16.31 33.35 . .. d 51 
AU HPV' HPVrwes lJ4 
Jt\ner "01. 2003. 15BCC .l<Jn bo .. 60%1- 28%/-
peR degeneno 
USA (C.hlom~) bIOpSies 5.81217.1922.nd I""" 9% beto-HPV lEI g.n.) iKe HPVI827 331 
36 & 21%cut Hpv) 
cutaneous 
Wh .. oilS gI"'Ped 
IC 14 pillenls ( IS specimens) Meyor .,,1 2003 .kin beta cutaneous PeR see 81 ... 
G,,"*,y RTR II p.Ile"" (16 .pecmen,) blop."" ~h.(muc ... O 47%1<3\\ 75%173\\ o.von'"'" """'" ~ ond HPVt 1.-1, tS (ll ,. ... 1 
_") 
H~ Humen papllomevrus sec Squamous eel CIIcnorna IC Immuooto"'f!etent plbents ts Immonos""pressed p.oents OR Odds mot. CI confidefl(e III«V1t RTR rN I'lr'ISP_t,ecflltnt AI( IIC1ItIc: k.., ... * "'" \I'IOW'\_ n IWI'btt 
NSE not sun exposed, Sf- ,un exposed NS Not ,,,,nllcenla' 5'4 level CIS cardoome " SIN 
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8- HPV-D A prevalence In palJen15 .. sec Of 8CC 
~ , , . ~~ cy. m 
,. J.. ,Ii, 
te BCe 19 pllbenls{19 
--. specI11eIlS) sec 11 p"''''' FAI'PC~ Fonkmd eta!. (12 specs) itr.,.. 
2003 .m l_ SI_ 
S.e<ltn&AIJ_ bKlpstes bola 33'.4, J3% 504 .. ,_ 21% '21% ar.,- III 
IS BCe 5 p"''''' (6 ... ..,. lPflIo-'I 
;r:mens) sec 11 p"'"" IHPV3I 921 ~ IS 
II"e<!ITlensl I_I CIS nooc>td .... r:scc-
5 AlHPV 71% 
T ermorshulZen eot 8 11M 2~ 
1I..2004, 1he 156 sec plucked 15 HPVI 17"4 PCR~ 
Nelher10nds 320conooll eyebrown 20 HPV15 17".4 (E/9<"O 
han 24 HPV2O" 33% 
38 HPV24 25% HPVl8 32'4 
te 64 pOllenlS 119 sec, 56 
SIocI<1leIh .,.!, BCe) .m PCR~ 
2004, Ge<mony RTR 18 P-::~, {11 sec, 8 bIOpSies .. 37%'- 75%'· 48%'. -,. l.....ol 22 HP\I!)tO._ {llg .. " 
lesIOn 
swabl Toooft' .. ~.,.,,,, ~ 
"'"n ......... 
Fonlund ,'et sec 31 b""",." beta PCRoMvo_ Soeoos I 
2004, Swed.n BCe 109 perieSIOn.eU 58%119'.4181%1 63%' .... 176%' lcon""""" 
lor1IeadI 94'4/81% 82'416 .... {llg ... , 
Soeoos 2 4' 
5 
bUllock _ljIIttw._ 
(swll>.) 
5 HP'15 13% 
8 HPV8 3% 
Sou.k .1.1. 2006 , 14 sec plucked 15 HPVI5 2% PCRoMvo_ 
AU1traba ha .. 20 HPV20 17% (E/ go"'l 
24 HPV24 14% 
38 HMI 13% 
btb 
bt" 
Hlgt\el t-f"V..()NA deCedlOft 1\ 
Forllund e'at , sec 82 sk .. IpKII11 speel .. , 1~ PCRoMvo_ W .. upostd I~rt 
2007 Swed.n BCe 126 blo!>'1es .. 15 .. ·PKM.2 P-l "Stvptd' .... ,<0 IpKlts2 {lIgen., 0._ ...... ,2 
17% 7% 
--85 sec (30 w .... n .. '" seC) Internal control 72 pen4uIOn 'Il)" 504% 
A.g.'.'a!, 2008, 95 og....,.,ched ."'''nol .k. 
.. 
.Jpha 8% PCR Ot9.n •• 
USA controts (WIth two S8fTl11e on bIOpSies btl. 49% (ll gen.) 
from sun-exposec! and one gamma r4 
from not-sun .xoosed skrl 
Andensoo .1 at 
2008 Swed.n sec 72 sk. "ha b ... PCR oMvo ...... (rew'" on type In ben"," 121 bIOpSIeS cutaneous Iny58% Iny-39"4 P-) O'toc ....... ....,IsC ........ For;~~~~~07, (llg"'" 
Inya..% any 78% 
HPYS, 8,15, 20, 24, HP'I5, t , 11,20, 24, 
P.,.,., .1 , 2008, sec 101 .kn 36, andfOl 38 62% 36,'_ 31 41% PeR dtgeMtlle 
USA BCe 101 blOpsleJ beta Spec,.., 64 .. Spec'" I 47% lEI g.nt) Sptcl .. " 3J% Specl .. 2 57 .. 
Specl .. 3,4.5 33% Specie. 3,_,5 30% 
sec & CIS •• ro.d In some srudy IF",'und .I./. 2003 Asg.'" 11., 2008) 
HPV Human papllomavrus, sec Squamous cd CSCflOrM IC Imnwnocorr.,lIll!lnt patients IS Irmlunosuppressed patients OR Odds 1'111105 CI confidence ",I!IVII RTR renal msplanl fKip_nt AA anlC k.lf'ltMIS Nt< not known n nUmOtf 
NSE not sun exposed, SE sun nposed, NS Not slgnkanl at 5% leve~ CIS carcinoma In sItU 
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APPENDIX C 
HPV-DNA prevalence in hair follicles, normal skin, psoriasis, viral 
warts, actinic keratoses and carcinoma in-situ, peri-Iesional 
samples and other disease. 
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c- HPV-ONA prevalence in hair follicles, normal skm, psonasis. viral warts. ac/Jmc keratoses and carCInoma m-s,/u. perJ-lBSlOn.a1 SilJTIpies and o'ller drsease 
PLUCKED HAIR 
Boun.an II al, 
11)9-, nl~ 
l'c:Ulerun..u 
So:un~ ,1 ilL. 
19?IJ,TIIt' 
Ne-lMrblll'U 
&UTlJlfI,/~L. 
200t. AustLllu 
MC),Ullol.,Jl)fIl. 
GcUn.&ll 
"·olr rlllL, 2004, 
AUSlll.,,& 
CeunMl)' 
Dc Kt:mHlg 1141. 
2006, TIlt' 
Ncthcdmd. 
Ie 1:1 pc.cnts (38 ipC"Clmt'ns) 
Rlll 26 p:lhcntt (4" tip«unefll) 
Ie IlS pJol,irnLi 
With N~lSC ~=69) 
U.llho"c(N=66) 
IS 31 p.UJe11U 
\t'~:~~;~9) 
cAp.&.lU 
12 paIlcnu Wllh BCe Ot so: 
J::! control. 
63 p,hcnt. (sampk, ?) 
CpA PUVA+ .. k.utlSk.uIC~ 
(16pat~nts) 
Gp B PlJVA + no .tun Ca (35 
p'llUCIILI) 
Gge: n(l PUVA + no .klll G (30 
p:Ulcn!.) 
23 patl!:'nl~ OVC'! Z~:u pcooc! 
plurWh..a 
plucLt-dh;uu 
pluci.Ld~n 
pluc:1u-d h:al[' 
Plucked h.t.lu 
pluclu-d halu 
(m pJbenlS WIth 
pIOUUIS) 
plucked h.at, 
Ixu 
Ixu 
Ixu 
beu, cutaueout.. 
,}ph. (on",ouri 
Ixu..!ph, 
'Ullh 16. 
t\-~Ithuur- 1;-. 
\lol1h 63*. 
\\i,..~ur-6"". 
56', 
)G", 
CpA 7J'. 
Gp B 6cr. 
Cpe: 3.'" 
(P -001 :adlusr~ 
>g<; 
PO)S&tI.'~fOm., 
HPVDNAO~t 
';:0, 100' 
.-.;, 
P01.<=nn ... 
1.J 1"_) 
P\I·PCRR.,.\.H 
(E) .,-n<l 
'''''~'''':'. '' ~''''''-
~'I.~' 
\~\~~"':~ ~ ~. 
~I bl'qu"ot tW\' \JI h (nee ... Cp 
UP\" ~ II .. '\10 ) 
Inf}y,I~,t ..... t" Z" tl,P.U ~I 61 
.. 2n" ..... ".._ 
d,e 2 yUIL 96-
(21 !l;. md n6 
motlth!...C.~...:L 
sec Sq\JMnUW ccoli c:uc nlUIIl.l, Bee BJ.Sai ceU CUCU10m:l, NMSC 1I1Xl-mt'ianonu .lull C.1UCef'", Ie 1nu11tlJlVCQlTlpC'Ienr pmetlt', IS Immlllhnltppf1"UC'd p.dlC'lIt,. ("'op.&,- ~I", RJi.\ fP~tk hybllda.:.II'1IQ1I .u .... v.lfP\ 
N~ nc;,n"lgmlirllOt::t~ S'/, level 
SKIN SWABS 
POllltllld ,fDl, 
1999, SWCde-1I 
Anlonllon ,'uJ. , 
2000, Swedcn 
-\Iotrubl ,1 II!., 2006. 
C.'lu.ch 
H!Uwl ,t ul 2007. 
Swrcicn 
.. pllltlen't(lli 'pecuTlC'n.) 
Ie Sfl p:"~JC;I1Ls (4811 'pccuncn.) 
RTR S2 PllllCllt, (2c.o 'Pecuncn.) 
Duly.1t 28 p:UltIIt1 (140 
'..,C('lnlC'II') 
H Ie 
8R11\ 
42fe 
II RTR 
nounal.lun beu 
,Ll" 1'01:.1)1 btot.l.CUUIIC'OIl" 
:&lrh .. (11\...,0'1.11) 
.\bu tur.lb. b • ., 
IklUfW~t 
(fvlC'hC'MQ g:vntna. bct:s 3Jltl 
2 wnplu (mC'.lIl ~.mbdA l)'JX' 
Ulnc 6,3 )"U") 
&1 
}9", "s-. 
00", 
P. 
- 6'Y' .• (I-ulllpk) 
il',(?d 
nrnplc) 
(- '*8', pclWlknt 
IIlICC~Il} 
'~~ 
.... 
" 0)', 
100' . 
-I •• 11-
u:snplC' 
9O".;ll?" 
"""rk ( •. 1)"· PC("~CI\I 
ultt'Cllon' 
PCRck~nrt'le 
tLI~or) 
sec: S~\I.unol~ ce\1nuCinOlllJ .. Bec Dnal (eU C'lltnnom:a. Nl\lSC non-mcl .. alloma WI' ('.U1o,;CC'. Ie lmnllll\OCompetenl pJf'lcnl.t, IS hnnulOo.llpptt'lIC'd p"" .. nl". HP\ Hunun rtpU¥JIll.J°/II\LJ 
PE RILESION 
-\'WII ,Iul. 19?5, 
uC'ollIny& 11IP1U1 
W,rl.lI1rl"u£, 
2000, GClnlllI'IY & 
p"l,lnti 
FOltllllld ,1 Ill, 
.:!OOl, 
S\I"rdrll& 
t\IUII:lIt.. 
f'UI.IUild Ifill. 
20lH 
Swrcl(,11 
A't't.ln".ll,~I!, 
L·S. \ 
14 rllllirnu (2 1 tp<'cnncn,) 
6pcu IS e,d,d 
prnlnHJn~1 II.) BCC 
N=JI 
Ie l8 plncllI'S (>I I tp«uncll.) 
IS 21p.lT lwtt (TIrl! 1j 
spt'"mt"" B .! I spccuncll.) 
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QUESTIONNAIRE 
STUDY: Skin cancer among organ transplant recipients 
Thank you for taking part in this study. Please complete this questionnaire prior to 
your scheduled appointment time. Please use black ink and capital letter. If you 
have any difficulties, you can discuss them with our nurse at your appointment. 
All information that you supply to us will remain 
strictly confidential 
Study ID ____ (for office use) 
195 
Date of questionnaire completion _1_1 __ 
Hospital _____ (for office use) 
Hospital number (for office use) 
Interviewer (for office use) 
Surnarne ________ _ 
Forename 
------------
Address 
POST CODE ____ _ 
Date of birth _1_1 __ 
Sex: (please circle one) MALE I FEMALE 
Country of birth ___________________ __ 
~ameofGP _____________________________ _ 
Address of GP 
POST CODE ____ _ 
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IQ1l How many brothers and sisters do you have? ___ _ 
IQ~ In your family, were you the fust, second, third, etc born? _ ___ _ 
IQ~ Did you regularly share a bedroom as a child? (circle one) YE,' / • TO 
IQ~ Did you regularly share a bed as a child? (circle one) YE ' / • TO 
IQ~ Are you currently married or living with a partner? (circle one) 'trK ' / 
IQ61 How many children do you have? ___ _ 
IQ71 How many people usually live together in your household? ____ _ 
IQ81 What is the highest teclmical, professional or academic qualification you have completed? 
(tick one) 
"0" level or equivalent 
"A." level or equivalent 
college/university degree 
clerical or commercial quali fications (eg secretarial, apprenticeships) 
N one o f these, other 
(a) If other, please specify: _________ _ 
(b) At what age did you leave school? ______ -Jyears 
IQ~ Do you or have you ever regularly smoked cigarettes? (tick one) 
N O 
X'ES I am a current smoker 
YES I am an ex-sm oker 
{(yoNr OI/S1J1er is "NO ",Please go to Questioll 10 (QI0) 
(a) On average, how many cigarettes do you smoke or did you used to smoke each day? 
(circle one) 
Le than 5 5-9 10-19 ~ Iore than 20 
(b) At what age did you start smoking? 
(c) If you no longer moke, how long ago did you stop? 
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IQl~ During the last year, about how often have you drunk alcohol? (rick one) 
Never 
Former drinker, but now stopped 
< 1 day per week 
1-3 days per week 
3-6 days per week 
Daily 
Jjy07lr allSlver ZJ "Never" please go to Question 11 (Ql1 ) , 
(a) On days when you drink, about how many glasses of alcohol do you have? (a l~la n i 
eqw'valent to a small botde ofbeerj a glass ofwinej a single measure ofspin'O 
Beer _____ _ 
Wine ____ _ 
Spirits ____ _ 
(b) On days when you drink, when do you usually take alcohol? (circle one) 
With a meal Not with a meal 1 0 regular pattern 
IQl~ How often do you exercise enough to make you sweat or get out of breath? (circle one) 
Never/rarely less than once a week once a week 2-3 times a week most dar 
I§gj Current height. ___ _ 
IQl~ Current weight ____ _ 
IQl~ Ethnicity: (circle one) 
White Asian Oriental Black 
Other ______ _ 
IQlSI What is your current occupation? -----------
IQ161 Have you ever had an outdoor occupation? (circle one) I T. ' / 1 0 
(a) If yes, which one? __________ _ 
and for how many years? ___ years 
IQl~ Have you ever had any outdoor hobbies? (circle one) YE /1 ( 
(a) If yes, which one(s)? _________ _ 
and for how many ears? ___ years 
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jQ18jHave you ever lived abroad? (circle one) 1'E / TO 
{[your allSlver is "NO "please go to Question 19 (Ql ~) 
Could you please fill in all places you have lived, fo r at least 6 months, starting from when 
you were born? 
rJlmm~"\ 'OOJ~ ~ (iIlIIIU." ' ...... ""ll 
jQ19j In the last year, about how many times did you visit a renal doctor? (circle one) 
never once tWlce three times four or more times 
jQ2~ In the last year, about how many times did you visit a skin doctor? (circle one) 
never once twlCe three times four or more times 
jQ2~ Have you ever been given advice on how to protect your skin from sunlight from any of the 
following? 
Renal doctor: Yes / No / Can't remember (circle one) 
Skin doctor: Yes / No / Can't remember (circle one) 
Renal nurse: Yes / No / Can't remember (circle one) 
GP: Yes / No / Can't remember (circle one) 
Media: Yes / No / Can't remember (circle one) 
Other person: Yes / 0 / Can't remember (circle one) 
If yes, from who? _____ _ 
(a) When did you get this advice? 
Bet r my first tran plant: Ye / 10 / Can' t remember (cltcle one) 
1\ fter my first tran plant: Ye / To / Can' t r member ( ire! one) 
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(b) How many times have you been given this advice? (circle one) 
1 ever Only once A few times Often Can't remember 
(c) Have you ever received written advice (eg a leaflet) about protecting yourself from 
sunlight? (circle one) 
Yes / 0/ Can't remember 
IQ2~ Skin type: (tick one) ~ Eye colour: (tick one) 
Never tans, always burns 
Rarely tans, usually burns 
Usually tans, can burn 
dark brown 
hazel 
Always tans, rarely burns 
Asian/Middle Eastern 
green 
blue 
African/ Afro-Caribbean 
IQ2~ What was your NATURAL hair colour at 18 years of age? (rick one) 
Black 
Dark brown 
Light brown 
Blonde 
Red 
IQ2~ Do you use suncream? (circle one) 
Never Sometimes Usually Iway 
{[your aI/Siller is "Never" p/eaJe go to Question 26 (Q26,l 
(a) How do you use it? (circle one) 
Only when it is sunny Daily all year Daily for part of year 
(b) If you lise it daily, which months would you lise it in the UK? (plea e circle each rele ant 
month) 
Janua.ry February March April May June 
July August September October o\rember December 
(c) What factor suncream do you mainly use? (circle one) 
2-5 8-10 15-25 more than 25 
(d) Approximately how many tubes of suncream do ou use each ear? (clIcle one) 
ooe 2 3 more than 4-
(e) Where do Oll appl uncream? (clIcle one) 
Fa e oly Face and hand. \1\ :\:po 'cd area 
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IQ2~ During the summer, do you specifically try and avoid being directly e}"-po ed to 
the sun? (ctrcle one) 
1 ever , ometimes Usually Always (Clrcle one) 
Ijyour answer is "Never "please go to Question 27 (Q2~) 
(a) If you try and avoid being directly exposed to the sun, which times would you do thi ? 
(please circle all relevant times) 
9am l Oam llam l 2pm lpm 2pm 3pm 4pm Spm 6pm 
IQ2~ Do you dress to protect yourself against the sun (eg wear a hat)? (circle one) 
Never Som etimes Usually Alway 
IQ2~ Do you ever go on holiday to sunny countries? (circle one) YES/ 
If yes, how often? (circle one) 
Once every 2-3 years or less O nce a year More than once a rear 
IQ2~ What do you understand are the main reason(s) why transplant patients should take extra 
precautions in the sun? (please answer in one or two sentences) 
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IQ3~ Have you ever had skin cancer diagnosed? (circle one) 
Ifyour allSJver is 'NO "please go to Question 31 (Q31) , 
lfyes, what year(s) was it ftrst diagnosed? ______ _ 
How many skin cancers have you had diagnosed? ____ _ 
Draw on the ftgure below the position of your skin cancer; (ij),OI( htlt'f bad mort Ih(1I/ Ollt, plfllJ( 
draw these 011 the figure also, as well as the year thl!)' were diagnosed) 
left left right 
IQ3~ Have you ever had any other cancer before? (circle one) YE / 1 0 
(a) lfyes, what type(s)? _____ _ 
(b) And what year(s) was it diagnosed? -----
IQ3~ Has anyone in your family had SKIN CANCER before? (circle one) 
\TE,S / 0 / 0 1 'T KN W 
lfyes, was it your ... ? (circle one or more) 
Mother/Father Brother/Sister Son/ Daughter unt/ Uncle Other _____ _ 
IQ3~ Has anyone in your family had any OTHER CANCER before? (circle one) 
\TE,S / NO / 001 'T KNOW 
lfyes, was it your ... ? (circle one or more) 
I ther/Father Brother/ Si ter .'on/ Daughter ~-\.unt/Uncle Other. _____ _ 
If yes, what cancer(s) ___________________ _ 
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IQ3~ Have you ever had skin warts? (circle one) 
{{your answer is "NO "please go to Question 35 (Q35,1 
a) How old were you when it started? ____ years 
YE /.0 
b) Did you have this condition before your transplantation? (circle one) "it.' 
If YES, did immunosuppressive therapy make it? (circle one) 
Better o change Worse Don't know 
IQ3~ Have you ever had genital warts? (circle one) YE,' / NO 
{(your anSllJer is "NO" please go to Question 36 (Q36) 
a) How old were you when it started? years 
b) Did you have this condition before your transplantation? (circle one) "i'E,' / 
If YES, did immunosuppressive therapy make it? (circle one) 
Better No change 
IQ3~ Have you ever had shingles? (circle one) 
{(your answer is "NO "please go 10 QIICstioll 37 (Q3 ~) 
Wor e 
a) How old were you when it started? ___ -Jyears 
Don't know 
YE.' / 1 
b) Did you have this condition before your transplantation? (circle one) "i'E. / TO 
If YES, did immunosuppressive therapy make it? (circle one) 
Better No change Worse Don't know 
IQ3~ Have you ever had acne? (circle one) YES/N 
{(yollr aI/Siver is "NO "please go to Question 38 (Q38) 
a) How old were you when it started? ___ -.lyears 
b) Did you have this condition before your transplantation? (circle one) YES / 0 
If YES, did immunosuppressive therapy make it? (circle one) 
Better o change Worse Don't know 
IQ3~ Have you ever had eczema? (circle one) YES / 0 / DOl 'T KNOW 
{(voNr a1/S1l'Cr is ''No "please go to Question 39 CQ39). 
a) How old were you when it started? ____ y, ears 
b) If you no longer have eczema, how long ago did it top? _____ _ 
c) Please give details of relap es or flares in di ease: ..... . 
• , • •• •• •• •• , •• • •• • •••••• • ••• , ••• • • • •••••••••••• o •••••• ••• ••• •• •••••••••• • •••• • ••••••••• 
.. . .. .. . .. . .. . .. .. . .... ... ..... . .. .. . .. . . " ... ............... ................... ...... . 
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9 
d) What is your current treatment? 
---------------------------
e) What was your previous treatment? (circle one) 
hospitalisation/uv treatment/ tablets/topical / other ____________ _ 
f) Did you have this condition before your transplantation? (circle one) \ "'L ' .'0 
If YES, did immunosuppressive therapy m ake it? (circle one) 
Better o change Worse Don't kno\\' 
g) Do you have a family history of eczema? (circle one) YES / NO 
If YES, who in the family is affected? 
Mother/Father Brother/Sister Son/D aughter Aunt/ Uncle Other. _________ _ 
h) Do any of the following make your eczema worse? (circle one or more) 
Wool Cat H ousehold dust Grass pollen Tree pollen Drugs Others 
If "others" or "drugs", please specify: ___________________ _ 
IQ3~ Have you ever had asthma? (circle one) YES / 0 
{( yollr atlSlver is "NO ",please go to Question 40 CQ.J.O) 
a) How old were you when it started? ______ -Jyears 
b) Did you have this condition before your transplantation? (circle one) YES / NO 
If YES, did immunosuppressive therapy make it? (circle one) 
Better No change Worse D on't know 
c) Do any of the following make your asthma worse? (circle one or more) 
Wool Cat H ousehold dust Grass pollen Tree pollen Drugs Others 
If "others" or "drugs", please specify: __________ _ 
IQ4~ Have you ever had hayfever? (circle one) YES / 1 0 
{[jo/(/" answer is "NO "please go to Qllestioll 41 CQ-Il) 
a) How old were you when it started? _____ --Jyears 
b) Did you h ave tIus condition before your transplantation? (ctrcle one) YE: i '0 
If YES, did immunosuppressive therapy make it? (ctrcle one) 
Bett r o change \,\ 'or e Don' t know 
c) Do any of the following make your hayfe er wor e? (ctrcle Onto or mor ) 
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Wool Cat Household dust Grass pollen Tree pollen Drugs Others 
If "others" or "drugs", please specify: __________ _ 
IQ4~ Have you ever had nettle rash/urticaria? (circle one) YE.' / ~ 
If)our answer is 'NO "please gp to Question 42 (Q42) 
a) How old were you when it started? ____ years 
b) Do any of the following make it worse? (circle one or more) 
Wool Cat Household dust Grass pollen Tree pollen Drug Other 
If "others" or "drugs", please specify: __________ _ 
c) Did you have this condition before your transplantation? (circle one) 'YE,' / 0 
If YES, did immunosuppressive therapy make it? (circle one) 
Better No change Worse Don't know 
IQ4~ Do you suffer from psoriasis? (circle one) YES / 
Ifyour anSlver is 'NO "please go to Question 43 (Q43) 
a) How old were you when it started? ____ years 
b) How many patches do you currently have? (circle one) 
1-2 3-4 5-9 10+ 
c) Did you have this condition before your transplantation? (circle one) YE ' / 
If YES, did immunosuppressive therapy make it? (circle one) 
Better No change Worse Don't know 
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\Q4~ What is your renal diagnosis? ______ _ 
IQ4~ In what year was your renal disease fust diagnosed? ____ _ 
IQ4~ Have you ever been on dialysis? (circle one) I 'E: / ' 0 
(a) If yes, how many years in total were you on dialysis? ______ _ 
(b) What type of dialysis did you have? (circle one) 
Haemodialysis / Peritoneal dialysis 
\Q461 In what year did you first have a renal transplant? _____ _ 
IQ4~ How many transplants have you had? _______ _ 
IQ4~ Prior to transplantation, for how many years were you on dialysis? ___ _ 
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BEFORE 
~bout how many MOLES did you have on your skin? 
Match your answers with the pictures below (Moles are small browlI, black or pillk. 
either raised or flat skin markings that do flOt change after sun exposure) Please tick 
one box 
I had no moles I had a few moles I had some moles I had many mole 
\Q50\ About how many FRECKLES did you have? 
Match your answers with the pictures below for face and anus 
• FACE (Tick one) 
I had no freckles I had a few freckles I had some freckles I had many freckles 
• ARMS (Tick one) 
, 
.. 
-. 
:.\ .. 
. ::', 
::: 
'" 
I had no freckles I had a few freckle I had orne freckle 
I had many freckle 
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~ Before your transplant, how many times in your life did you have a sunburn? A sunbunJ 
means Jllhen y our skin is red and painf,,1 l'ON may blister and peel (circle one) 
Never 1-2 3-5 6-10 ~fore than 10 
IQ5~ Before the age of 18, how many times did you have a sunburn? (circle one) 
Never 1-2 3-5 6-10 fore than 10 
IQ5~ Before your transplant, how many times did you sunbathe? (circle one) 
Never 1-2 3-5 6-10 lore than 10 
IQ5~ Before your transplant, how many times in your life have you had a sunny holiday abroad? 
Never 1-2 3-5 6-10 [ore than 10 (circle one) 
IQ551 Before your transplant, how many times in your life have you used a sun-bed? 
Never 1-2 3-5 6-10 More than 10 (circle one) 
IQ561 Before your transplant, did you have any outdoor hobbies? (circle one) 
YES/NO 
Ifyes,~hat? __________________________ _ 
IQ5~ Before your transplant, did you ever use sunscreens? (circle one) I~S / 
If yes, how often did you apply sunscreen when you were in the sun? (cucle one) 
Rarely ,omeurnes Usually .Almo t always 
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IQ5~ About how many MOLES do you have on your skin now? 
Match your answers with the pictures below (Moles arr small brow1/. black orpillk. 
either raised or flat skin markings that do not change after SUIl exposurr) Please tick 
one box 
I have no moles I have a few moles I have some moles I have many mole 
IQ5~ About how many FRECKLES do you have now? 
Match your answers with the pictures below for face and arms 
• FACE (rick one) 
I have no freckles I have a few freckles I have ome freckles I have many freckle 
• ARMS (rick one) 
I have no freckle I ha e a few freckle I ha e ome freckle 
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~ Since your transplant, have you been advised to stay out of the sun? (circle one) 
YE~ / NO 
IQ6~ Since your transplant, how many times have you had a sunburn? (circle one) 
Never 1-2 3-5 6-10 ;\Iore than 10 
IQ6~ Since your transplant, how many times did you sunbathe? (circle one) 
Never 1-2 3-5 6-10 More than 10 
IQ6~ Since your transplant, how many times have you had a sunny holiday abroad? 
(circle one) 
Never 1-2 3-5 6-10 ~lore than 10 
IQ6~ Since your transplant, how many times have you used a sun-bed? (circle one) 
Never 1-2 3-5 6-10 More than 10 
IQ6s1 Do you currently have any outdoor hobbies? (circle one) YE' / 1 
Ifyes,what? __________________________ _ 
IQ661 Since your transplant, do you ever use sunscreens? (circle one) \ 'E: / 0 
If yes, how often do you apply sunscreen when you were in the sun? (circle one) 
Rarely Sometimes Usually Almost always 
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~ If you have had children, in what year was each of your children born? 
1" Child 
2nd Child 
3'd Child 
4th Child 
5th Child 
6th Child 
7'h Child 
8th Child 
9th Child 
10th Child 
~ Have you ever had an abnormal smear test? (circle one) 
If yes, in what year? _______ _ 
IQ69\ Do you still menstruate? (circle one) \ 'ES / 0 
If your periods have stopped, how old were you when this happened? __ ----Jyears 
IQ7~ Have you ever had a hysterectomy? (circle one) \'ES / 
If yes, in what year? _____ _ 
IQ7~ Have you ever used the oral contraceptive pill? (circle one) "'i'ES / 0 
Ify01H mIs/per Ix "NO" please go to Question 66 {Q66,1 
If yes, about how old were you when you fust used the pill? _____ -Jyears 
lue you currently using the pill? (circle one) YES /1 0 
If not, about how old were you when you last came off the pill? years 
For how many years in total did you use the pill? years 
~ Have you ever used honnone replacement therapy (HRT)? (circle one) YES / 10 
If yes, about how old were you when you first used HRT? years 
Had your period stopped before you started using HRT? (circle one) 1'E: / TO 
For about how many years in total have you used HRT? year 
lue you now using HRT? (circle ne) \'E~ / T( 
What i the nam e of the m ost recent type of HRT you ha e u ed? _____ _ 
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(Information from patient notes) 
Patient IDNUM: 
----
CURRENT MEDICATION: 
HAS THIS PATIENT HAD: 
Cutaneous squamous cell carcinoma r'ES / 0 / D 'TKN W (circle one) 
If yes, date fust diagnosed __ _ 
What stage? ____ _ 
Basal cell carcinoma r'E / NO / DON'T KNOW (circle one) 
If yes, date first diagnosed __ _ 
Malignant melanoma 'r'ES / NO / DON'T KNOW (circle one) 
If yes , date fust diagnosed __ _ 
What stage? ____ _ 
Actinic Keratosis YES / 0 / DON'T KNOW (circle one) 
If yes, date first diagnosed __ _ 
Carcinoma in situ (Bowen's disease) YES / NO / DON'T KNOW (circle one) 
If yes, date fust diagnosed. __ _ 
Lymphoma / PTLD YES / 0 / DO 'T KNOW (circle one) 
If yes, date first diagnosed __ _ 
Cytomegalovirus YES / O/DO 'TKNOW (circle one) 
If yes, date first diagnosed __ _ 
Herpes simplex 'r'ES/ /D 'TKN W (rocle ne) 
If yes, date first diagnosed _ _ _ 
J, 
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Ques tions about skin cancer, if the patient has had one diagno ed 
On how many separate occasions has a skin cancer been diagnosed? __ _ 
FOR THE FIRST TUMOUR DIAGNOSED: 
What was the year of diagnosis? ____ _ 
What was the histology? _________ Was it? (circle one) inva i,'e or i ll si'lf 
What was the location of the tumour? 
H ead Back Chest Abdomen Leg rm 
FOR THE SECOND TUMOUR DIAGNOSED: 
What was the year of diagnosis? ____ _ 
What was the histology? _________ Was it? (circle one) invasive or i ll si'lf 
What was the location of the tumour? 
Head Back Chest Abdomen Leg rm 
FOR THE THIRD TUMOUR DIAGNOSED: 
What was the year of diagnosis? ____ _ 
What was the histology? _________ Was it? (circle one) invasive or ill silll 
What was the location of the tumour? 
H ead Back 
Have you taken a blood sample? 
Have you taken a hair? 
Chest bdomen Leg 
(circle one) YES / 
(circle one) YE. / 0 
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The CD includes: 
Appendix E1: Adjusted odds ratio (OR) by risk factors from the questionnaire for each 
single HPV type, among Caucasian OTR controls from London and Oxford (N=425) 
Appendix E2: Adjusted count ratio (CR) for multiple HPV seropositivity by risk factors 
from the questionnaire, among transplant Caucasian controls from London and Oxford 
(N=425) 
Appendix E3: Adjusted count ratio (CR) for multiple HPV seropositivity by risk factors 
from the questionnaire, among transplant Caucasian controls from Oxford (N=182) 
Appendix E4: Adjusted count ratio (CR) for multiple HPV seropositivity by risk factors 
from the questionnaire, among transplant Caucasian controls from London (N=243) 
Appendix E5: Seroprevalence for single HPV type between OTR with skin type V and 
VI and between Asian and Black individuals (the 2 largest groups of non-Caucasian pa-
tients) of Oxford and London 
Appendix E6: Seroprevalence for multiple HPV types between OTR with skin type V and 
VI and between Asian and Black individuals (the 2 largest groups of non-Caucasian pa-
tients) of Oxford and London 
Appendix E7: Multiple HPV seroprevalence by genus and mean number (SD) of multiple 
HPV seropositivity per Caucasian transplant, IC and dialysis patients across genus 
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Appendix E8: Multiple HPV seroprevalence by genus and mean number (SO) of multiple 
HPV seropositivity per non-Caucasian transplant and dialysis patients across genus 
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